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Bacterial toxins are a broad category of molecules ranging from small organic compounds
and peptides to large multi-domain or multi-meric enzymes. Several important diseases
are caused primarily by bacterial toxins including botulism and diphtheria. Paradoxically,
the same toxins have proven useful for the treatment of muscular disorders and cancer, re-
spectively. Given their importance in medicine and their utility as drugs, it is desirable to
attain a greater functional and mechanistic understanding of toxin families. However, a full
description of any sequence’s functionality must incorporate an understanding of the evo-
lutionary processes that produced them, and currently little is known about these forces.
Using a bioinformatic approach, this thesis presents analyses of three bacterial toxin fam-
ilies: clostridial neurotoxins, which cause botulism and tetanus; diphtheria toxins, which
cause diphtheria; and large clostridial toxins, which contribute to the infections produced
by various clostridia, including Clostridioides difficile. The detection of toxin-related se-
quences from bacterial genomes allows the discovery of toxin variants that may have gone
undetected by other methods of toxin identification. Based on the available genomic data,
toxin families that cause disease in humans appear to be broader than previously imagined.
Toxin-related sequences are capable of performing unique functions compared to the toxin
variants more traditionally associated with human disease. By examining human toxins in
evolutionary terms, it is possible to identify the functional innovations that have occurred
to result in human specificity, as well as delve more deeply into the relationships between
toxin sequences and their functions. Thus, the studies presented here provide examples
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Material in this chapter has been published as part of Doxey et al. [1]. The published
manuscript is available from here:
1. Doxey, A. C., Mansfield, M. J., & Montecucco, C. (2018). Discovery of novel bacterial
toxins by genomics and computational biology. Toxicon, 147, 2-12. [1].
https://doi.org/10.1016/j.toxicon.2018.02.002
1.1 Overview
In this chapter, I introduce key terms that are used throughout the thesis. I frame these
discussions around the terms’ historical definitions, and consider how their definitions have
changed over time. I begin by discussing the history of pathogenicity and virulence factors.
I then focus upon toxic proteins, both in terms of the history of toxin identification as well
as their mechanisms, structures, and functions. I discuss the impact of genomics on the
field of bacterial toxins, followed by a brief overview of the theoretical and methodological
background for the bioinformatic techniques necessary to interpret the data and results of
subsequent chapters. In the last section, I provide an outline of the thesis document.
1.2 Pathogens, virulence factors, and toxic proteins
In its simplest terms, pathogenicity can be defined as the capacity for a microbe to cause
damage to a host [6]. The modern usage of the term arose shortly after the development
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of the germ theory of disease. At this time, experiments on toxigenic bacteria contributed
significantly to the burgeoning field of microbiology, and strongly informed ideas about
pathogenesis. Klebs and Löffler’s identification of the microbe that causes diphtheria led
to the discovery of its toxin, a substance produced by the microbe in infected tissues but
capable of causing damage far from the site of infection [7, 8]. Around the same time,
Koch’s isolation and growth of the tuberculosis bacterium [9] systematized the process for
establishing pathogen-disease causality, and developed into what is now known as Koch’s
postulates. Stated plainly, the fulfilment of Koch’s postulates requires: 1) isolation of a
microbe from diseased tissues, common to all cases of the disease; 2) the organism must
be grown in pure culture; 3) inoculation of the microbe into a host must produce the same
disease; 4) the organism must be isolated from the infected animal and grown in pure
culture once more [10]. Together, the observations that specific microbes cause diseases
through toxins or through infection supported the idea that pathogenicity was an intrinsic
property of specific microbes.
However, it now seems clear that the idea that specific microbial species are pathogens
and others are not is an oversimplification [6, 11, 12]. Although some bacterial lineages
are strictly pathogenic - for example, obligate intracellular parasites like chlamydia species
[13] - pathogenicity is a property found broadly across the kingdom Bacteria, and is not
limited to any particular taxon. Conversely, closely related bacteria can vary greatly in
pathogenicity, as is the case for strains of Escherichia coli [14]. Some pathogenic microbes
produce asymptomatic infections, and bacteria that would normally not be considered
pathogens can cause serious infections in immunocompromised individuals [15]. Therefore,
it is perhaps more appropriate to consider pathogenicity the result of an interaction between
a particular microbe with a particular host. On the pathogen side, variables like strain-
specific differences must be considered, and on the host side, immunity/susceptibility and
the protective effects of the host’s microbiome must be considered [16].
In a broad sense, all properties of a pathogen that contribute to pathogenicity may be
considered virulence factors [17, 18]. However, this all-encompassing definition may lack
specificity. As pointed out by Weiss and Hewlett [19], although core metabolic properties
common to many bacteria like purine metabolism are not typically considered virulence fac-
tors, they are required for virulence in Salmonella [20]. Similarly, even though lipopolysac-
charides are a component of all gram negative membranes, Salmonella specifically modifies
its O antigens to evade immune detection [21], and its O antigens are therefore considered
virulence factors. The apparent difficulty in defining what constitutes a virulence factor
has led some to call for the development of a virulence factor classification scheme akin to
enzyme commission numbers [18], and some resources that attempt to categorize virulence
factors like the Virulence Factor Database are widely used [22]. Nevertheless, in its most
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common usage, the virulence factors of a pathogen include general physiological and life
cycle properties like flagella [23], sporulation [24], dormancy [25], and membrane structure
[26], as well as microbial products that are specifically produced to target and modify a
host’s physiology. Toxins are one example of such a targeted virulence factor.
The word “toxin” is derived from the ancient Greek τοξικός (toxikós) relating to the
bow or use of the bow, or more specifically, poison for smearing on arrows. The word
was introduced into the modern scientific lexicon by Brieger, who primarily worked on
toxic metabolites derived from putrefied tissues (“ptomains”) [27, 28]. Brieger introduced
the term toxin to describe tetanus toxin, which he had unsuccessfully attempted to iso-
late; evidently, Brieger thought it was worth distinguishing from other poisonous sub-
stances. Indeed, biological toxins can be broadly classified into several categories: small
organic molecules, modified amino acids, and other low molecular weight metabolites; short
polypeptide chains, including bacteriocins; and large protein toxins. It is the category of
large protein toxins that is of interest for this thesis, and more specifically large protein
toxins produced by bacteria. The word “toxin” is used throughout the thesis to refer to
this case.
1.3 History of bacterial toxin identification
In the early 1880s, Klebs and Löffler had identified the microbe responsible for diphtheria,
and had demonstrated that the disease was caused by microbial toxin production, but they
were unable to isolate the toxin itself. Roux and Yersin achieved the isolation of diphtheria
toxin (DT) in 1888 [29]. It took nearly one hundred years to develop an explanation for
Roux and Yersin’s success. After DT production was found to be related to culture iron
concentration [30], the molecular mechanism for this phenomenon was proposed by Murphy
et al. in 1976: DT expression could be controlled by an iron-inducible repressor [31, 32].
Thus, DT is only expressed in conditions of iron depletion. Apparently, Klebs and Löffler
had not allowed their cultures to reach saturation.
The discovery of diphtheria toxin provided evidence that bacterial pathogens might
produce substances primarily (or solely) responsible for infectious diseases. A similar ap-
proach was quickly and successfully applied to other diseases and toxin families, including
tetanus toxin [27, 33, 34, 35] and botulinum toxin [36]. A generalization of the approach,
which can be thought of as an application of Koch’s postulates, is visualized in Figure
1.1 (adapted from Figure 1 of Doxey et al. [1]). After observing a clinical phenotype, the
suspected microbial agent must be isolated and cultivated. Then, its toxin must be purified












Figure 1.1: A generalized bacterial toxin identification method. Following an outbreak of a disease, the
causative microbe must be isolated and cultivated, then production of a toxin must be determined, in
accordance with Koch’s postulates. Once this toxin is determined to be the cause of disease, additional
biochemical (and recently, genomic) characterization is possible. Adapted from Doxey et al. [1].
mechanistic details can be determined, which is discussed in greater detail below. The
initial success of this toxin identification strategy held much promise for understanding
toxin-related diseases, but proved difficult for cases like anthrax, cholera, and pertussis.
The major toxins that contribute to those illnesses were only described much later (in 1954,
1959, and 1982, respectively) [37, 38, 39, 40, 41].
Bacterial toxins are now understood to be the protein products of transcribed and
translated genes, encoded within bacterial genomes. As such, toxin characterization meth-
ods developed with the emergence of genetic, microbiological, and molecular biology tech-
niques. Techniques like molecular cloning, protein expression, purification and crystallog-
raphy, molecular imaging, and sequencing allow different aspects of toxin function to be
interrogated in much greater resolution. Since their discovery in the 1880s, the mechanisms
used by many toxin families have been elucidated. In general, toxins can be divided into
two types: those that act on the extracellular plasma membrane, and those that act on in-
tracellular substrates within host cells [42, 43]. Toxins that act on intracellular substrates
must first gain access the host cytosol. Various bacterial secretion systems are used to
inject effectors directly into host cells, some of which are toxic. Secretion systems used
to transport effectors into host cells are mostly associated with gram negative pathogens,
although similar secretion systems are found in gram positive pathogens [44, 45]. For ex-
ample, type III secretion systems (T3SS) are employed by pathogens like Salmonella [46],
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Pseudomonas syringae [47], and Escherichia coli [48], while the type IV secretion system
is used in Legionella species. Toxins that are not transported directly into host cells by
secretion systems must translocate into cells some other way, mediated by a specialized
toxin domain or complexed partner protein(s). Toxins with their own translocation mech-
anism can be classified as “AB” toxins, containing functionally distinct active (“A”) and
binding/translocating (“B”) components. The AB toxin architecture is common among
bacterial toxin families, but the specific mechanisms for toxin binding, translocation, and
enzymatic activity are variable.
1.4 AB toxins: structure and function
Many bacterial toxin families possess AB toxin architecture. The A component is an
enzyme that chemically modifies a host substrate. The B component is responsible for
binding one or more receptors on the host cell surface, as well as translocating the A
component into the cytosol. The A and B components can be encoded in a single gene
or encoded by separate genes. If the A and B components are encoded in separate genes,
either A or B component may be a hetero- or homomeric complex comprised of one or more
A/B components. As an example, the cholera toxin of Vibrio cholerae is a complex of a
single A fragment and a homopentameric B fragment (AB5) [49], while the pertussis toxin
of Bordetella pertussis is comprised of a single chain A subunit with a heteropentameric B
complex containing four different proteins (technically AS1BS2BS3B2xS4BS5, although this
notation is never used) [50].
Toxin A components modify host substrates through a wide range of enzymatic activ-
ities. Known toxin enzyme types include proteases, ADP ribosyltransferases, adenylate
cyclases, glucosyltransferases, and DNases 1. Enzymatic modification of the host substrate
elicits a change in the host’s physiology, which can have subtle or dramatic phenotypic
consequences depending on the toxin’s target. For example, pertussis toxin disrupts im-
mune processes yielding increased and more persistent infectivity [54], whereas a single
molecule of diphtheria toxin is sufficient to halt protein synthesis and kill human cells [58].
In general, the targets of toxins are involved in conserved, constitutively expressed cellular
processes like cell cycle regulation or protein synthesis [42], contributing to the severity of
intoxication. Toxin A components with the same enzyme type can have similar sequences
1For reference: diphtheria, pertussis, and cholera toxins are ADP-ribosyltransferases [51], botulinum
toxin and anthrax lethal factor are metalloproteases [52, 53], Bordetella pertussis CyaA and anthrax edema
factor are adenylate cyclases [54, 55], large clostridial toxins are glucosyltransferases [56], and cytolethal
distending factors are DNases [57].
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and function, distantly related sequences but similar functions, or else have limited se-
quence and functional similarity 2. The enzymatic specificity of the toxin A component
plays a role in determining host resistance and susceptibility, as the orthologous targets
of toxins may vary between different hosts. This explains the resistance of rats and chick-
ens to tetanus [59]. However, the enzymatic specificity of the A component by itself is
inadequate to explain host specificity or pathological severity. Although some botulinum
toxins and tetanus toxin cleave the same substrate at the same site, they yield nearly
opposite phenotypes (flaccid versus spastic paralysis). In this case, the key difference is
where cleavage occurs: for botulinum toxin, the toxin acts directly at neuromuscular junc-
tions and paralyzes muscles, but tetanus is instead transported to the spinal cord, causing
unbalanced muscular contraction [60, 61].
The B component of AB toxins is responsible for localizing the toxin to host receptors,
and then facilitating the A component’s entry into host cytoplasm. The binding receptors
for toxins include a large variety of proteins and lipids, which can be glycosylated or non-
glycosylated. Toxin binding may involve or require multiple simultaneous receptors (as
in botulinum toxins and large clostridial toxins) [62, 63, 64], or toxin multi-merization
(as in anthrax toxin, pertussis toxin, and cholera toxin) [65, 66, 67]. As well, closely-
related toxins within the same family may utilize different receptors [68, 69, 70]. After
a toxin binds its receptor(s), it is internalized by receptor-mediated endocytosis [71, 72].
Further trafficking through the host varies between toxin families. Within a single cell,
some toxins translocate through early or late endosomes while others are transported to
the endoplasmic reticulum prior to translocation. Toxins may additionally be trafficked
between different host cells [73]. For many toxins, it is the acidification of late endosomes
that facilitates translocation, as the decrease in pH induces conformational changes in the
toxin B component. These changes allow the B component to form a pore through which
the A component is translocated [74, 75], which may involve partial or complete unfolding
of the A component [76, 77]. Toxin A and B components are generally linked by one or
more disulfide bonds. If the A and B components of the toxin are produced as a single
polypeptide chain, it must first be cleaved by bacterial or host proteases, and linked to one
another by a disulfide bond. The details of proteolytic activation are known for some toxins
2An example for each of the three cases. 1) Botulinum and tetanus toxin A components are homologous
protease toxins that share around 30% amino acid identity and have significant functional similarities; 2)
The A components of diphtheria toxin and Pseudomonas aeruginosa ExoA components are distantly re-
lated ADP-ribosyltransferases that share around 18% amino acid identity, but both target the diphthamide
residue of eukaryotic elongation factor 2; 3) diphtheria toxin and cholera toxin A components are both
ADP-ribosyltransferases, but have little else in common, even using different catalytic mechanisms for
ADP-ribosyltransferase activity. See Simon et al. [51] for an in-depth review of ADP-ribosyltransferase
toxins.
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(diphtheria toxin is activated by the host’s furin protease [78], and large clostridial toxins
contain an autoproteolytic cysteine protease domain [79]) and unknown for others (the
activating protease for botulinum toxins is currently unknown). At any rate, the disulfide
bond(s) linking the A and B components becomes reduced during or after translocation,
thereby liberating the A component within the cytosol. Once inside the cytosol, the A
component is able to perform its toxic enzymatic function.
1.5 The genomic era of toxin biology
All of microbiology has been profoundly influenced by the development of whole-genome
sequencing. In the last 15 years, the cost to determine an organism’s whole genome has
greatly decreased, and new genomes are being sequenced at an incredible rate (Figure 1.2).
Third generation sequencing technologies have the potential to further improve on some of
the issues associated with previous platforms (namely, the limitations caused by small read
lengths [80, 81]). The field of bacterial toxin biology has benefited greatly from genomic
sequencing. Indeed, toxigenic human pathogens were among the first bacterial genomes
sequenced, starting with Helicobacter pylori in 1997 [82], and Pseudomonas aeruginosa
and Vibrio cholerae in 2000 [83, 84] (see Figure 1.2 for other milestones). Whole genome
sequencing has become a routine technique for monitoring and surveying toxigenic mi-
croorganisms, including isolates from clinical and non-clinical environments [85]. For some
toxin families, whole genome sequencing has revealed toxin families like botulinum toxins
can vary by 70% or more amino acid identity [86, 87, 88].
Nevertheless, a sequence-centric understanding of virulence and toxin biology has be-
come widely adopted, aided in part by whole genome sequencing. The sequence-centric
paradigm necessitates modifications to ideas like Koch’s postulates [89, 90] and pathogenic-
ity [17, 6, 11, 12]. New sequences are now produced much more quickly than can be func-
tionally characterized. As a result, methods for rapidly identifying sequences of interest
from genomes or other sources are a necessary component of toxin classification. Bioin-
formatic techniques have been adopted to address this problem. In addition to quickly
identifying and classifying toxin sequences, bioinformatic sequence-based toxin identifica-
tion contributes a parallel to the classical toxin identification model (Figure 1.2): toxins
can be discovered based on their similarity to other toxin sequences, in the absence of an
observed diseased phenotype. Including consideration for toxins that do not produce ob-
vious pathology is important because of the possibility that the primary function of some
“toxins” may be to prevent and avoid host responses. The bioinformatically-predicted ty-
phoid toxin of Salmonella Typhimurium [91] may be an example of this phenomenon, as
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Figure 1.2: The graph above shows the exponential increase in the NCBI microbial genome database
over time (as of September 22, 2019). The release dates for the first complete genome sequences of several
important toxigenic bacteria are indicated. Approximate market release dates for several sequencing tech-
nologies are also noted, including solid-phase amplification sequencing (Illumina), single-molecule real-time
sequencing (SMRT; Pacific Biosciences), and nanopore sequencing (ONT; Oxford Nanopore Technologies).
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it is possible that the role of typhoid “toxin” may be to promote asymptomatic infection
[92].
The bioinformatic approach to toxin identification has already proven successful for
identifying novel toxins related to several toxins families. In 2008, a novel ADP-ribosyl-
transferase related to Pseudomonas aeruginosa ExoA was discovered in Vibrio cholerae
through a combination of suppression subtractive hybridization and bioinformatic compar-
ison to other toxin sequences [93]. This sequence, termed cholix toxin, was found to function
as an ADP ribosyltransferase targeting eukaryotic elongation factor 2 [94], similar to diph-
theria toxin and ExoA. Cholix toxin has been suggested to play a significant role in the V.
cholerae life cycle, and belongs to a large and diverse family of toxin-related sequences [95].
In another example, the genome of a virulent strain of Bacillus cereus was sequenced and in
silico searches revealed a locus containing genes similar to anthrax protective antigen and
anthrax lethal factor [96]. Anthrax lethal factor contains an inactive vegetative insecticidal
protein-related ADP ribosyltransferase and an active C-terminal metalloprotease domain,
which cleaves MAPK kinases [53]. The lethal factor-related sequence in B. cereus, termed
certhrax, was found to enter cells using a homolog of anthrax protective antigen, and pos-
sesses an active ADP ribosyltransferase but lacks the metalloprotease domain [96]. The
target of certhrax was determined to be vinculin [97], implying a role in immune evasion,
although recent studies suggest its role may be to decrease virulence rather than enhance
it [98]. Finally, a study by our group in 2015 reported the first botulinum toxin-like se-
quences outside of Clostridium, found in the genome of a strain of Weissella oryzae [99]. In
spite of its low sequence identity to BoNTs (around 18% amino acid sequence identity), the
protein was found to be capable of cleaving VAMP2, a known target of botulinum toxins
[100], at a unique cleavage site [101]. Structural characterization of the metalloprotease
domain by Košenina et al. [102] revealed a uniquely open and charged substrate binding
pocket, which the authors suggest to potentially confer additional unique functionality. In
each of the examples listed above, the sequence-centric approach to toxin identification
has revealed toxin-related sequences with unique properties. All of these discoveries were
enabled by genomic sequencing and bioinformatic analysis.
1.6 Background for bioinformatic methodology
The enormous influx of sequencing data necessitates the development of new techniques for
organizing and interpreting biological information. As described in the previous section,
toxin biology has already gained from the adoption of bioinformatic techniques. In this
section, I describe the background for bioinformatic approaches to sequence comparison
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and analysis, which are used throughout the thesis.
Sequence similarity and homology
Two sequences that share an ancestor are homologous, and are termed homologs. Generally,
homologous sequences are more similar to one another than they are to non-homologous
or unrelated sequences. As such, the most straightforward way to detect homology is
to detect sequence similarity, normally through the process of sequence alignment. The
alignment’s quality is then assessed according to some scoring criteria. Ideally, the scoring
criteria award high scores to high quality alignments, and are capable of distinguishing
them from low-score, poor quality alignments. Sequence alignment is fundamental to
bioinformatics and the core of the widely-used BLAST algorithm [103]. An alignment
between two sequences is assigned a score, and the statistical significance of that score is
normally evaluated by calculating its expectation value (E -value). For BLAST, the E -
value for an alignment with score S between two sequences with lengths m and n is given
by the following formula:
E = Kmne−λS
Here, K and λ represent scaling factors for the search space size and scoring scheme.
Alignments with scores higher than what is expected by chance given the length of the
alignment will produce low E -values. In addition, the BLAST algorithm scales the E -values
by database length, filters matches in repetitive regions, and employs heuristic filters to
avoid exhaustive computation [103]. Besides BLAST, there are many alternative sequence
search algorithms with their own advantages and disadvantages [104, 105, 106, 107, 108].
The detection of statistically significant sequence similarity between two sequences,
as measured by E -values or otherwise, provides evidence that sequences are homologous
[103]. Sequence similarity implies functional similarity, although the relationship between
sequence similarity and function is not altogether straightforward [109]. Since sequence
similarity implies functional similarity, sequences displaying sufficient evidence for homol-
ogy are often assumed to perform similar functions. The process of transferring known
functions to similar sequences of unknown function is termed functional annotation. Irre-
spective of the particular search algorithm or sequence similarity metric, many bioinfor-
matic analyses involve collecting, comparing, and annotating sets of homologous sequences
(including all of the chapters presented in this thesis).
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Remote homology detection
Inferring homology by comparing individual query sequences to particular target sequences
is limited in its ability to capture all members of a sequence family, as any pairwise com-
parisons may produce alignments with identities below statistical significance [110, 111].
Algorithms better suited to detect more distant relationships usually incorporate informa-
tion from multiple target sequences, and can perform iterative searches to discover more
distantly related sequences. Model-based searches like PSI-BLAST’s position-specific scor-
ing matrices [112] or HMMER’s hidden Markov models [113] use this strategy to search
more broadly than particular query sequences. Profile-to-profile searches, such as those
found in the HHsearch suite [114], may be capable of detecting even more distant rela-
tionships [115]. In some cases, matching a query sequence to one or more sequences with
solved structures can help to identify underlying structural similarities between distantly
related sequences (for example, the structural threading approach used by PHYRE [116]).
Functional annotation
After one has identified a set of homologous sequences, it is desirable to estimate what
their biological function(s) might be. Most functional annotation methods use homol-
ogy for function prediction, which relies on databases of annotated sequences. Annotated
databases include Pfam [117], CATH [118], SCOP [119], COG [120], and PANTHER [121].
More specialized resources can be used for other types of information, including KEGG for
metabolic pathways [122], the PDB for protein structures [123], and MEROPS for proteases
[124]. Meta-search utilities like InterProScan combine information from multiple databases
to provide more comprehensive annotations [125, 126]. At low sequence identities, it be-
comes more difficult to infer homology and infer function. In these cases, the addition of
information extraneous to the sequence itself can be helpful to infer the function of the
sequence. This might include the conservation of key functional motifs, partial or complete
protein domains, or association with particular genes or genomic elements [127].
Evaluating relationships between homologous sequences
Homologous sequences can be classified through their mechanism of divergence [128]. Or-
thologs are homologous sequences that have diverged as a result of speciation between or-
ganisms, paralogs have diverged after a gene duplication event, and xenologs have diverged
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following a lateral gene transfer event 3. Ascertaining the particular nature of a homolo-
gous relationship can be difficult, since the processes of gene duplication, speciation, and
lateral gene transfer occur continuously and simultaneously. Further complicating matters
are cases of partial gene deletion, recombination, and fusion, which create lineages with
partial similarities to multiple gene families. Some of these difficulties can be addressed,
or at least detected, through careful analysis and inspection of multiple sequence align-
ments and phylogenetic trees. Tools for generating multiple sequence alignments include
MUSCLE [129], ClustalO [130], and MAFFT [131] programs.
Phylogenetic techniques, which generally rely on multiple sequence alignments, are
commonly used for analyzing sets of homologous sequences. These methods aim to con-
struct a model (a tree) that describes the relationship between a set of sequences, given
a model of how those sequences are evolving. Parsimony methods generate a tree with
the assumption that the smaller numbers of changes are more likely than larger numbers
of changes, and neighbour-joining methods attempt to generate a tree based on distances
between sequences [132]. Model-based methods like maximum likelihood and Bayesian
generate trees based on explicit statistical assumptions about the types and rates of sub-
stitutions [133, 134, 135, 132]. An accurate phylogeny should reproduce the ancestry the
sequences in the tree, indicating their order of divergence and making it possible to evaluate
the relationships between particular substitutions and functions. There are many useful
applications for phylogenetics. One is the generation of species trees based on shared
taxonomic markers, which attempt to trace back speciation events within or between taxo-
nomic groups, and potentially a tree of all life [136, 137]. Phylogenies can be used to detect
sites or branches that evolve more quickly than expected and thus potentially represent
adaptations (positive selection) [133, 134], or identifying evolutionary events that produce
functional differences between different family members (functional shifts) [138].
1.7 Thesis outline
The broad theme of the work presented in this thesis is the discovery and bioinformatic
analysis of bacterial toxin homologs. The thesis is structured as five chapters. This first
introductory chapter provides historical and methodological background information to aid
interpretation of the following data chapters. The three data chapters are organized by
toxin family (described in Table 1.1). The first data chapter (Chapter 2) presents analy-
ses of botulinum neurotoxins and contains four subsections, the first two concerning the
3The 2005 review by Koonin [128] features a nuanced and detailed discussion of the molecular evolu-
tionary dynamics surrounding the concept of homology.
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discovery of neurotoxin-related sequences in Enterococcus faecium and Chryseobacterium
piperi, the third concerning overview on the family’s molecular evolution, and the fourth an
analysis of the evolution of the neurotoxin gene cluster. The second data chapter (Chapter
3) focuses on diphtheria toxins and contains two subsections, the first of which is related
to the discovery of diphtheria-like sequences, and the second related to an analysis of the
structures of two diphtheria-like sequences. The third data chapter (Chapter 4) is related
to the translocation apparatus of large clostridial toxins and its distribution in a number
of pathogenic species. The final chapter (Chapter 5) features a discussion of general and
specific information gained from preceding chapters, including technical and methodolog-
ical considerations that affect results and their interpretation, and concludes with a short
prospective for the field.
Table 1.1: Summary of thesis chapters.
Chapter Toxin family Section Description
Chapter 1 1 Introduction
Chapter 2 BoNT
2.1 Identification of a botulinum neurotoxin-like
toxin in Enterococcus faecium
2.2 Bioinformatic discovery of a toxin family in
Chryseobacterium piperi with sequence simi-
larity to botulinum neurotoxins
2.3 Genomic insights into the evolution and ecol-
ogy of botulinum neurotoxins
2.4 Comparative genomics and evolution of the
BoNT-associated P47/OrfX gene cluster
Chapter 3 DT 3.1 Identification of a diphtheria toxin-like genefamily beyond the Corynebacterium genus
3.2 Structural characterization of diphtheria
toxin homologs
Chapter 4 LCT 4.1 The C. difficile toxin translocase is a con-
served apparatus for bacterial protein deliv-
ery into host cells
Chapter 5 5 Conclusions
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Chapter 2
Evolution and diversity of botulinum
neurotoxins
Material in this chapter has been published or is currently in preparation for publication.
The published materials are available from the following sources:
1. Zhang, S., Lebreton, F., Mansfield, M. J., Miyashita, S. I., Zhang, J., Schwartzman,
J. A., Tao L., Masuyer G., Martínez-Carranza M., Stenmark P., Gilmore M.S., Doxey
A.C., & Dong M.D. (2018). Identification of a botulinum neurotoxin-like toxin in a
commensal strain of Enterococcus faecium. Cell host & microbe, 23(2), 169-176. [2].
https://doi.org/10.1016/j.chom.2017.12.018
2. Mansfield, M. J., Wentz, T. G., Zhang, S., Lee, E. J., Dong, M., Sharma, S. K., &
Doxey, A. C. (2019). Bioinformatic discovery of a toxin family in Chryseobacterium
piperi with sequence similarity to botulinum neurotoxins. Scientific reports, 9. [3].
https://doi.org/10.1038/s41598-018-37647-8
3. Mansfield, M. J., & Doxey, A. C. (2018). Genomic insights into the evolution and
ecology of botulinum neurotoxins. Pathogens and disease, 76(4), fty040. [4].
https://doi.org/10.1093/femspd/fty040
4. Mansfield, M. J., Lee, E. J., & Doxey, A. C. (2019). Comparative genomics and
evolution of the BoNT-associated P47/OrfX gene cluster. Manuscript in preparation.
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2.1 Identification of a botulinum neurotoxin-like toxin
in Enterococcus faecium
2.1.1 Introduction
BoNTs are one of the most dangerous potential bioterrorism agents (category A and tier
1 select agents) [139]. They have also been utilized to treat many medical conditions
as well as for cosmetic applications [140]. There are seven well-established serotypes of
BoNTs (BoNT/A-G). They are composed of a light chain (LC) and a heavy chain (HC)
[141, 142, 143], connected via an inter-chain disulfide bond. The LC is a zinc-dependent
metalloprotease. The HC contains the translocation domain (HN) and the receptor-binding
domain (HC). BoNTs target neurons and block neurotransmission by cleaving host proteins
VAMP1/2/3 (BoNT/B, D, F, and G), SNAP25 (BoNT/A, C, E), or syntaxin 1 (Syx 1,
BoNT/C). These three proteins mediate fusion of synaptic vesicles to plasma membranes
and are the prototype of the SNARE family proteins (soluble NSF attachment protein
receptor) [144, 145].
Genes encoding BoNT proteins reside within two types of gene clusters [146]. Both
include a gene encoding NTNH (non-toxic non-hemagglutinin protein), which forms a
complex with BoNTs and protects them in the gastrointestinal (GI) tract [147]. One type
of gene cluster expresses additional proteins HA17, HA33, and HA70, which facilitate
the absorption of toxins across the epithelial barrier [148, 149]. The other type encodes
proteins with unknown functions; these are designated OrfX1, OrfX2, OrfX3, and P47
[146]. Multiple mechanisms contribute to horizontal gene transfer and the recombination
of BoNT clusters, including being located on plasmids or phages and the presence of
transposases. Recent genomic studies revealed a growing number of subtypes and mosaic
toxins [150, 151, 152, 153, 154]. A new serotype, BoNT/X, was also recently identified in
a Clostridium botulinum strain [155].
The evolutionary origin of BoNTs remains a mystery. Recent studies reported a homolog
of BoNT in a gram-positive bacterium Weissella oryzae, designated BoNT/Wo [99, 101].
However, BoNT/Wo is quite distinct from BoNTs. First, the sequence identity between
BoNT/Wo versus other BoNTs is around 14%-16%, below the normal range for the mem-
bers of the BoNT family (28%-65%). Second, the two cysteines that form the essential
inter-chain disulfide bond in BoNTs are not conserved in BoNT/Wo, suggesting a distinct
mode of action. Third, the BoNT/Wo gene is not in a typical BoNT gene cluster.
Enterococcus faecium is a core commensal member in the human gut and widespread
in most terrestrial animals [156, 157, 158, 159]. Since the 1970s, E. faecium has become
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a leading cause of hospital-acquired multi-drug-resistant (MDR) infection of the blood-
stream, urinary tract, and surgical wounds [160, 161]. Compounding the problem, the
enterococci serve as collection and distribution points for mobile elements, exemplified by
acquiring and transmitting a variety of antibiotic resistance to gram-positive and gram-
negative species [162].
As a part of an ongoing diversity study, we have collected and sequenced a growing
number of enterococcal strains. One strain, IDI0629, was recently isolated from cow feces in
South Carolina in the US. Genomic sequencing revealed that it contains a BoNT-like toxin
gene (GenBank: OTO22244.1), tentatively designated BoNT/En. BoNT/En represents
the first neurotoxin-related sequence to be found in Enterococcus species, as well as the
closest relative to the BoNT family outside of the genus Clostridium. The gene encoding
BoNT/En is located within an OrfX-type gene cluster flanked by transposases, suggesting
that the unit may have been laterally transferred into Enterococcus, and may be capable
of additional transfer events.
2.1.2 Methods
Bioinformatic identification and analysis of BoNT/En
BoNT/En was discovered using BLASTp with BoNT/X as a query sequence against the
nr database with default parameters (BLOSUM62, gap existence = 11, gap extension =
1, with conditional compositional score matrix adjustment) [112]. As of April 2017, this
search space covered a total of 231,827,651,552 bases and 200,877,884 sequences. Domains
were annotated using the hmmsearch command of the HMMER package against the Pfam
database (v31.0, [117]). Genomic architecture visualized using genoPlotR (v0.8.6, [163]) in
R. BoNT sequences representing all major lineages (A-G, F5A, and X) were aligned in a
multiple alignment using ClustalO (v1.2.1, [130]), then pairwise identity between BoNT/En
and the others was calculated in a 50 amino acid sliding window across the length of the
multiple alignment with a step of 1. Regression splines were calculated using the splines
base package in R.
2.1.3 Results
BoNT/En shows 29%-38.7% identity with the other BoNTs and is most closely related to
BoNT/X (Figure 2.1A). All key BoNT motifs are conserved in BoNT/En (Figure 2.1B), in-
cluding the zinc-dependent protease motif HExxH (residues H225-H229) in the LC [52], two
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cysteines that may form an inter-chain disulfide bond (C424 and C438), and a ganglioside-
binding motif SxWY in the HC (residues S1250 to Y1253) [164]).
The gene encoding BoNT/En is located within a typical OrfX gene cluster, preceded
by a gene encoding NTNHA and containing putative orfX2, orfX3, and p47 genes (Figure
2.1C). A gene located 5′ to orfX2 showed a relatively low degree of sequence similarity
to orfX1 and was therefore designated as an orfX1 -like gene. The BoNT/En gene clus-
ter is flanked by a 1,719-bp direct repeat sequence (90.1% nucleotide identity), with two
truncated non-functional copies of a repB gene on each side. This region also contains
a putative phage endolysin, an insertion element (IS204), three putative site-specific re-
combinases, and additional hypothetical genes. There is also a putative Phd-Doc cassette
within this region, an addiction module (a type of toxin-antitoxin system) usually utilized
to maintain mobile elements. The occurrence of direct repeats flanking the pBoNT/En
cluster suggests that this region was acquired by a repUS15 plasmid precursor through
homologous recombination within conserved repB sequences, potentially mediated by as-
sociated putative recombinases. This also suggests that the BoNT/En cluster may be
mobile by additional mechanisms beyond conjugation.
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Figure 2.1: BoNT/En is a unique BoNT serotype. (A) The maximum likelihood phylogeny of full-length
BoNT amino acid sequences demonstrates that BoNT/En forms a distinct lineage, grouping most closely
with BoNT/X. The percentages of protein sequence identity for each BoNT serotype with BoNT/En
are noted. Rapid bootstrap support values are indicated at the base of each group, with the scale bar
representing the number of estimated substitutions per site. (B) A schematic drawing of the domains
of BoNT/En in comparison with BoNT/A. Shared, conserved motifs necessary for BoNT function are
highlighted. The sliding window analysis, which compares segments of 50 amino acids in BoNT/En to
all other BoNT serotypes, demonstrates that BoNT/En is not a mosaic of known toxin serotypes. (C)
BoNT/En is encoded within an OrfX-type gene cluster (blue, with p47 in yellow). As observed in other
BoNT clusters, the cluster is flanked by insertion sequences (dark grey).
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2.1.4 Discussion and Conclusions
BoNT-like gene clusters have not previously been identified in any bacterial species outside
of Clostridium and no toxins of E. faecium have been reported before now. It is discon-
certing to find a member of potent neurotoxins in this widely distributed gut microbe,
which is a leading cause of hospital-acquired infections [157, 161]. The rarity of BoNT/En-
producing E. faecium in strains sequenced so far may reflect its recent acquisition, or may
be due to the relatively limited sampling of clade B strains from wild ecologies. To know
the scope of the natural diversity of genes harbored by enterococci and to monitor the
emergence of new strains, it will be critical to survey the enterococci beyond lineages that
commonly cause infection now. Many important questions remain unknown including the
evolutionary origin of BoNT/En and the host species/cell types targeted by BoNT/En.
Nevertheless, the capability of E. faecium to acquire a BoNT gene cluster could create
emerging strains with severe consequences. Furthermore, the possibility of introducing a
BoNT cluster into MDR E. faecium strains could pose a significant biosecurity threat.
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2.2 Bioinformatic discovery of a toxin family in Chry-
seobacterium piperi with sequence similarity to
botulinum neurotoxins
2.2.1 Introduction
Clostridial neurotoxins (CNTs), including botulinum neurotoxins (BoNTs) and tetanus
neurotoxin (TeNT), respectively, are the causative agents of botulism and tetanus and
are the deadliest known biological toxin family, with LD50 values ranging from 0.1 to
1.0 ng kg−1 [165]. Owing to their extreme toxicity, BoNTs are potential bioterrorism agents,
and yet also have enormous utility as protein therapeutics [166, 100]. BoNTs are produced
by Clostridium botulinum, a polyphyletic taxon classified solely by the presence of the
neurotoxin, and several other species of Clostridium. Neurotoxin genes reside in distinct
gene clusters encoded on the chromosome, plasmids or phages. All BoNTs are neighboured
by genes encoding non-toxic non-hemagglutinin proteins (NTNHs), a homolog of BoNT
that lacks the HExxH motif and forms part of the progenitor toxin complex. There are
currently seven universally accepted, antigenically distinct BoNT serotypes, designated
BoNT/A-G, as well as several recombinant mosaics (C/D, D/C, and F5A). A new BoNT
serotype (BoNT/X) has been recently identified in the genome sequence of C. botulinum
strain 111 [155]. A subtype numeral (e.g. BoNT/A1) is also designated to label a growing
number of divergent sequences within serotypes [167].
The extreme toxicity of BoNT is a consequence of its unique structure and function
(Figure 2.2). BoNTs are initially produced as a single polypeptide chain, which is then
cleaved by bacterial or host proteases to result in a light-chain (LC) and heavy-chain (HC)
which remain linked by a disulfide bond. The HC contains two functional domains: the
N-terminal translocation domain (HN) and the C-terminal receptor-binding domain (HC).
The receptor-binding HC domain can be further divided into two subdomains, consisting of
an N-terminal laminin-like jelly roll fold (HCN) and a C-terminal ricin-type beta-trefoil fold
(HCC). BoNTs recognize motor nerve terminals by targeting neuronal receptors, including
SV2 for BoNT serotypes A/D/E/F, and synaptotagmin I/II for BoNT serotypes B/G/DC,
with polysialogangliosides as co-receptors [168, 169, 68, 170, 69, 70, 171, 172, 173, 174, 175,
176]. After neuronal binding, BoNTs are internalized within endocytic vesicles. At low pH,
the HN, which forms an all alpha-helical bundle structure, transports the partially unfolded
LC into the cytosol. The LC, composed of a ∼400 residue N-terminal zinc metalloprotease
domain, then cleaves intracellular SNARE proteins including VAMPs, SNAP25, and syn-
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Figure 2.2: Botulinum neurotoxin (BoNT) protein and gene structure. (a) BoNTs are composed of
four distinct structural domains (PDB identifier 3BTA). A single BoNT protein is cleaved into a smaller
enzymatic component (the light chain, LC, which encodes a zinc endopeptidase) and larger binding and
translocating component (the heavy chain, HC, which encodes the translocase domain HCN and binding
domains HCC). The receptor-binding domain is further divided into two subdomains, HCN and HCC,
which adopt a laminin G-like beta-sandwich fold and a beta-trefoil fold, respectively. The light chain and
heavy chain are linked by a disulfide bond. (b) The genes encoding BoNT proteins are generally found
in one of two main gene architectures. The bont genes are always located next to a paralogous non-toxic
non-hemagglutinin (ntnh) gene, but the two types are distinguished by their surrounding components,
which consist of hemagglutinin (ha) or orfX genes. Currently, the only known example of altered synteny




Recent work by our research group [99] reported a divergent BoNT homolog in the
genome of Weissella oryzae, which suggested that BoNT-related proteins are not limited
to the genus Clostridium [101]. This hypothesis has been further supported by the re-
cent discovery of BoNT/En, a novel BoNT in Enterococcus faecium strain IDI062 [2, 181],
which was demonstrated to cleave both SNAP25 and VAMP2. The presence of BoNT ho-
mologs in Weissella and Enterococcus raises the intriguing possibility that a larger family
of BoNT-related toxins exists in a broader range of bacterial taxa [1]. These homologs
may include not only toxins with globally conserved domain architectures, but potentially
distant homologs of BoNTs with more divergent domain architectures, sequences and func-
tions [154, 4].
Here we present a large-scale bioinformatic screen for putative toxin genes in all cur-
rently available genomes. Unlike previous studies, we did not limit our searches to the
detection of complete homologs, but also considered detectable similarities involving indi-
vidual BoNT domains to increase the chance of detecting distant homologs. Our analysis
identified hundreds of putative toxins, and revealed a novel toxin family from Chryseobac-
terium piperi [182] that exhibits distant homology to BoNTs and has a similar domain
architecture. We re-sequenced the genome of C. piperi to confirm and further analyze the
genomic context of these toxins, and also examined their potential toxicity by transfection
assays into human cells. These toxins target a yet unknown class of substrates, potentially
reflecting divergence in substrate specificity between the metalloprotease domains of these
toxins and the related metalloprotease domain of clostridial neurotoxins.
2.2.2 Methods
Ethics statement
Experiments were performed in accordance with the procedures approved by the Institu-
tional Animal Care and Use Committee (IACUC) at Boston Children’s Hospital (protocol
#3030). All experiments were performed in BSL-2 laboratory settings.
Detection, comparison, and analysis of bont-like genes
Sequences were retrieved using PSI-BLAST with default parameters (BLOSUM62 scoring
matrix; expect threshold 10; gap open 11; extension 1) from the nr database on (March
26, 2017) [112]. Initial homologs were discovered by searching with BoNT/A1 (NCBI
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accession number ABS38337.1) with up to two rounds of PSI-BLAST. Then, in order
to retrieve all possible sequences from each sequence family, different queries were used to
search for specific BoNT homolog subfamilies (Chryseobacterium: WP_034681281.1, Acti-
nobacteria: Streptomyces sp. NBRC 110027 GAO13068.1, fungal: Metarhizium anisopliae
KFG81441.1) and reiterating to convergence. BoNT homologs identified this way were
added to a set of known BoNT and NTNH proteins representing all known serotypes, in-
cluding the recently discovered BoNT/F5A (KGO15617.1), BoNT/X (KGO12225.1), and
BoNT/En (WP_086311652.1). Sets of M91 peptidases and diphtheria toxins were also
retrieved via PSI-BLAST, with diphtheria toxin (PDB accession number 4AEO.1) and E.
coli NleD (WP_069191536.1) as the original queries. These sets of M91 peptidases and
diphtheria toxins were pruned to remove identical sequences using Jalview [183].
All-by-all sequence pairwise alignments were generated with needle (of the EMBOSS
package, v6.6.0.0; [106]) with default parameters (gap open = 11, gap extend = 1, EBLO-
SUM62 scoring matrix). In Figure 2.3, percent similarity was used over percent identity in
order to allow divergent homologs to cluster more accurately. Principal coordinate analysis
was performed in R on a distance matrix of pairwise similarity values using the default
dist() and cmdscale() functions.
Domains were annotated with hmmscan (v3.1b2, available from http://hmmer.org/)
against the Pfam database v31.0 [117] with an E -value cutoff of 1×10-6. Annotations were
subsequently confirmed by comparison to the Conserved Domain Database with relaxed
cutoffs (v3.16, [184]), and alignment to BoNTs. For Figure 2.3, the BoNT homologs with
the most BoNT-like annotations were depicted to facilitate comparison between categories.
Comparison of proteases from BoNTs, BoNT-like proteins, and M91 peptidases
All BoNT homologs possessing a putative peptidase domain (i.e., possessing an HExxH
motif) were aligned with BoNT and M91 peptidases using Clustal-Omega with defaults
(v1.2.1, [130]), manipulated and colored in Jalview [183]. Only regions corresponding
to the peptidase domain boundaries were used, the positions of which were estimated
based on alignment with domain boundaries of BoNT/A1 (PDB structure 3BTA). The
same alignment procedure was used to identify the putative translocation region of BoNT
homologs (Figure 2.9). After identifying putative domains in BoNT homologs, the segments
were combined and realigned.
A maximum likelihood phylogeny for BoNT, BoNT homolog, and M91 peptidases was
generated using RAxML (v8.2.4, [135]) with automatic model selection and 4 gamma-
distributed rate categories (see simplified cladogram in Figure 2.5, for the full tree see Fig-
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ure 2.6). Bootstrap support was calculated using 1000 rapid bootstraps. The same align-
ment was used to infer a Bayesian phylogeny using MrBayes [185] (with the ML-selected
substitution model VT, 4 gamma-distributed rate categories, and 1,000,000 MCMC sam-
plings; the consensus tree with 25% burn-in is depicted in figure 2.6).
Pairwise global alignments were generated using BoNT/A1 (ABS38337.1) against the
220,362 metallopeptidase sequences available in the MEROPS database (retrieved Feb. 7,
2018) using needle from the EMBOSS package (v6.6.0.0, [183]). The alignment parameters
were as follows: a gap open penalty of 11 and gap extension 1, with the BLOSUM62 sub-
stitution matrix. Raw alignment scores were averaged across peptidase families according
to their MEROPS group, and visualized in R.
Structural modelling of BoNT-like proteins and M91 peptidases
Structural templates were identified for Cp1 (C. piperi, accession WP_034687872.1) using
the LOMETS meta-server [186] on July 18, 2017. Templates (PDB identifiers: 3BTA:A,
1XTG:A, 5BQN:A) were selected based on highest significant threading alignments (nor-
malized Z-scores: 5.12-1.21, identity: 17-21%). Structural modelling and refinement was
done through I-TASSER [187], and the model with the lowest C-score was selected. For
E. coli NleD, structural templates were identified through GeneSilico Metaservers (PDB
identifiers: 1Z7H:A, 1EPW:A, 3BWI:A, 3DEB:A, 3BON:A, 2QN0:A, 2A97:A, 3DDA:A,
1XTG:A, 1ZB7:A, 1F0L:A, 3FFZ:A, 1YVG:A, 2FPQ:A, 2G7K, 5BQN:A, 2NYY:A, 1T3C:A,
3V0A:A, 3FIE:A, 1RM8:A, 1E1H:A, 3VUO:A, 2A8A:A, 3D3X:A, 3DSE:A) were selected
from COMA (score ≤ 5.4×10-7, identity: 19%), HHblits (score: 100, identity: 13-20%),
and HHsearch (score: 96.3, identity: 13-19%) on July 15, 2017. Structural modelling was
carried out through PRIMO’s pipeline [188]. Identified template sequences were aligned to
M91 with T-Coffee Expresso [189], which uses 3D-Coffee to incorporate structural informa-
tion during alignment. A total of 20 homology models were created with slow refinement
based on the resulting alignment using MODELLER [190]. The model with the lowest
DOPE Z-score was selected. Structural quality was assessed with Ramachandran plot
analysis using PROCHECK [191]. Models were visualized using Chimera [192].
Re-sequencing and annotation of the Chryseobacterium piperi genome
Methods, materials, and platforms used in the sequencing and assembly of C. piperi are de-
scribed in Wentz et al. [182]. The closed genome is accessible at the DDBJ/ENA/Genbank
under the accession number CP023049. MiSeq and RS-II reads utilized in assembly are
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available at NCBI SRA under accessions SRX3229522, SRX3231351, SRX3231352. Figure
2.9 was generated using the program Circos [193].
HEK 293T cell transfection and cell number counting
HEK 293T cells were dispensed on 24-well plate at the density of approximately 0.2 ×
106 cells/well. After 24 h, cells were transfected with 0.5 µg vehicle vector (pcDNA3.1(+)),
Cp1-LCWT(1-398 aa), Cp1-LC H209A and Cp1-LC E210Q plasmids with PolyJet reagent.
Pictures were taken 48 hours after transfection. Cell numbers were counted and combined
from three different pictures.
HEK 293T cell death assay
HEK 293T cells were dispensed on 60 mm dish at the density of 2.5 × 106 cells/dish.
Cells were transfected with 2.5 µg vehicle vector (pcDNA3.1(+)), Cp1-LC WT, Cp1-LC
H209A and Cp1-LC E210Q plasmids by using 5 µL PolyJet. Cells were harvested 24 hrs
after transfection and washed with cold phosphate-buffered saline (PBS). Cell density was
adjusted to 1 × 106 cells/mL. Hoechst 33342, YO-PRO-1 and propidium iodide stock
solution (1 µL Invitrogen) were added into 1mL cell suspension. Cells were incubated on
ice for 20-30 min. Stained cells were analyzed by flow cytometry (BD/Cytek FACSCalibur
DxP 11). UV excitation was used for detection of 460 nm emission of Hoechst 33342 dye,
488 nm excitation was used for detection of the 530 nm emission of YO-PRO-1 dye, and
575 nm emission of propidium iodide. Cell populations separated into three groups: live
cells showed low levels of blue fluorescence, apoptotic cells showed bright green and blue
fluorescence, and necrotic cells showed bright red fluorescence.
Cleavage of SNARE proteins by Cp1-LCs
HEK293T cells were dispensed on 24-well plate at the density of 0.3 × 106 cells/well. 24 h
later, cells in a single well were transfected with 0.5 µg vehicle vector (pcDNA3.1(+)), Cp1-
LC WT (1-398 aa), Cp1-LC H209A, Cp1-LC E210Q, together with syntaxin 1, SNAP25,
VAMP2 in pEGFP-C1 as indicated in Figure 2.10. Cells were harvested 48 hours after
transfection and lysed in RIPA buffer (50mm Tris, 1% NP40, 150mm NaCl, 0.5% sodium
deoxycholate, 0.1% SDS, 400mL per 10 cm dish) plus protease inhibitors. Cleavage assay
was conducted by mixing cell lysates of vehicle vector, Cp1-LC WT, Cp1-LC H209A, Cp1-
LC E210Q and GFP fused syntaxin 1, SNAP25, VAMP2 respectively and incubating the
mixtures at 37 ◦C for 30 minutes. Samples were analyzed by immunoblot.
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2.2.3 Results
Genomic data mining uncovers proteins with BoNT-like domains
We screened the NCBI GenBank database (March 26, 2017) comprised of 94,396 prokary-
otic, 4,123 eukaryotic, and 7,178 viral genomes, for potential homologs of BoNTs over one
or more domains. Using PSI-BLAST with selected BoNT sequence queries (see Meth-
ods), we detected a total of 311 protein sequences displaying at least partial homology to
BoNTs with an E -value below 0.001 (see table in Appendix A A.2). The data set includes
all known BoNT serotypes, and an additional 161 predicted toxin sequences, all of which
are experimentally uncharacterized to date. We performed all-by-all pairwise alignments
and clustered the toxins using principal coordinates analysis (PCoA). The toxins clustered
largely into three main groups, which differ in domain composition and detectable simi-
larities to BoNTs (Figure 2.3). Group I includes a large family of ADP-ribosyltransferase
toxins, including diphtheria toxin-like sequences [5] and putative ADP-ribosyltransferase
toxins (ADPRTs) from entomopathogenic fungi (Table S1). These sequences possess par-
tial similarity only to the BoNT translocation domain (17.3% maximum sequence identity,
PSI-BLAST E -value = 7×10-40). Group II is formed by M91 family peptidases such as the
Escherichia coli type III effector toxin NleD, which cleaves host JNK and p38 [194]. These
sequences possess remote detectable homology to the BoNT-LC with 14.9% maximum
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Figure 2.3 (previous page): Bioinformatic detection of bont-related genes in microbial genomes. (a)
PCoA ordination of pairwise percent similarities reveals groups of sequence subfamilies with partial similar-
ities to BoNTs. A large family of ADP-ribosyltransferase toxins (grey), which includes diphtheria toxin-like
proteins and a large family of predicted toxins from entomopathogenic fungi, possess similarity only over
the translocase domain (cluster I). M91 peptidases have similarity to the BoNT LC and group separately
(white; cluster II). BoNT and NTNH form distinct groups with more divergent relatives (red to orange;
cluster III). Within cluster III, BoNT-related sequences possess the following characteristics, in order of
decreasing similarity to BoNT: the Weissella BoNT-like protein displays evidence for all BoNT domains;
the Chryseobacterium sequences have strong similarity in the LC, HN, and HCC domains; two genes in
Mycobacterium chelonae encode separate LC-like peptidase and HC-like HN/HCC domains; Actinobacte-
ria spp. sequences are similar only within the LC and HN domains. (b) InterPro domain predictions
for Chryseobacterium piperi BoNT-like protein Cp1 (WP_034687872.1), reveals a similar predicted archi-
tecture to BoNT. Its translocase-like domain is annotated as diphtheria-like, and contains two predicted
transmembrane helices. (c) Comparison of BoNT/A1 peptidase domain to C. piperi putative peptidases
and proteases in the MEROPS database. Except for peptidase M27 (not pictured), the peptidases from
Chryseobacterium produce the highest-scoring global alignments, followed by peptidase M91. Both C.
piperi peptidases and M91 peptidases score higher than all other known peptidase families.
Group III contains BoNTs, NTNHs, the Weissella toxin and several uncharacterized
proteins (Figure 2.3) that share multiple domains in common with BoNTs (Figure 2.4)
and are therefore of considerable interest [1, 147]. Among the uncharacterized proteins
are nine partial and full-length homologs from the genome of Chryseobacterium piperi, two
from Mycobacterium chelonae, and five from other Actinobacteria. Several of these organ-
isms are associated with disease; some Chryseobacterium species are known opportunistic
pathogens [195, 196], Acaricomes phytoseiuli is a pathogen of mites [197], and Mycobac-
terium chelonae is a human pathogen associated with skin, soft tissue, and bone infections
[198]. We termed these proteins “divergent BoNT homologs” given their distant but signif-
icant detectable evolutionary relationship to BoNTs (Fig. 1a 2.3) and similarity of domain
architecture (Fig. 1b 2.3). As shown for a representative protein from this group (putative
Chryseobacterium toxin, “Cp1”, NCBI accession number WP_034687872.1), these proteins
are predicted by InterProScan [125] to contain a BoNT-like three domain architecture com-
posed of a metalloprotease domain, central translocation domain and a C-terminal ricin-
type beta-trefoil domain (Figure 2.3), each of which are analyzed in greater detail below.
Cp1 for example possesses detectable homology to BoNTs spanning multiple domains (Fig-
ure 2.4), but has low sequence identity (17% identity between Cp1 and BoNT/A compared
to >=28% identity between BoNT family members) indicative of a distant evolutionary
relationship.
To further confirm this detected relationship, we compared BoNT/A1-LC to the C.
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Figure 2.4: Pairwise local alignment and associated E -value between BoNT/A1 and Chryseobacterium
toxin computed using lalign/plalign from the FASTA package. The alignment shown in (a) was generated
using a PAM250 scoring matrix, which was selected since it models remote relationships with sequence
identities of ∼20%. The pairwise alignment spans multiple domains of BoNTs including the BoNT LC
peptidase (red), translocation domain (green) and binding domain (with subdomains blue and cyan). (b)
Domain structure predicted by Phyre version 2.0.
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MEROPS database [199], consisting of 220,362 sequences from 102 families (Figure 2.3).
Based on alignment scores, the C. piperi toxins displayed stronger similarities to BoNT-LC
than to all other known protease families, and the M91 protease family ranked second.
Chryseobacterium toxins are a novel toxin family distinct from but related to
BoNTs
Next, the alignment of protease domains from BoNTs and the divergent BoNT homologs
was analyzed further perform sequence, structural, and phylogenetic analysis (Figure 2.5).
Phylogenetically, BoNT-LCs grouped into a distinct clade, with BoNT/X and BoNT/En
forming divergent early branching lineages (Figure 2.6). The BoNT clade is outgrouped
by lineages consisting of the predicted toxins from Weissella, Chryseobacterium, and My-
cobacterium, although the precise branch order is difficult to resolve with the available
data. Nonetheless, the BoNTs together with the Weissella, Mycobacterium, and Chry-
seobacterium toxins form a distinct clade from the peptidase M91 group with high statisti-
cal confidence (83% maximum likelihood bootstrap support and 100% Bayesian posterior
probability) (Figure 2.5 and Figure 2.6). Protease domains from the actinobacterial tox-
ins group more distantly, and the clade of distantly related M91 family proteases forms
a lineage distinct from BoNTs and the divergent BoNT homologs (Figure 2.5). Despite
some variable segments and low sequence identity (BoNTA1/Cp1: 17.6%), the protease
domains from C. piperi and other divergent BoNT homologs possess detectable homology
to the BoNT-LC (bl2seq E -value = 2×10-6 between Cp1 and BoNT/A1) and conserve
key functional residues found in BoNTs (Figure 2.5). These residues include: the critical
HExxH zinc-coordinating active site motif; the third zinc ligand Glu-261; the functionally
important Glu-350 which shapes active site fine structure, the active site stabilizing motif
R363-x-x-Tyr366 [200], and the cysteine residues that form the disulfide bridge between
BoNT LC and HC [201] (Figure 2.5).
Consistent with phylogenetic analysis, the predicted structure of the protease domain of
C. piperi toxin is most similar to BoNT-LC (7.0 Å RMSD versus 12.0 Å for E. coli NleD;
both models based on BoNT template structures) (Figure 2.5). Although experimental
structure determination is required to confirm these models, several obvious structural
differences can be inferred based on the models and sequence alignments. One insertion is
common to BoNT-LCs and the divergent BoNT homologs, and absent in NleD and other
M91 peptidases (Figure 2.5), which makes extensive contacts with SNAP25 (51 inter-
residue contacts <2 Å) and VAMP2 (91 inter-residue contacts <2 Å) in BoNT co-crystal
complexes (Figure 2.7). This insertion may therefore have contributed to an ancestral shift















































































































































































































































































































































































































































































































































































































Figure 2.5: Comparison of the BoNT-LC with homologous domains from BoNT-like toxins and M91 family proteases.
(a) Phylogenetically, the peptidases of BoNT and BoNT homologs group separately from distantly related peptidase M91
sequences. Statistical support for the tree is indicated as maximum likelihood bootstrap value and Bayesian posterior
probability (percentage). Structural comparison of BoNT/A (iii; PDB 1XTG) with homology models of Chryseobacterium
Cp1 (ii) and E. coli NleD (i) reveals two regions that are unique to BoNTs and BoNT-like proteins: the lower alpha-helical
region, which interacts directly with SNARE substrates, and the C-terminal region that plays a role in catalytic product
removal. (b) M91 peptidases (i), divergent BoNT homologs (ii), and BoNT-LCs (iii) have conserved features. These include
the HExxH zinc-coordinating and catalytic residues, the zinc ligand E261, the active site-refining E350, and RxxY motif. The
cartoon of the multiple alignment above reveals two regions unique to BoNTs and divergent BoNT homologs, shown in teal and
purple respectively. The identities of proteins labeled 1-14 are: 1 - WP_037712107.1, Streptomyces sp. AA4; 2 - EFL04418.1,
Streptomyces sp. AA4; 3 - WP_083906476.1, Acaricomes phytoseiuli ; 4 - GAO13068.1, Streptomyces sp. NBRC_110027,
5 - WP_055473237.1, Streptomyces pathocidini; 6 - WP_070931163.1, Mycobacterium chelonae; 7 - WP_034681281.1,
Chryseobacterium piperi ; 8 - WP_034687877.1, Chyrseobacterium piperi ; 9 - WP_034687193.1, Chryseobacterium piperi ; 10
- WP_034687872.1, Chryseobacterium piperi ; 11 - WP_027699549.1, Weissella oryzae; 12 - WP_086311652.1, Enterococcus
BoNT/En; 13 - BAQ12790.1, BoNT/X; 14 - ABS38337.1, BoNT/A1.
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Figure 2.6: Maximum likelihood and Bayesian consensus phylogenies of peptidase amino acid sequences
from BoNT, distant BoNT homologs, and M91 peptidases. In both the maximum likelihood (a) and
Bayesian (b) phylogenies, the peptidase M91 sequences form a monophyletic group (red) distinct from
the BoNTs and BoNT homologs (various colours). Although the branch order differs between the two
methods, the grouping of BoNT with BoNT homologs from Weissella (cyan), Chryseobacterium (green),
and Mycobacterium (light grey) is well-supported. The differences in branch order may be related to long
branch attraction, since the sampling of some lineages is low, and so are BoNT to BoNT homolog percent
identities. However, in both trees, the distant BoNT homologs from phylum Actinobacteria are basal to the
group of BoNT and other BoNT-like sequences. The ML phylogeny was generated using RAxML (v8.2.4)
with 1000 rapid bootstraps, and the Bayesian tree with 1,000,000 MCMC generations using MrBayes
(v3.2.4). Support values values are indicated at each node (bootstrap values for maximum likelihood
and posterior probability percentage for Bayesian), and branch lengths represent estimated numbers of
substitutions per site.
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Figure 2.7: Structural visualization of BoNT-LC specific insertions. The two insertion regions identified
by comparing the BoNT LC to peptidases from distant BoNT homologs and peptidase M91 sequences
(dark green) share extensive contacts (black lines) with VAMP-2 (red) and SNAP25 (tan) in co-crystal
complexes with BoNT/F (PDB identifier 3FIE) and BoNT/A (PDB identifier 1XTG).
insertion common to BoNT-LC and the divergent BoNT homologs (Figure 2.5) forms part
of the hydrophobic SNAP25 binding pocket [202], and has been shown to mediate catalytic
activity and product removal [203]. Lastly, a region corresponding to the “belt” region
present in BoNTs was identified in C. piperi toxins based on multiple sequence alignment,
but this region did not display significant sequence similarity to BoNT, suggesting that it
is highly divergent or unrelated.
In addition to conservation in the peptidase domain, the divergent BoNT homologs from
Chryseobacterium and other species possess significant similarity to the BoNT transloca-
tion domain (22% identity, bl2seq E -value <1×10-5), particularly across the region 593-686
in BoNT/A1 (Figure 2.8). This region has been suggested to form a channel-forming am-
phipathic alpha helical motif that assists in translocation [204, 205, 206]. Unexpectedly,
BLAST searches of this region also detected a segment of the diphtheria toxin (DT) translo-
cation domain (residues 286-325, helices TH5-TH6/TH7, PDB identifier 4AE0) [207],
which was consistent with structural predictions for this region made by PHYRE (Fig-
ure 2.4). Sequence alignment revealed a common region of sequence similarity flanking a
motif ([K/R]x(8)PxxG) within the translocation domains of the divergent BoNT homologs,
BoNT, and DT (Figure 2.8). Although the functional significance of this shared motif is
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unclear, the detectable similarity to both BoNT and DT translocation domains strongly
suggests a translocation-related function for this region in Cp1 and other divergent BoNT
homologs.
Lastly, following the translocation domain, the divergent BoNT homologs possess a
receptor-binding domain that is predicted to adopt the same fold as the BoNT HCC sub-
domain (Figure 2.3 and Figure 2.4). A ricin-type beta-trefoil fold was predicted for the
C-terminal region of the putative C. piperi toxins by three separate methods (HHpred,
Pfam, and Phyre with E -values <0.001). The beta-trefoil domains from C. piperi toxins
exhibited at most 17% sequence similarity to the HCC in BoNT; therefore, the extent to
which they are homologous is unclear at this point. Interestingly, a ricin-type beta-trefoil
domain from the C. botulinum hemagglutinin, HA33, was identified as the top template by
PHYRE (2.4), indicating that if this domain is not related to the HCC in BoNT, it may be
homologous to other ricin-type beta-trefoils that are encoded within BoNT gene clusters.
Genome resequencing of C. piperi confirms presence of toxin gene clusters
The putative C. piperi toxins are located on three separate contigs (2, 44, and 59) in the
original draft C. piperi genome (NCBI accession JPRJ01, 89 total contigs). To verify a
C. piperi origin for these contigs, determine extrachromosomal content, and enable fur-
ther genome-wide analysis, C. piperi was acquired from ATCC and sequenced on Illumina
MiSeq and Pacific Biosciences RS-II sequencing platforms. A closed genome 4.5 Mbp in
length, 35.3% GC content, and 250X coverage was produced and analysed (Figure 2.9).
No plasmids were observed. The assembly revealed a toxin gene cluster (GC1) located
at 1399-1432 kbp which contains the Cp1 gene as well as 6 other genes with detectable
similarity to BoNTs and an alternating pattern of presence/absence of the HExxH motif
(Figure 2.9 and Table A.2). A second toxin gene cluster (GC2) is located at 3,287-3,312
kbp containing two additional genes with detectable similarity to BoNTs (Figure 2.9). The
genes located in this region have similarity to BoNT over different regions, and may con-
tain or lack the catalytic HExxH motif. Similar to bont gene clusters, HExxH-positive
homologs in C. piperi are flanked by genes that also possess detectable partial homology
to BoNTs, but lack the active site motif. The paralogous nature and genomic arrangement
of these gene pairs resemble that of ntnh and bont, which raises the possibility that the
HExxH-negative genes may play a similar role to ntnh in bont gene clusters. Further, these
HExxH-negative proteins uniquely contain an IBC1 (“Isoprenoid_Biosyn_C1 super fam-
ily”) domain at the N-terminus similar to class I terpene-synthases, whose role is unclear.































































GVTSNRSPLAVVTFTQAQAGPLARNPIYQATHSAGWGAAVGANLVGAPEQTAVFVI TSEDNDS PKENKTA DGANLTDEKATATGAVTATLASVI VILPGLI GQSAVVLMGI ANDGIAKEV KHPEHDNIGT
N 1












































LFYVIALVQESGNMWSLIVARQGEKNSGEDQLIVLIVYVNKDREDLFYVSTSNIDTLNESTIA SKGNMTLERQKTSIVK NSDVITTMFDVILQDIKVSLKI KDASDTLIVTMLSVSLIAVI LVI PFYYVI CGALPYLAKLNLVI SGDNMDSELTIAVYQLAR HARKQDEGKHDNYF
N 1






























































































































































































































































































































































































































VPIFGV IDALVSKGHECQDFIGLATIMLVQGVEALI VIGSLATSAEDNESDAGELAI VEQIDNR QNLRKHSRHEKGRNDWTIFYAP
N




Figure 2.8: Translocase similarity between BoNTs, BoNT-like toxins and diphtheria toxins. A subdomain
of BoNT translocases contains significant similarity to diphtheria T domains (DT in the above) as well as
the translocase region of BoNT-like toxins. One segment of similarity (I) corresponds to the transmembrane
TH5 helix in diphtheria toxins and a loop in BoNTs. A second region (II), including a K(x)8PxxG motif,






























































































Figure 2.9: BoNT-like toxins reside within two toxin gene clusters in the genome of Chryseobacterium
piperi. (a) Re-sequencing with a combination of Illumina and PacBio resulted in a closed genome with
a single circular chromosome. Yellow bands reflect the local alignment of the toxin containing con-
tigs (shown in b and c) from the initial JPRJ01 assembly against an intermediate assembly (black),
and the closed genome (CP023049). Annotated insertion sequences (red ticks), SRX3229522 read map-
ping to CP023049 (gray histogram), and GC skew (blue/red histogram) are also indicated. The closed
genome contains two separate toxin gene clusters (shown in b and c). The chromosomal loci that con-
tain the toxin gene clusters have several notable features. First, there is evidence of gene duplication
and pseudogenization among toxin genes, including an apparent split of a BoNT-like gene homolog into
two genes, consisting of an HExxH-positive peptidase domain (CJF12_06315) and a “heavy chain” cod-
ing sequence containing a diphtheria-like translocase and a C-terminal ricin-type beta trefoil domains
(CJF12_06305). Genes neighbouring the toxin gene cluster include putative response regulator genes
(e.g., CJF12_06360, CJF12_06365, CJF12_06370, CJF12_06375), and several different types of trans-
posases (e.g., CJF12_06285, CJF12_06290, CJF12_14525, CJF12_14555, CJF12_14620). These genes
may potentially have a role in the expression or lateral transfer of these toxin gene clusters. Full gene
annotations for the clusters are available in Table A.2.
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Several genomic features surrounding the C. piperi toxin gene clusters indicate an ori-
gin via mobile element insertion. First, homologous regions to GC1 and GC2 were not de-
tected in any other available Chryseobacterium genomes, suggesting non-Chryseobacterium
origins. Second, numerous transposases are present including two IS110 family trans-
posases, a IS200/IS605 transposase 18-40 kbp upstream (CJF12_06430, CJF12_06460,
CJF12_06500), and an IS1182 family transposase (CJF12_05985) 30 kbp downstream of
GC1. IS110 transposases have been previously shown to flank other bont gene clusters [151].
A disrupted IS982 family transposase pseudogene (CJF12_14555) is located immediately
upstream of CJF12_14550 and flanking GC2 are complete and partial IS1595 family, IS-
Chpi, insertion sequences (CJF12_14525 and CJF12_14620). Third, genes neighbouring
Chryseobacterium toxin gene clusters were found to possess homology to genes in M. che-
lonae (e.g., the closest homolog of CJF12_14560 was M. chelonae WP_064393402.1, with
71% amino acid identity), consistent with the detected similarity between the C. piperi
toxins and M. chelonae genes (Figure 2.5).
C. piperi toxin is a novel metalloprotease toxin that induces necrotic cell death
Given the substantial sequence variation between predicted C. piperi toxins, we selected
WP_034687872 (Cp1) for experimental characterization based on it having the greatest
sequence similarity to BoNTs among the C. piperi toxins over catalytic and functional
sites (around 35% amino acid similarity). Initial protease assays of recombinant Cp1-LC
against known BoNT substrates, including syntaxin 1, VAMP2, and SNAP25, yielded neg-
ative results (Figure 2.10). Although Cp1-LC did not display activity against canonical
BoNT targets, the conservation of the active site residues and similarity to M27 and M91
metallopeptidases suggested the possibility of other targets. We elected to test for broad,
metallopeptidase-induced toxicity via transfection and subsequent expression of the Cp1
LC cDNA in human embryonic kidney HEK293T cell line. Two Cp1-LC mutants contain-
ing point mutations at the HExxH motif (H209A and E210Q), were utilized as negative
controls.
As shown in 2.11, the expression of wild-type Cp1-LC resulted in a cell death phenotype
in HEK293T cells. These cells stopped proliferating and were visibly shrunken, eventually
dying and detaching from culture plates. Cell counts after 48 hours revealed an almost
4-fold reduction in the number of cells (Figure 2.11). No cell death phenotype or significant
reduction in cell number was observed in the H209A and E210Q mutants, confirming that
the observed toxicity is likely metalloprotease-dependant. To further confirm the effect
of Cp1-LC, we performed cell apoptosis assays by flow cytometry using Hoechst 33342,




































































Figure 2.10: Cp1 does does not cleave canonical BoNT substrates. HEK293T cells were transfected
with vehicle vector, Cp1-WT, and two Cp1 mutants that abolish metalloprotease activity (H209A and
E210Q), and separately with plasmids containing syntaxin, SNAP25, and VAMP2. Cells were then lysed
in RIPA buffer, and cleavage of SNARE proteins was evaluated by mixing lysates from SNARE-producing
cells with vehicle, Cp1-WT and Cp1 mutant strains, followed by incubation at 37 ◦C for 30 minutes. The
samples were then analyzed by immunoblot with anti-syntaxin 1, SNAP-25 and VAMP2 antibodies; Cp1
proteins were blotted with anti-FLAG antibody. Actin served as control for equal sample loading.
(green), and dead cells (bright red and some green) are visualized by fluorescence. The
percentage of necrotic death was much higher in cells transfected with Cp1-LC than in
cells transfected with control plasmid, H209A, or E210Q mutants (greater than 10-fold
increase). In contrast, the percentage of cells labeled as apoptotic death did not change
appreciably. These results suggest that expression of Cp1-LC leads to necrotic death of
cells, and that the cell death depends on the protease activity of Cp1-LC, although the
specific target(s) of Cp1-LC remains unknown at this point.
2.2.4 Discussion and Conclusions
Our survey of existing bacterial genomes reveals a diverse set of BoNT-related proteins out-
side of Clostridium such as those present in Chryseobacterium spp., a genus that includes
pathogens of non-human hosts. Compared to the recently discovered BoNT in Entero-
coccus faecium (BoNT/En, ∼29% overall sequence identity to BoNTs across full length
sequence) and the BoNT homolog in Weissella oryzae (∼20% overall identity to BoNTs),
the Chryseobacterium BoNT-like toxins are more distantly related to BoNTs (∼15% over-
all identity to BoNTs). This is supported by sequence and phylogenetic analysis of the
light chain, which demonstrates that the homologs from C. piperi and other species cluster
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Figure 2.11: Expression of Cp1-LC in HEK 293T cell caused cell death, which is metalloprotease activity
dependent. (a) HEK 293T cells were transfected with vehicle vector (pcDNA3.1(+)), Cp1-LC WT, and
two mutants (H209A, E210Q) which abolished metalloprotease activity. Cells were observed and images
were taken under inverted microscopy after 48 hrs. Cells transfected with Cp1-LC WT showed a dramatic
cell death phenotype, becoming shrunken and detaching from the plate. Cells transfected with vehicle
vector and protease activity-abolishing point mutants were not affected. (b) Cell numbers were counted in
defined field of images taken in (a). The number of cells transfected with Cp1-LC WT were dramatically
reduced compared to other treated cells. (c) Cell apoptosis assay was carried out with Chromatin Conden-
sation/Membrane Permeability/ Dead cell Apoptosis kit. Transfected cells with vehicle vector, Cp1-LC
WT and mutant plasmids were analyzed by flow cytometry. Transfection with the Cp1-LC WT plasmid
increased the necrotic population of HEK 293 T cells, which is not observed in cells transfected with the
vehicle vector or Cp1 point mutants.
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present in the BoNT family that are lacking in C. piperi ; specifically, the C. piperi toxins
have weaker alignments to the translocation domain, lack the belt region, lack a detectable
LamG-like HCN subdomain present in the BoNT family, and lack the toxin accessory genes
neighbouring the proteolytic toxin gene (including NTNH, and HA or P47/OrfX proteins).
These trait differences suggest that, if BoNTs and C. piperi toxins do indeed share common
ancestry, one of two scenarios have taken place: either the divergent BoNT homologs have
lost some of these key BoNT features, or alternatively, these features emerged along with
the BoNT lineage and may have differentiated BoNTs from their evolutionary relatives.
Although one cannot distinguish between these two scenarios conclusively, we postulate
that the latter scenario is more likely given the increased taxonomic and sequence diversity
observed in the divergent BoNT-like toxin lineages.
The cytotoxic activity of C. piperi toxin in HEK293 cells, combined with the lack of pro-
tease activity against common BoNT substrates, suggests that the C. piperi toxin may have
different targets in human cells. Given the degree of sequence and structural conservation
observed between the protease domains of C. piperi toxins and BoNT-LC, it is tempting
to speculate that C. piperi toxins may target different proteins with characteristics similar
to SNAREs such as coiled-coil motifs. The future identification of the substrates targeted
by Chryseobacterium toxin, Weissella toxin and others, combined with determination of
their structure, will be important for not only illuminating the function and mechanism of
these new toxins, but understanding the evolutionary novelties that occurred within the
BoNT LC responsible for its gain of activity against neuronal SNAREs. Further, it will be
important to explore the functionality of full-length Cp toxins and to determine whether
they are expressed in their native host organism. Finally, if the protease domains of BoNT-
related toxins have altered specificity to BoNT-LC, this may have significant biomedical
and biotechnology applications through the engineering of BoNT-derived therapeutics that
target different cell types.
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2.3 Genomic insights into the evolution and ecology of
botulinum neurotoxins
2.3.1 Introduction
Clostridial neurotoxins (CNTs) include both botulinum neurotoxins (BoNTs) and tetanus
neurotoxin (TeNT). Various bont gene types exist, and can be classified into seven distinct
serotypes (plus TeNT) based on their serological properties, designated by the letters A-
G. Each serotype contains subtypes designated with roman numerals (e.g. BoNT/A1)
[167]. Several clearly identifiable recombination events have resulted in mosaic toxins
comprised of more than one serotype, as in the C and D clades (termed C/D and D/C,
based on which serotype represents a greater proportion of the sequence), as well as an F5/A
hybrid [151, 208]. CNTs are found in various Clostridium spp. and Clostridium tetani.
Clostridium species are Gram-positive spore-forming anaerobes and are ubiquitous in the
environment (e.g. soil, water and sediments), but can also be found in the gastrointestinal
microbiota of humans, animals and other species. CNTs and clostridia have undergone
a separate evolution, with clostridia forming an ancient class of bacteria with a complex
phylogenetic history, and CNTs emerging more recently in a subset of clostridial lineages.
Genes encoding BoNT proteins are found in the species C. botulinum, C. argentinense, C.
sporogenes, C. baratii and C. butyricum, although the species C. botulinum is polyphyletic,
and not all strains of these species are neurotoxigenic [209, 210, 88]. Consistent with the
mobility evidenced by their scattered phyletic distribution in Clostridium, bont genes can
be encoded on the chromosome, plasmids or phages. They are found within characteristic
gene clusters, typically flanked by genes that enhance mobility, such as transposases and
insertion sequence elements [211, 212, 213, 214, 88]. TeNT is encoded on a virulence
plasmid of C. tetani of variable composition, but all contain the tetanus regulator tetR
and a collagenase gene [215].
BoNTs are the most potent known toxins, and have evolved a unique and complex
mechanism of toxicity. BoNT is composed of an N-terminal zinc metalloprotease domain
(the light chain) which is disulfide linked to a heavy chain composed of a translocation do-
main and two binding domains. The mechanism of action involves entry into a host (e.g.
mammal, bird or fish) through a wound or absorption through the gut, circulation of the
toxin through the bloodstream and lymphatic system, binding to receptors on the presy-
naptic membrane of neuromuscular junctions, delivery into neurons by receptor-mediated
endocytosis, pH-mediated translocation into the cytoplasm and cleavage of intracellular
SNARE proteins, thereby inhibiting neurotransmitter release and ultimately leading to
flaccid paralysis.
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Aiding BoNTs are additional neurotoxin-associated proteins (NAPs) which are encoded
within bont gene clusters. These include an immediate downstream non-toxic paralog (non-
toxic non-hemagglutinin, or NTNH), as well as either hemagglutinin (ha) genes (encoding
HA proteins) or orfX genes (encoding OrfX proteins), dividing the gene clusters into two
main types. Strains may possess one or more toxin gene clusters, which may be the same
or different toxin cluster types. NTNH and the three HA proteins form complexes that
associate with BoNT, and these complexes protect the toxin in the gut environment and
mediate attachment to the gut epithelium via E-cadherin [148]. There is some evidence
for additional roles for the “nontoxic” NAP complex [216].
Although much work has been done to elucidate these properties and other mechanistic
details of the CNTs, the evolutionary history of the CNT protein family remains mostly
unknown. Here, we synthesize the information about the evolution of BoNTs based on the
available literature in combination with an analysis of recently described BoNT-related
sequences derived from microbial genomes. Together, these data provide insights into how
the CNT family may have originated and diversified, and at the same time highlights some
of the outstanding questions in the evolution of CNTs. Finally, we propose potential future
directions and hypotheses for additional explorations of CNT evolution.
2.3.2 Methods
Data sources
A data set representing known BoNT subtype amino acid sequences was collected, a list
of which is available from Peck et al. [167], with the addition of BoNT/X, BoNT/En,
and the BoNT-like sequences from Weissella (NCBI accession number WP_027699549.1)
and Chryseobacterium (WP_034687872.1). A list of accession numbers used is available
in Table A.3.
Phylogenetic analysis
Full-length BoNT sequences were aligned using Clustal Omega version 1.2.1 [130] with
default parameters. A maximum-likelihood BoNT phylogeny was generated using RAxML
version 8.2.4 [135] with automatic substitution model selection and four gamma-distributed
rate heterogeneity categories, with 1000 rapid bootstraps. For Figure 2.12, the tree was
midpoint rooted and visualized using FigTree (available from http://tree.bio.ed.ac.
uk/software/figtree/). The features mapped on the tree were determined from a num-
ber of sources, available in Table A.3.
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2.3.3 Results
Where did BoNTs come from?
Although there is considerable knowledge on the BoNT mode of action (see Rossetto,
Pirazzini and Montecucco 2014 [142] and Pirazzini et al. 2017 [100] for recent reviews), the
physiological benefit of bont genes to their bacterial hosts is less clear. The BoNT protein
does not appear to provide an obvious fitness benefit to its producer, nor is it essential
for survival [217, 154]. With this in mind, how and why did such a toxin evolve? This
fundamental question about the origins of botulism and tetanus has been a mystery since
these toxins were first discovered over a century ago. The origins of BoNTs have been
elusive for several reasons, but the most important is that, prior to a few years ago, there
were no known evolutionary relationships between BoNTs and other protein families that
could shed light on their ancestry.
In a 2006 paper, B.R. DasGupta speculated on the evolutionary origins of these toxins,
suggesting that their ancestors were not found within the genus Clostridium, but instead
were ultimately derived from viral polyproteins. This hypothesis was based on several
pieces of evidence, including the independent action of different domains within the toxin,
the observation that viral metalloproteases also known to cleave cellular proteins, and the
conceivable notion of viruses as quintessential vectors for the transfer of foreign DNA into
a host genome. It was also suggested that there is no reason that such toxins should
necessarily be limited to cleaving SNARE proteins from vertebrates, and that the toxin
family may be far more ancient.
Roughly a decade later, our research group provided evidence for DasGupta’s hypothesis
by identifying a distant, but clearly related, homolog of BoNTs in the genome outside of
the Clostridium genus [99]. This protein, encoded within the genome of an organism
called Weissella oryzae SG25, possesses all the properties that are expected of a divergent
homolog: remote sequence similarity but with detectable homology, conserved domain
architecture, and conserved active sites and functional motifs. Follow-up work by Zornetta
et al. [101] then confirmed the W. oryzae BoNT-like toxin to possess similar activity to
BoNTs by cleaving VAMP2, but interestingly, at a unique W-W bond unlike any other
BoNTs. Whether this protein is truly a neurotoxin, however, remains unknown, as does
its preferred host or even cell type. Why such a toxin exists within Weissella, a lactic-acid
fermenting species isolated from the grains of Japanese rice, is also unclear. Regardless
of these uncertainties, the Weissella homolog provided an indication that there may exist
a larger family of divergent BoNT-like toxins in non-clostridial species that could provide
insights into their ancestry and evolution.
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Following the discovery of the W. oryzae bont-like gene, numerous additional BoNT-
like toxins have now been identified by genomic data mining methods. First, a novel
BoNT-like protein in C. botulinum str. 111, nominally named BoNT/X, was shown to
result in botulism-like flaccid paralysis when injected into mice [155]. This activity was
caused by catalytic cleavage of VAMP, a canonical BoNT target, which was cleaved at
a novel site. Furthermore, Zhang et al. recently identified and characterized a BoNT-
like toxin in Enterococcus faecium str. DIV0629 [2]. This Enterococcus BoNT-like gene,
“BoNT/En”, possesses all the hallmarks of a BoNT: the presence of all BoNT domains
and key functional motifs, and is located within an orfX -like gene cluster. Injection of
the full-length BoNT/En protein into mice did not result in paralysis, but injection of the
BoNT/En light chain ligated to the BoNT/A heavy chain resulted in flaccid paralysis.
Thus, BoNT/En is unable to specifically bind and enter mouse neurons, but is capable
of cleaving neuron substrates. Indeed, expression of the toxin in cultured neurons reveals
surprisingly broad protease specificity, cleaving VAMP2 and SNAP25 at unique sites, as
well as several additional SNARE proteins (i.e. SNAP23) with lower efficiency. Like
Weissella toxin, BoNT/En appears to have been laterally transferred into this strain of
Enterococcus from an unknown source, and so its functional role in Enterococcus is unclear.
Independently, the BoNT/En gene cluster has been identified bioinformatically by two
other groups: Williamson et al. [218] and Brunt et al. [181] who proposed the name
eBoNT/J for this toxin.
Mansfield et al. [219] and Wentz et al. [182] discovered a highly divergent group of
BoNT-like toxins in the genome of Chryseobacterium piperi str. CTM, as well as additional
BoNT-like genes in other Actinobacteria. One of the predicted C. piperi BoNT-like toxins
induced necrotic cell death in human kidney cells, but was not found to cleave common
SNARE substrates of BoNTs. Ultimately, the C. piperi toxins represent a distantly related
group of toxins that share partial similarities to BoNTs, and provide a model for under-
standing the unique molecular changes that have occurred leading up to the BoNT lineage,
particularly with respect to the evolution of the BoNT-LC. Additionally, it is important to
note that, to date, the aforementioned BoNT-like proteins have only been examined bio-
chemically in isolation from their host organism and biological context. Considerable work
is needed to characterize the environmental conditions in which BoNT-like proteins are
produced by their host organisms, the degree to which they are active, and their potential
host and substrate specificity.
Lastly, fragments of bont-like genes have been detected in environmental metagenomic
samples, including the termite gut [1]. Because these are only fragments and have not
been assembled into larger contigs, it is unclear whether they are derived from full-length
homologs of BoNTs. Further sequencing and analysis will be necessary to confirm whether
44
these represent true BoNT homologs, and elucidate their relationship to other BoNTs. In
this work, we provide an updated phylogenetic analysis that includes bona fide BoNTs
and recent, computationally identified bont-like genes from non-clostridial species. Using
the tree as an evolutionary framework, we discuss key questions regarding the evolution of
BoNTs such as: What features emerged specifically in the lineage leading to BoNTs? How
has host and substrate specificity evolved? What was the function of the BoNT ancestor?
How have serotypes diverged? And what was the function of the BoNT’s evolutionary
precursors? Finally, we speculate on the possible ecological roles of BoNTs for their natural
hosts, which may also shed light on the functions of other BoNT-like genes that will
undoubtedly continue to be identified in future genomes and metagenomes.
A phylogeny of BoNTs and BoNT-like genes
Figure 2.12 reveals an updated phylogenetic tree of BoNTs and BoNT-like proteins. Al-
though construction of an accurate phylogeny is complicated by recombination and lateral
gene transfer events, this is nonetheless a useful representation of relationships between
the BoNTs. Mapped onto the tree are various conserved and variable features that provide
insights into BoNT evolution. By including recently identified divergent BoNT homologs
(e.g. Weissella toxin), it is possible to root the BoNT phylogeny and infer evolutionary
directionality in the tree, as well as estimating a possible order in which various clades
emerged. The tree is largely consistent with previous phylogenetic analyses [220, 181],
dividing the family into serotypes. BoNT/E and F form one major group, which forms a
larger clade with BoNT/A. This clade is sister to a clade containing B, G and TeNT. The
clade containing C and D appears to have diverged earlier in the history of the family. Fi-
nally, BoNT/En and BoNT/X cluster together along an early diverging lineage that forms
a sister group to the other BoNTs. Beyond BoNT/X and BoNT/En is the Weissella toxin
which diverged before the lineage leading to all BoNTs, and may even predate the origin of
the BoNT clade. Finally, the Chryseobacterium toxin represents a divergent sister lineage
to BoNTs and the Weissella toxin, outgrouping the entire tree. While it shares detectable
















































































































































































Figure 2.12 (previous page): Maximum likelihood phylogeny of full-length BoNT amino acid sequences
with bioinformatically identified BoNT-like homologs. Genomic locations, gene cluster contents, protein
domains, conserved motifs, and light chain target substrates are indicated where possible. Partial positives:
NTNH-like proteins in Weissella and Chryseobacterium might be unique paralogs rather than NTNH or-
thologs; BoNT domains are more difficult to detect in Weissella and Chryseobacterium. Inferred positives:
the presence of conserved cysteine residues in BoNT/En, BoNT/X and Cp1 imply a similar disulfide bond,
but this has yet to be observed experimentally. Most SNARE substrates are indicated as inferred positive,
since we were unable to find experimental evidence of substrate cleavage for all subtypes.
Origin of TeNT and its surprising lack of diversity
In most respects, TeNT is similar to BoNTs. All BoNT domains are present in TeNT,
demonstrating sequence homology across the length of the molecule, sharing an average
of 36% identity with BoNT serotypes. Both TeNT and BoNTs function by binding and
entering neurons and cleaving SNAREs; further, TeNT cleaves VAMP2 at the same site
as BoNT/B [221]. The most important difference is the location of this cleavage event:
BoNTs cleave SNAREs within cholinergic nerve terminals, while TeNTs undergo retrograde
axonal transport and target inhibitory neurons in the central nervous system [222]. This is
the cause of pathological differences between botulism, characterized by flaccid paralysis,
and tetanus, which is characterized by uncontrollable spasms. The TeNT gene is found
only in the species C. tetani, where it is encoded on a plasmid.
According to the tree, TeNT is not a sister lineage to BoNTs, nor is it even the most
divergent member of the BoNTs (Figure 2.12). Rather, TeNT is nested within the BoNT
tree as an early diverging member of the B + G clade. TeNT has a number of unique
properties, the most obvious of which is the lack of NAPs. TeNT is not found in BoNT-
like gene clusters, and is not flanked by ntnh or ha/orfX genes. Based on the phylogeny, the
most parsimonious explanation is that the TeNT lineage has lost these NAPs rather than
multiple individual gain events. The secondary loss of NAPs in the TeNT lineage suggests
either that these proteins did not play an important role for the TeNT ancestor, or that
TeNT gained a novel function to obviate the need for NAPs. Perhaps this reflects the
differences in physiological environment between TeNT, which is produced in wounds, and
BoNT, where NAPs may confer greater specialization for the gut environment. Overall,
TeNT is most likely an “evolutionary outlier” in the history of the BoNT family, having lost
ancestral traits while gaining novel functionality, and illustrates the potential for BoNT
functional divergence.
Another anomalous characteristic in the TeNT lineage is the relative lack of sequence
diversity among TeNT genes compared to the various BoNT serotypes. Comparative ge-
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nomic analysis of C. tetani strains has confirmed this limited variation, and shown that
despite variation elsewhere in the C. tetani genome, the tetanus toxin exhibits very low
variation (>98% identity) [215, 223]. Despite this, it is notable that there is an increased
proportion of variable sites in the binding domains, particularly in the HCC domain, which
could hint at positive selection for adaptive shifts in binding [224, 225].
Does the lack of TeNT sequence variation simply reflect a lack of sampling, where
known TeNTs are simply a subset of a larger repertoire of TeNT-like sequences in the
environment, or are there other functional or evolutionary constraints that limit TeNT
sequence variation? The answer to these questions is still unclear.
Evolutionary diversification within the BoNT family
Given recently sequenced genomes of Clostridia [88] and the identification of BoNT-like
toxins by genomic data mining [1], there has been considerable diversification within the
BoNT tree. How and why have the different serotype lineages emerged and diverged from
one another? Related to this question, why are the branches between serotypes so deep -
between-serotype amino acid percent identities may be as low as 30% - with comparatively
minimal variation within serotypes?
The structure of the BoNT tree is suggestive of an ancient adaptive radiation followed by
extensive anagenesis in each lineage. One possibility that could explain this phenomenon is
that different serotypes have been produced by host-pathogen co-evolutionary diversifica-
tion [226, 227]. Co-evolution between host receptors and virulence factors is well established
and is known to drive accelerated evolution and diversification [228, 229, 230, 231, 232].
Several lines of evidence support the idea of BoNT-host coevolutionary diversification.
Different serotypes appear to exhibit host-specific adaptations: human botulism is mostly
caused by serotypes A, B, E and rarely F; avian botulism is mostly caused by types C/D
and E [233, 234, 235, 236]. Recent work suggests that even subtle changes in BoNT may
result in an alteration or refinement of host specificity; for instance, under laboratory con-
ditions human neuron sensitivity to BoNT/B was increased significantly by the mutation
of a single residue in the binding domains [237]. While the extant serotype lineages may be
the outcome of long-term host-pathogen coevolution, their initial diversification may have
arisen through these types of minimal host specificity-altering amino acid substitutions.
Co-evolution has potentially occurred not only between BoNTs and their receptors
but also between BoNTs and their SNARE substrates [224]. It has been suggested that
sequence variation across vertebrate VAMP1 reflects a selective pressure to evade cleavage
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by BoNT [238]. In humans, however, BoNT cleavage sites are highly conserved, suggesting
little to no selective pressure from BoNT [59].
Repeated evolution of substrate specificity in the history of BoNT
BoNTs have undergone several shifts and/or refinements in substrate specificity during the
course of their evolution (Figure 2.12). The vesicle-associated SNARE VAMP, or synap-
tobrevin, is cleaved by serotypes B, D, F, G, X, TeNT, En and the Weissella BoNT-like
protein, and the outer membrane-associated SNAP25 is cleaved by A, C, C/D and En (see
Pirazzini et al. [100] for a comprehensive review of cleavage sites). BoNT serotypes typi-
cally cleave one of these SNAREs at a specific site, with the exceptions of BoNT/C, which
also cleaves syntaxin, and BoNT/En, which cleaves both VAMP and SNAP25. BoNT/F
subtypes are capable of cleaving VAMP2, but F5 and F5A cleave at a unique site.
The substrate specificity of BoNTs is diverse and has a scattered distribution on the
phylogenetic tree (Figure 2.12), which may reflect inherent evolutionary plasticity in sub-
strate recognition. By evolutionary parsimony, there are at least three substrate shifts
that must have occurred in the evolution of BoNTs, with the BoNT ancestor most likely
cleaving VAMP2 (which is also consistent with the recently determined specificities of di-
vergent BoNT-like toxins). In this model, A, C and E have independently shifted toward a
SNAP25 specificity from an ancestor possessing a VAMP2 specificity. This apparent paral-
lel evolution toward SNAP25 specificity suggests that each of these lineages has separately
adapted through different substitutions and substrate recognition mechanisms. This is con-
sistent with the observation that A, C and E employ unique modes of SNAP-25 substrate
recognition and cleavage [239].
It is puzzling that BoNTs have potentially undergone multiple substrate specificity
shifts while retaining the conserved function of SNARE cleavage. Why, for example, have
BoNTs not diverged in substrate specificity to cleave one of the thousands of other possible
targets in the cell? Determining the events that have contributed to substrate specificity
shifts is complicated by the extended contacts between substrates and the light chain, as
exosites distant from the active site significantly contribute to binding efficiency, and the
importance of different exosites varies among serotypes [240, 241].
Evolution of the BoNT ancestor
In addition to questions exploring the diversification of BoNT serotypes and subtypes, a
fundamental evolutionary question concerns the origin of BoNT itself. It can be reasoned
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that if the BoNT clade is defined by its neurotoxic function, then the ancestral lineage lead-
ing to BoNT is that separating the Weissella and Chryseobacterium toxins from BoNTs
(Figure 2.12). Thus, although the first neurotoxic BoNT likely originated within an an-
cestral Clostridium species, as suggested previously [220], earlier BoNT-like ancestors may
have existed elsewhere (the phylum Actinobacteria has been suggested as one possible
source [219]).
Although the function of the divergent BoNT-like toxins is still unclear, it is possible
that some of them are cytotoxins rather than neurotoxins, and may even target non-
neuronal SNAREs as it has been suggested previously [217]. Interestingly, C. piperi toxin
induces kidney cell necrosis and although its target is still unknown, it does not cleave
common SNAREs and thus does not appear to be a neurotoxin. Similarly, despite cleaving
VAMP2, Weissella BoNT-like toxin has yet to be confirmed as a bona fide neurotoxin and
lacks some key features (e.g. disulfide bond separating the LC and HC) that are essential
for BoNT-like neurotoxicity.
The features found uniquely in the BoNT clade which are absent in these early diverging
lineages are nonetheless of considerable interest, as these may differentiate neurotoxic from
cytotoxic activity. By evaluating BoNT features in a phylogenetic context (Figure 2.12), it
is possible to infer which features may have been gained in the lineage leading to BoNTs,
and may thus have contributed to the evolution of neurotoxicity. These include (but are
not limited to) the following:
1. Emergence of the BoNT gene cluster
2. Evolutionary shifts in the “light chain” protease domain
3. Modification of a pre-existing translocation domain
4. Gain of the SxWY motif
Emergence of the BoNT gene cluster
An important innovation that coincides with the emergence of the BoNT lineage is the
appearance of the bont-ntnh synteny and flanking hemagglutinin or orfX genes. The bont-
ntnh synteny is a derived feature of all CNTs except TeNT. It is interesting that the more
divergent relatives of BoNTs (Weissella and Chryseobacterium) lack most of the hallmarks
of bont gene clusters. That is, although the Weissella BoNT-like toxin gene is located
next to a paralog with some similarities to NTNH, there are no neighbouring ha or orfX
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genes. Similarly, numerous pseudogenes and duplicates are found near the BoNT-like
toxin genes in C. piperi, and the immediately neighbouring genes are perhaps analogous
to NTNH (they possess M27-like protease domains but lack HExxH motifs). However, the
surrounding genes and the “NTNH-like” analogs found in C. piperi do not appear to be
direct orthologs of those in BoNTs.
Based on this, it appears that the BoNT OrfX and HA gene clusters evolved in the
ancestral BoNT lineage (marked in Figure 2.12). How did this occur and from where did
these associated genes originate? It is quite clear that NTNH is a paralog of BoNT and
evolved by a tandem gene duplication followed by divergence [242, 147]. The origin of the
OrfX and HA proteins, however, is more unclear. Bioinformatic analyses have suggested
that some of these proteins may be derived from an ancestral toxin gene cluster, since
statistically significant sequence similarity was detected between HA proteins and other
clostridial toxins (Doxey et al. 2008). Notably, homology was detected between the HA70
component of BoNT gene clusters and the major virulence factor, CPE, C. perfringens
enterotoxin. This prediction has been further supported by the recently solved structure
of HA70 (Amatsu et al. [243]; PDB identifier 3WIN), whose closest structural neighbour
in the Protein Data Bank is also CPE (PDB identifier 3AM2, p-value = 3.57×10-9). The
HA33 component of BoNT gene clusters is homologous to ricin type beta-trefoil domains
found outside of the BoNT gene cluster [244, 242], such as Bacillus thuringiensis toxins
(e.g. WP_088070506.1) and Lysinibacillus sphaericus mosquitocidal toxin. The OrfX
gene clusters also possess intriguing similarities to other toxin gene clusters outside of
Clostridium spp., found in species of Paenibacillus, B. thuringiensis and others.
Based on these similarities, the HA and OrfX gene clusters appear to be derived from
pre-existing toxin gene clusters that are present in pathogens that are related to Clostrid-
ium. It is therefore possible that an ancestral BoNT-like toxin fused together with a pre-
existing HA or OrfX gene cluster by recombination and perhaps lateral transfer. Given the
phylogenetic distribution of HA and OrfX homologs, it appears that this ancestral gene
fusion may have occurred within an ancestral Clostridium species. Further bioinformatic
analysis of the distribution of OrfX and HA genes in genomes and metagenomes may shed
further light into the origin and evolutionary diversification of the bont gene cluster.
Origin and evolution of the BoNT light chain
The BoNT LC forms a distinct sequence family, and is classified as peptidase family M27
under the “MA” clan based on MEROPS [199]. Notably, in addition to the BoNT and TeNT
light chains, this clan contains additional protease families, many of which are found in
toxins, and include anthrax lethal factor (family M34), bacterial collagenase (M9) and IgA
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proteases (M26 and M64). Proteases are classified under the MA clan based on a shared
catalytic mechanism and gluzincin motif (Xaa-Xbb-Xcc-His-Glu-Xbb-Xbb-His-Xbb-Xdd,
where Xaa is hydrophobic or Thr, Xbb is uncharged, Xcc is any amino acid except Pro
and Xdd is hydrophobic [245].
Based on these similarities of function and mechanism, it should be expected that the
BoNT LC is ultimately derived from another family of MA proteases. Mansfield et al.
[219] recently provided evidence for this evolutionary hypothesis by identifying similarities
to peptidase family M91, a family of type III effector peptidases that includes E. coli NleD
and also Xanthomonas HopH1. Interestingly, the divergent homologs of BoNTs such as
Chryseobacterium toxins possess overlapping peptidase M91 and peptidase M27 annota-
tions. The Pfam database lists M91 as the only domain family with detectable similarity
to M27 (see Pfam identifier PF01742), further supporting a link between these families. As
shown by Mansfield et al. [219], the M91 domain of type III effector proteases shares nu-
merous catalytic features found in BoNT-L, including not only the HExxH motif but also
the third zinc ligand E261, the catalytically important E350 and an RxxY motif (residue
numbers relative to BoNT/A, PDB identifier 3BTA). There are additional functional sim-
ilarities between the two families, as both peptidase M91 type III effectors and the BoNT
light chain are bacterial protease toxins that cleave intracellular eukaryotic targets.
However, it is the differences between the two that are perhaps more interesting from an
evolutionary standpoint. The M91 peptidase type III effector proteins, which consist of a
single protease domain, are injected into host cells by the type III secretion system directly,
while BoNTs enter cells by receptor-mediated endocytosis and subsequent translocation
into the cytosol by the activity of the heavy chain. M91 proteases are not known to cleave
SNAREs, instead cleaving JNK and p38 in host cells [246, 194], thereby disrupting the host
immune system. Although these substrates are quite different, as are the effects of their
cleavage, there is another possible functional similarity: p38 is involved in endosomal fusion
and trafficking [247]. Thus, although the function of the hypothetical M91-LC ancestor is
unknown, these commonalities suggest that it may have been involved in disrupting vesicle
function.
One of the clear differences between BoNT light chain peptidases and the peptidase
M91 family is the presence of two insertion regions, conserved among all BoNTs and present
to some extent in BoNT-like proteins. The first insertion is found from residues Phe 282-
Leu 345 in BoNT A1 (PDB identifier 3BTA), and includes residues that contribute to the
SNARE substrate binding pocket. The second is found at the C terminus (Lys 371 to
the end of the LC), and changes in these regions have significant effects on toxin activity
[248, 203, 249]. Considering the different substrates of the two peptidase members, it is
possible that these insertion regions play a role in the SNARE specificity unique to BoNT
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LCs, and quite possibly the BoNT-like toxins as well.
The species in which a hypothetical M27-M91 ancestral protease first evolved is also an
interesting question, as type III secretion systems are limited to Gram negative organisms,
and CNTs are limited to Gram positives. Perhaps the idea put forth by DasGupta [217]
of a viral origin of BoNT provides a partial explanation for the occurrence of BoNT-like
genes in such distantly related taxa. At this point, however, the repertoire of BoNT-like
genes outside of Clostridium is still too narrow to be able to infer a lineage in which BoNT-
like toxins first evolved, and the directionality of the relationship between M27 and M91
proteases (i.e. which came first) is also unclear.
Origin and evolution of the translocation domain
The translocation domain is one of the most puzzling aspects of BoNT function and evolu-
tion. Iterative PSI-BLAST searches starting with BoNT translocation domains as queries
detect homologous regions in BoNT/X and BoNT/En, as well as the divergent BoNT-like
toxins from Weissella and Chryseobacterium. Thus, at least some portion of the translo-
case domain appears to have been present in the common ancestor prior to the emergence
of true BoNTs.
The complexity of the translocation mechanism makes it unlikely that the translocase
domain evolved uniquely in the BoNT ancestor. A more likely explanation is the repur-
posing of pre-existing, functionally similar protein domains, most likely from other toxins.
Indeed, homologs of the translocation domain can be found in a large family of putative
toxins from entomopathogenic fungi [219] (e.g. the region from residues 379 to 513 of NCBI
accession XP_008602550.1). Many of these fungal sequences contain predicted N-terminal
ADP-ribosyltransferase domains rather than BoNT-like proteases. Assuming these genes
originated from a common source, the large phyletic distance between fungi and bacteria
necessitates an ancestral lateral transfer event, although it is difficult to determine the
directionality of this transfer. Regardless, these fungal sequences possess translocase-like
domains that are more similar to BoNTs than any others in current databases, suggesting
that the translocase domain exists outside of the BoNT family alone.
In addition to these entomopathogenic fungal toxins, another possible distant relation-
ship to the translocase domain may be the T domain of diphtheria toxin [219]. Statistically
significant sequence similarity between the two can be detected after two PSI-BLAST iter-
ations, and common motifs can be identified which span most of the diphtheria T domain
and an N-terminal portion of the BoNT translocase domain. This sequence similarity,
and the presence of conserved motifs, is surprising considering the structural difference
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between the two translocase domains - the diphtheria T domain possesses a different fold
than BoNT translocases. However, it is possible that these similarities provide evidence
for the “molten globule” model of BoNT translocation in which translocation involves the
unraveling of tertiary structures [250, 251, 252, 253, 142]. Thus, it is possible that the
detected relationship between the translocase domains of BoNT and DT reflects structural
similarities that only become apparent in the molten globule membrane insertion interme-
diate state. Importantly, however, if there is a relationship between the BoNT and DT
translocases, it only involves the N-terminal portion of the BoNT translocation domain.
The C-terminal portion of the BoNT translocation domain, which adopts an extended
alpha helical bundle structure, is still of unknown origin.
Evolution of the binding domains
Both of the heavy chain binding domains (the N-terminal binding domain HCN and C-
terminal binding domain HCC) are detectable in all BoNTs, including divergent variants in
the Weissella BoNT-like toxin, and thus were likely present early in the BoNT ancestor.
In the Chryseobacterium toxins, ricin-type beta trefoil domains can be detected in the
C-terminal regions, which may be homologous to the BoNT HCC domain, although the
HCN (LamG) domain is not currently detectable based on sequence similarity or structure
prediction approaches (e.g. threading). Thus, it is possible the BoNT ancestor possessed
a domain architecture similar to the C. piperi toxins, consisting of a BoNT-like LC and
translocase domain, but only part of the receptor binding machinery. This ancestral HCC
domain may have targeted different cell surface receptors, which is consistent with the ab-
sence of the SxWY motif in the early-diverging BoNT-like lineages (Figure 2.12). Adaptive
evolution of the HCC and gain of the LamG (HCN) domain may have been key evolutionary
innovations that resulted in the emergence of neuron binding in the BoNT ancestor. An
ancestral gain of the HCN LamG domain is entirely possible given that the broader LamG
domain family is widespread outside of BoNTs; LamG domains homologous to HCN do-
mains are present in non-BoNT proteins including Vibrio MSHA biogenesis protein MshQ
(ALM69800), and ALP-like superfamily proteins from Bacillus spp. (WP_071711091.1).
The gain of the HCN LamG domain at the base of the BoNT lineage, potentially from other
bacterial LamG-domain containing proteins such as these, may have brought with it an
increased ability to bind phospholipids on neuronal cell surfaces [254, 255].
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The numerous links to insects
One of the recurring themes that appears when analyzing homologs of BoNTs and the
other members of the gene cluster is a link to insects. Homologs of OrfX and HA pro-
teins can be found in insecticidal gene clusters; partial homologs of BoNTs can be de-
tected in entomopathogenic fungi; BoNT-like gene fragments have been identified in insect
gut metagenomes. Do these links reflect evolutionary similarities to invertebrate-specific
BoNTs or BoNT-like toxins? Is it possible that some of the identified BoNTs are already
adapted for invertebrate hosts? Or, do these similarities reflect other roles that insects
play in the BoNT life cycle?
What is the ecological function of BoNT in environmental clostridia?
One last fundamental question about the origin of BoNT concerns not the evolution of
its molecular function, but rather the adaptive value it provides for the bacterium in its
natural environment [154]. It has been hypothesized that BoNT operates as a method
for the spread of the pathogen through rapid killing of vertebrate hosts, as is commonly
seen in cases of avian botulism. As described by Rossetto, Pirazzini and Montecucco [142],
botulism in the wild is propagated through a life cycle involving vertebrate decomposition
and invertebrate predation. BoNT-producing clostridia are ingested or enter wounds, kill
the animal, the animal carrying C. botulinum spores is decomposed by other organisms
such as necrophagous fly larvae, which pick up the spores, intoxicate additional animals
(e.g. birds) when they are ingested, and the cycle continues. However, there is still one
unanswered question regarding the role of BoNTs in this life cycle - what is the adaptive
value of neuroparalysis? After all, there are many possible toxin modes of action that could
kill an organism, so what is the ecological value of paralyzing the host with such extreme
specificity?
According to forensic entomology, animal decomposition takes on a predictable succes-
sion of stages: fresh, bloat, active decay, advanced decay and dry decay, and each stage
is associated with specific arthropod species that have adapted to that stage to efficiently
use resources and proliferate [256, 257]. How might BoNT-induced paralysis influence a
decomposition cycle such as this in the wild? By paralyzing the host, C. botulinum may
effectively favor certain species of necrophagous invertebrates such as blowflies, effectively
“freezing” the host before later stages of decomposition occur. A paralyzed host would
provide fresh tissue before later stages of decomposition are initiated by the microbial
necrobiome (anaerobic bacteria, fungi), and thus a major competitive advantage to these
early-stage necrophagous insects, especially if they are also the vectors of C. botulinum
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spores. It is tempting to speculate that BoNTs may therefore have originally evolved
due to competition between scavengers in decomposition. It is also conceivable that some
BoNTs may have evolved broader host specificity to target not only the host vertebrate
but also target competing necrophagous invertebrates.
Members of the Calliphoridae are known to harbor C. botulinum spores, lending cre-
dence to the idea of a link to necrophagous insects [258, 259]. The exact nature of the
relationship of BoNTs to insects and decomposition, however, remains to be seen. It is also
important to note that there is not one but potentially many ecological cycles that involve
different BoNT-producing taxa and different hosts.
With this in mind, it is tempting to speculate that the divergent BoNT-like toxins from
Chryseobacterium, Weissella and Enterococcus could be part of similar ecological cycles
in the wild but with different host organisms than those typically studied in the context
of bacterial pathogenesis. Alternatively, it is also possible that these BoNT-like toxins
reflect remnants of earlier cytotoxin lineages that predate the evolution of BoNT and its
neuroparalytic role in decomposition. Future studies that examine the ecological life cycle
of C. botulinum in the wild, and evaluate the fitness impact of BoNT on C. botulinum, its
vectors and the broader “necrobiome” community will likely shed light on these important
questions.
2.3.4 Conclusions
Traditionally, BoNTs have been defined based on their neuroparalytic activity and their
occurrence in C. botulinum and related species. In the post-genomic era that has generated
over a hundred thousand bacterial genomes, it is still true that bona fide BoNTs exist
predominantly within Clostridium, perhaps with the exception of the recently identified
BoNT from E. faecium (BoNT/En). However, BoNT-like toxins with divergent activities
exist outside of the Clostridium genus and may be remnants of a much older lineage of
toxins. Several key features differentiate BoNTs from BoNT-like toxins and likely played
a role in their evolution, including acquisition of NAPs, substrate specificity changes in an
ancestral LC, extension/modification of the translocation domain, gain of the HCN binding
domain and adaptive changes in binding specificity within the HCC domain. The precise
order that these evolutionary events occurred, all of which may have affected the function
of the ancestral toxin, is for the moment difficult to discern. All of the BoNT domain
families appear to have existed in some form within the ancestral precursor to the BoNT
lineage. Thus, it is conceivable that a three or four-domain BoNT-like cytotoxin existed in
an ancient species (Clostridium or elsewhere) which targeted non-neuronal SNAREs, and
subsequently adapted to become a neurotoxin.
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Assuming that BoNTs have functionally differentiated from precursors that were already
toxins, their true adaptive benefit likely relates to their neuroparalytic effect on the host.
To understand this adaptive role, it is important to examine in detail the role of BoNTs
in its ecological life cycle. We suggest that this role may be to delay the occurrence of
decomposition to provide a competitive advantage to necrophagous invertebrates that are
specialized for early stages, which in turn benefit toxigenic C. botulinum by facilitating its
dispersal.
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2.4 Comparative genomics and evolution of the BoNT-
associated P47/OrfX gene cluster
2.4.1 Introduction
Botulinum neurotoxins (BoNTs) are produced by several species of Clostridium and cause
flaccid paralysis in vertebrates by cleaving neuronal SNAREs, thereby preventing neu-
ronal exocytosis [52]. The BoNT family includes at least 8 serologically distinct serotypes
denoted A-H [167]. The identification of several BoNT-related sequences in various bac-
terial genomes has further expanded the family: BoNT/X in C. botulinum str. 111 [155],
BoNT/En in Enterococcus faecium, and most recently PMP1 in Paraclostridium bifermen-
tans [260]. More distant relatives include the tentatively named BoNT/Wo in Weissella
oryzae [99] and Cp1 in Chryseobacterium piperi [182, 3].
The canonical BoNT serotypes are encoded adjacent to a sequence encoding a non-toxic
paralog known as non-toxic non-hemagglutinin (NTNH), and the bont-ntnh genes are lo-
cated within one of two characteristic toxin gene clusters. The first type is classified by
the presence of hemagglutinins (HAs), which are thought to protect the toxin in the gut
and contribute to binding the gut epithelium [148], but may have their own toxic effects
[216], and notably have similarity to clostridial collagenases and Clostridium perfringens
enterotoxin [242]. The second BoNT cluster type is characterized by OrfX proteins, which
remain mostly uncharacterized. Structural and functional experiments have suggested that
they play a role in binding lipids and increasing membrane permeability [261, 262], and
more recent evidence suggests a role in increasing the toxicity of the BoNT-like insecticidal
toxin PMP1 [260]. Toxin clusters containing orfX genes typically encode three OrfX pro-
teins (OrfX1, OrfX2, and OrfX3) and a P47 protein. All four of these proteins are partially
homologous to one another, with OrfX1 as the shortest protein. BoNT/X, BoNT/En, and
PMP1 are encoded in OrfX-type clusters, and their toxin sequences form an early-branching
lineage within the BoNT family [2]. The proteins in Weissella and Chryseobacterium are
not associated with typical BoNT clusters. Tetanus neurotoxin (TeNT) is also anomalous
in that the tent gene does not associate with either NTNH or OrfX/HA [263].
The OrfX-like proteins in C. botulinum str. 111, E. faecium, and P. bifermentans are
dissimilar to those in canonical BoNT gene clusters (varying by ∼70% amino acid identity
or more). However, the retention of the OrfX gene cluster across large species barriers
suggests that they perform a key function in the proliferation of bont genes.
In order to better characterize the OrfX protein family, as well as gain insights into
what their functions may be, we performed comparative genomic analysis of OrfX proteins
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and the gene clusters encoding them. OrfX gene clusters are found in a wide variety of
organisms and are associated with diverse toxin-related sequences, suggesting that OrfX
gene clusters are not unique to clostridial neurotoxins. Most notably, OrfX gene clusters
are found in several taxonomically distinct clades of pathogenic bacteria that target insect
hosts, which appear to undergo lateral gene transfer. Together, these findings imply that
the BoNT OrfX gene cluster is one type of a large class of insect-related toxin clusters,
which may also relate to the role of orfX genes in BoNT-type gene clusters.
2.4.2 Methods
Data set retrieval and curation
A representative set of OrfX proteins were retrieved by querying the NCBI non-redundant
protein database by two iterations of PSI-BLAST [112], combined with two iterations of
jackHMMer against the UniProt database [264]. The proteomes for each organism with a
match to either model were downloaded and redundancy was removed, in order to limit the
contributions of identical organisms and multiple versions of the same assemblies. Then,
the Clostridium-specific sets of OrfX1 sequences and OrfX2, 3, and P47 sequences were
separated from the search results, aligned using the L-INS-i algorithm of MAFFT (v. 7.407,
[131]), and used to create two HMM profiles with HMMER (v. 3.2.1, available from http:
//hmmer.org/; [113]). These two models were used to search the non-redundant proteomes
in order to improve the sensitivity of detecting all OrfX family members. For each OrfX
locus, the region 10kb up- and downstream of the outermost orfX gene boundaries were
extracted. Nucleotide fragments smaller than 10kb were therefore excluded. In total,
the non-redundant set of 212 proteomes yielded 213 nucleotide contexts (Brevibacillus
laterosporus str. 1951 contains two unique OrfX loci), which encode a total of 3684 protein
sequences, and 645 OrfX-related proteins. A summary of the final data set is available in
Supplementary Table A.4.
Genomic context analysis
For each nucleotide context, all-by-all translated BLASTX (TBLASTX; [103, 265]) searches
were performed. Comparisons were made at the protein level in order to allow alignments
between more distantly-related nucleotide segments, as well as allowing for genomic in-
sertions, deletions, inversions through six-frame translation. In order to normalize the
bit scores for each genomic context, which are variable in length, the bit scores for each
pairwise comparison were summed together and divided by the maximum bit score (that
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is, the score of a self-match). This results in a proportional bit score for every pairwise
comparison (or, a 213×213 matrix). This pairwise matrix was used to correlate the degree
of similarity between genomic contexts using Pearson correlation, and was visualized as a
heatmap using the R package pheatmap (v. 1.0.12, [266]) and as a directed network using
igraph (v. 1.2.4, [267]). For the simplified network in Figure 2.13, weak edges (edge weight
<0.01) and poorly connected vertices (degree <3) were dropped from the graph. The graph
was laid out using the Fruchterman-Reingold algorithm as implemented in igraph.
Phylogenetic analysis
All OrfX1, OrfX2, OrfX3, and P47 sequences were collected and deduplicated to yield
only unique sequences (reducing the total set of 645 OrfX sequences to 462 non-redundant
sequences). These sequences were aligned using the L-INS-i algorithm of MAFFT (v7.407,
[131]). A maximum likelihood phylogeny was inferred with the autoMRE bootstopping
criterion, automatic substitution model selection in RAxML [135] and depicted in FigTree
(available from https://github.com/rambaut/figtree/).
Genomic context and protein annotations
Genomic context diagrams were created using genoPlotR (v. 0.8.9, [163]). Gene annota-
tions provided for gene clusters in Figure 2.14 were generated by the NCBI Prokaryotic
Genome Annotation Pipeline [268]. Protein annotations used in Figure 2.8 were retrieved
through the EMBL InterProScan web server [126, 269]. In the case of overlapping annota-
tions, the domain start and end sites were enlarged to maximize the domain’s annotated
region.
2.4.3 Results
OrfX gene clusters are found in diverse taxa
OrfX proteins were detected through two iterations of PSI-BLAST [112] against the NCBI
non-redundant protein database as well as the UniProt database [264]. These results were
pooled, mapped back to proteomes (or segments comprising a full BoNT gene cluster), and
identical strains were removed. In order to improve the coverage of the OrfX search, the
OrfX homologs from Clostridium were aligned and used to generate two HMM models: a
combined model for OrfX2, OrfX3, and P47, and a second model for OrfX1 sequences which
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frequently went undetected with a combined model (see Methods). The set of proteomes
was then searched with the two models to capture all OrfX family members more sensitively.
For each OrfX cluster in a proteome, the 10kb region upstream of the first orfX gene and
10kb downstream of the last orfX gene was extracted, yielding a final set of 213 nucleotide
contexts containing 3684 protein sequences, 645 of which are OrfX-like.
Gene clusters encoding sets of OrfX-like proteins (hereafter referred to as OrfX gene
clusters, or OrfX clusters) can be found in diverse taxa (Figure 2.13a). This includes 8
different bacterial phyla, the fungus Fusarium, and the red alga Gracilariopsis. The largest
number of OrfX clusters is found in the bacterial phylum Firmicutes, as most gene clusters
in the data set are derived from the genomes of Clostridium species (94 genomic contexts,
487 proteins). Proteobacteria are the second largest contributor (83 genomic contexts, 282
proteins), followed by the Actinobacteria (16 genomic contexts, 55 proteins). Outside of
Clostridium, OrfX clusters are most commonly associated with Pseudomonas, Erwinia,
Paenibacillus, Streptomyces, and Brevibacillus genomes. Although some of these genera
are associated with human pathogenicity, the particular species and strains that appear to
contain OrfX gene clusters are not generally considered significant causes of human disease.
However, nearly all of the genomes containing OrfX gene clusters are associated with dis-
ease in other hosts. Many of these species are associated with phytopathogenicity: species
of Erwinia are mostly regarded as plant pathogens [270, 271]; the most numerous OrfX-
containing Streptomyces species, S. scabiei, is mostly known as a phytopathogen [272];
Fusarium species are fungal phytopathogens [273]. Interestingly, many other species con-
taining OrfX gene clusters are insect pathogens. The Pseudomonas group mostly consists
of environmental isolates and P. putida, which is a rare human pathogen but also has the
ability to kill insects [274]; Paenibacillus larvae causes lethal disease in honeybees, while
other members of the genus produce insecticidal toxins that promote plant growth [275];
some members of the genus Brevibacillus are insecticidal and nematocidal [276]; the genus
Arsenophonus includes both insect symbionts and pathogens [277, 278]; and, OrfX-related
proteins are found in at least one strain of Bacillus thuringiensis, which is well known for
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Figure 2.13 (previous page): OrfX gene clusters are found in diverse taxa. (a) A heatmap of correlations
between scaled pairwise TBLASTX scores. Blocks of shared correlations between gene clusters are related
to taxonomy, such as the large BoNT-containing OrfX clusters of Clostridium spp. The number of OrfX1-
like or OrfX2/3/P47-like genes varies between OrfX gene clusters. (b) A simplified directed network (edge
weights > 0.01, connectivity > 3, vertex size proportional to connectivity; see Methods) of correlations
between pairwise TBLASTX scores from (a) highlights the association of BoNT-containing Clostridium
clusters with other members of the phylum Firmicutes. The figure also highlights the relatively distant
relationship between Firmicutes-type OrfX gene clusters and those found in other bacterial taxa.
The OrfX gene cluster content of the genus Clostridium is most closely related to the
OrfX clusters of other members of the phylum Firmicutes in terms of sequence content
(Figure 2.13). The closest relatives of the canonical BoNT OrfX gene clusters are found in
Enterococcus faecium, Paraclostridium bifermentans, C. botulinum str. 111, which addi-
tionally encode BoNT/En, PMP1, and BoNT/X, respectively. The next nearest neighbours
are OrfX clusters from Bacillus sp. 2SH and B. thuringiensis str. AF8089089, which ad-
ditionally provide a link to the OrfX clusters in Paenibacillus and Brevibacillus. The weak
correlations between any of the bacterial OrfX clusters with the OrfX loci in the fungus
Fusarium, and the relatively strong correlations between Streptomyces spp. and Pseu-
domonas spp. together imply that lateral gene transfer events contribute to OrfX gene
cluster diversity. Potential lateral transfer events have previously been noted for Fusarium
species [280].
OrfX gene clusters associate with toxin-related genes
A common feature of OrfX clusters is the presence of toxin-related sequences. This in-
cludes BoNT-type OrfX clusters, as well as many diverse toxin-related sequences can be
found in OrfX gene clusters (Figure 2.14). In Brevibacillus laterosporus (Figure 2.14) and
Paenibacillus larvae several proteins have notable similarities to anthrax toxin components.
Anthrax toxins are multimeric proteins comprised of protective antigen (PA) proteins, the
adenylate cyclase anthrax edema factor (EF), and the metalloprotease anthrax lethal fac-
tor (LF) which additionally contains an inactive ADP-ribosyltransferase [55, 65]. Both
Paenibacillus and Brevibacillus clusters encode proteins with similarities to anthrax PA,
EF, and LF. RHS toxin-related sequences commonly associate with OrfX clusters, which
contribute to virulence in Vibrio species [281], and comparative genomic analysis revealed
that the family is highly diverse [282] and are also related to bacterial interspecific com-
petition [283, 284]. Evidence of toxic functionality is also seen in more distantly related
sequences, including ricin-type beta trefoil proteins in Paenibacillus larvae (a component
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of Clostridium perfringens enterotoxins [242] as well as ricin toxin itself [285]), type VI
secretion system components in Erwinia, and a protein containing an adenylate cyclase
domain in Rhizobium sp. Leaf386. As well, many OrfX clusters, including BoNT-type




Clostridium baratii str. 796-15
NZ_LUSO01000011








Binary toxin-like, Anthrax PA-like
VIP-like ADPR
Brevibacillus laterosporus str. 1951
RHPK01000003










Arsenophonus nasoniae str. DSM15247
NZ_AUCC01000047



















Clostridium botulinum A str. Chemnitz
KM233166
BoNT NTNH
Paenibacillus larvae subsp. larvae DSM 25719
ADFW01000001














Figure 2.14 (previous page): Genomic context of a selected set of diverse gene clusters containing
OrfX-related genes. As seen among BoNT-type OrfX gene clusters, OrfX gene clusters from other species
typically contain more than one OrfX-related gene (blue). Althoug the gene clusters are heterogeneous,
toxin-related genes are common among OrfX gene clusters (various colours). The BoNT-type OrfX clusters
of Clostridium species typically encode BoNT and NTNH proteins (orange), while RHS toxin-like (green),
B. thuringiensis Cry-like (brown), and anthrax toxin-like sequences are found in other species. Other
proteins encoded in OrfX gene clusters may contain weaker evidence of toxin functionality such as domains
associated with toxins, including ricin-type beta trefoils (yellow), adenylate cyclases (dark orange), and
type VI secretion system proteins (red-grey.
orfX genes have undergone several independent lateral transfers and duplica-
tions
In order to disentangle distinct OrfX subfamilies, we generated a phylogeny based on a
representative set of OrfX-related proteins (Figure 2.15). OrfX proteins associated with
BoNT-type OrfX clusters group separately from those found in other taxa, and form well-
supported and distinct clades consisting of OrfX1, OrfX2, OrfX3, and P47. The closest
relatives of BoNT-type OrfX clades found among Clostridium spp. are typically the OrfX-
like clades associated with BoNT-like toxin clusters, including those from C. botulinum
str. AM1195, C. botulinum str. 111, E. faecium, and P. bifermentans. The relationship of
OrfX-related proteins from BoNT and BoNT-like gene clusters is not monophyletic since
OrfX-related proteins from Bacillus species, Paenibacillus, and Brevibacillus occasionally
group more closely to one another. However, for each of OrfX1, OrfX2, OrfX3, and P47, the
BoNT, BoNT-like, and Paenibacillus-Bacillus-Brevibacillus groups are well-supported and
monophyletic. This reinforces that the BoNT-type OrfX gene clusters are closely related
to the clusters of the bacilli of order Bacillales. Additionally, the OrfX1 clade contains only
OrfX proteins derived from genomes of the Bacillales and Clostridiales, suggesting OrfX1
proteins may be an innovation specific to the gene clusters in these taxa.
The tree (Figure 2.15) provides strong support for clades of OrfX proteins found in
specific taxa. Two groups of OrfX-related genes in Erwinia group are well-supported and
appear to be most closely related to the clostridial P47 and OrfX2 clades. Two clades of
OrfX-related sequences in Pseudomonas are also well-supported, with one clade appearing
most similar to clostridial OrfX3 and the second forming a relatively independent lineage
stemming off earlier than the OrfX2-OrfX3 clade. A large clade of Streptomyces sequences
forms a group that diverges early in the OrfX3-related clade. The placement of these
monophyletic groups within the tree implies patterns of lateral gene transfer. Further,
Pseudomonas, Streptomyces, and Erwinia were more likely to have been the recipients of
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Figure 2.15: Maximum likelihood phylogeny of OrfX-related amino acid sequences. The clades of OrfX1,
OrfX2, OrfX3, and P47 proteins from BoNT-type OrfX gene clusters are indicated. The closest relatives
of BoNT-type OrfX proteins are generally the OrfX-related proteins of BoNT-like gene clusters (that
is, OrfX-like proteins from C. botulinum str. 111, E. faecium, and P. bifermentans, encoding BoNT/X,
BoNT/En, and PMP1, respectively). Other Firmicutes OrfX proteins are indicated in shades of purple,
with other colours indicated for taxa containing numerous OrfX relatives outside of phylum Firmicutes.
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As well, the tandem inheritance of multiple paralogs suggests that some of these events
occurred after the duplication and divergence of OrfX family members. Based on their
position in the tree, Erwinia most likely acquired a p47-orfX2 cluster, while Streptomyces
acquired only a copy of an orfX3 -like gene. The pattern in Pseudomonas is more difficult
to explain, as one clade appears to have diverged early from the OrfX2-OrfX3 clade, while
the other falls within the OrfX3-like clade. One possible explanation for this pattern is
the acquisition of an orfX3 -like gene followed by Pseudomonas-specific duplication and
divergence, although this is difficult to verify.
BoNT gene clusters as recipients and donors in lateral gene transfer
Based on patterns in OrfX gene cluster sequence content (Figure 2.13 and Figure 2.14) and
phylogenetic placement (Figure 2.14), it seems clear that orfX genes undergo lateral gene
transfer. To provide a clear example of this, two particular ORF gene clusters are high-
lighted: one from C. botulinum str. AM1195 genome and the other from Bacillus sp. 2SH
(Figure 2.16). The strain of C. botulinum has been noted as containing a hemagglutinin-
type BoNT B gene cluster [88], but also contains an additional OrfX gene cluster (Figure
2.16a). The OrfX proteins of this cluster are phylogenetically distinct from other BoNT-
type OrfX proteins (Figure 2.15), and the locus lacks a neurotoxin-like gene. In its place,
the OrfX gene cluster contains a hypothetical protein with significant similarities to in-
secticidal Bacillus thuringiensis δ-endotoxins. The acquisition of a Bacillus insecticidal
toxin gene is certainly atypical for BoNT-type OrfX gene clusters, and the phylogenetic
placement of its OrfX proteins suggests they are more closely related to the OrfX proteins
found among the Bacillales.
68
5kb




















































































































































































































































































Figure 2.16 (previous page): OrfX clusters exhibit clear evidence of lateral gene transfer events.
Here, the contents of two OrfX gene clusters are depicted: in (a), an OrfX gene cluster from Clostridium
botulinum str. AM1195 lacking BoNT-related genes, and in (b) an OrfX gene cluster from Bacillus sp. 2SH
containing an NTNH-like gene that is commonly associated with BoNT-type gene clusters. The OrfX gene
cluster in C. botulinum str. AM1195 is unique from other clostridial OrfX gene clusters in that its OrfX
proteins have low amino acid identity (∼30% identity), and they are phylogenetically distinct (see Figure
2.15). Further, the cluster contains a hypothetical protein with similarity to B. thuringiensis δ-endotoxin
unlike other OrfX gene clusters associated with BoNTs. In Bacillus str. 2SH, the OrfX gene cluster is
unique in containing an NTNH-like gene, which is only found in BoNT-type gene clusters. Together, these
results imply that OrfX gene clusters can be laterally transferred with or without associated BoNT genes.
The protein domain diagrams are annotated according to InterProScan annotations, and other gene colours
assigned according to their NCBI annotations.
The OrfX cluster found within the genome of an environmental Bacillus isolate (strain
2SH, [286]) is perhaps an example of the opposite phenomenon (Figure 2.16b). The Bacillus
sp. 2SH OrfX gene cluster contains three OrfX2, OrfX3, and P47-related sequences and
a single OrfX1-related sequence, as well as a protein with an RHS core domain, which
may be a potential toxin. More remarkable however is the appearance of an NTNH-like
sequence downstream of the OrfX1 locus. The protein (NCBI Protein accession number
WP_137842862.1) contains matches to the BoNT translocase and peptidase domains, but
lacks the catalytic HExxH motif necessary for zinc peptidase activity. The same property
is found in the non-toxic non-hemagglutinin genes typical of BoNT gene clusters. As far
as we know, this is the first identification of an NTNH-related sequence in a strain of
Bacillus. Assuming this OrfX gene cluster is truly a part of the Bacillus sp. 2SH genome
(and not contaminating DNA from another organism), there are two simple and plausible
explanations for this: that other NTNH-containing OrfX gene clusters exist in Bacillus
species which have yet to be detected, or else that an NTNH-positive OrfX gene cluster
was laterally transferred into this strain of Bacillus. In either case, the presence of an
NTNH gene in Bacillus is noteworthy because the ntnh gene is only known to be located
adjacent to bont genes, raising the possibility of Bacillus species containing neurotoxin-
related sequences.
2.4.4 Discussion and Conclusions
To date, BoNT proteins have been discovered within two types of gene clusters containing
either hemagglutinin (ha) or orfX genes. Little is known about the function of the OrfX
proteins, as the neurotoxin protein alone is sufficient for toxicity [287]. As seen among gene
clusters encoding BoNT serotypes with many traditional BoNTs, BoNT-related proteins
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from a wide variety of organisms are encoded in OrfX gene clusters. The broad conservation
of OrfX clusters in many species suggests that their function may have an important
contribution to the fitness of their associated neurotoxin genes.
Our searches against currently available genomes suggest that OrfX clusters are tax-
onomically widespread, much more than neurotoxin genes (Figure 2.13). The OrfX gene
clusters most similar to BoNT-type clusters are found in various species of the order Bacil-
lales, particularly within species of Paenibacillus and Brevibacillus. Outside of the phylum
Firmicutes, OrfX clusters can be found in species of Pseudomonas, Streptomyces, Erwinia,
and Arsenophonus. Remarkably, nearly all of the organisms with OrfX gene clusters are as-
sociated with pathogenicity in either plants or insects. Many specific OrfX clusters include
toxin-related sequences (Figure 2.14), including homologs of anthrax toxins in Paenibacil-
lus and Brevibacillus, RHS-related sequences, and homologs of the δ-endotoxins and Cry
toxins of Bacillus thuringiensis. Together, these results demonstrate a strong association
between OrfX gene clusters and insect pathogenicity.
Even when considering only Clostridium, it is clear that lateral gene transfer events
have helped to shape BoNT and OrfX gene clusters [152, 235, 146, 288]. This observation
is consistent with phylogenetic analysis of OrfX proteins across many taxa (Figure 2.15).
In Clostridium, the OrfX1, OrfX2, OrfX3, and P47 lineages form well-supported clades
which each have homologous representatives among members of the order Bacillales (that
is, Paenibacillus, Brevibacillus, and Bacillus spp.). The phylogeny also implies several
independent lateral gene transfer events consisting of different orfx gene combinations into
species of Pseudomonas, Erwinia, and Streptomyces. As well, the examples of OrfX gene
clusters in C. botulinum str. AM1195 and Bacillus sp. 2SH provide evidence of lateral
gene transfers of potentially non-BoNT-type OrfX clusters into Clostridium as well as the
transfer of a potentially BoNT-type OrfX cluster into Bacillus. The production of Cry
toxins has been described in other strains of C. botulinum [289], but their association
with an OrfX gene cluster is surprising. The source of the gene cluster in Bacillus sp.
2SH is unknown, but with currently available evidence seems most likely to be a species
of Clostridium, considering the limited taxonomic distribution of NTNH sequences. The
genome of Bacillus sp. 2SH was assembled from a thermal spring metagenome [286] with
temperatures varying from 20-37 ◦C, meaning interaction with toxigenic clostridia is at
least possible.
Numerous avenues support a link between OrfX proteins and insect pathogenicity. OrfX
gene clusters are found in disparate, distantly related taxa, and one of the few common
threads among them is a direct association with insect pathogenicity or a more broad
association with plants (and, therefore, herbivorous insects). As such, we propose that
the OrfX gene cluster is a modular toxin gene cluster related to insect pathogenicity. By
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extension, the presence of OrfX proteins encoded in BoNT-type OrfX gene clusters reflects
either an ancestral or an ongoing adaptation for targeting insects. The observation that
OrfX proteins enhance mosquitocidal toxicity corroborates the second claim, at least for the
BoNT-related protein PMP1 [260]. The large differences between OrfX proteins associated
with BoNT clusters compared to those in BoNT-related clusters like the one encoding
PMP1 (∼70% amino acid identity) suggests that the two groups may perform different
functions; this is perhaps analogous to the toxin complexes of Yersinia species, where the
complexes of different Yersinia species appear to have specific adaptations for different
host types [290]. Although comparative genomics is insufficient to explain the function
of OrfX proteins by itself, the analyses presented here strongly suggest that OrfX gene
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3.1 Identification of a diphtheria toxin-like gene family
beyond the Corynebacterium genus
3.1.1 Introduction
The history of bacterial toxins began in the 1880s with the isolation of a “diphtheretic poi-
son” [now termed diphtheria toxin (DT)] by Émile Roux and Alexandre Yersin in filtrates
of the organism Corynebacterium diphtheriae [29]. Roux and Yersin demonstrated that
filtrates of this “diphtheria bacillus” exhibited toxicity in guinea pigs, similar to that of
urine samples taken from children with diphtheria. From this landmark study, the field
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of bacterial toxinology was born as it was demonstrated for the first time that a bacte-
rial poison (or “toxin” from Greek: τοξικός, poison) was the causative agent of a human
infectious disease.
Although C. diphtheriae was first discovered by Klebs and Löffler in the early 1880s,
the history of diphtheria disease dates back much further. Early accounts of diphtheria
can be found in 2500-year-old writings by Hippocrates, and diphtheria-like epidemics were
reported in writings from the 1500s [291]. By the late 1800s, diphtheria was one of the
most devastating infectious diseases, and was one of the leading causes of childhood death
in the prevaccine era [292]. After the introduction of the diphtheria vaccine in the early
1920s, however, diphtheria-related mortalities began to drop dramatically, and since their
introduction vaccines are estimated to have prevented over 40 million cases of diphtheria
in the US alone [293]. The name “diphtheria” originates from the Greek word diphthera
(leather), relating to the leathery pseudomembranous films formed in throats of diphtheria
patients. The disease is characterized by an infection of the upper respiratory tract by
toxigenic C. diphtheriae, leading to ulceration of the mucosa and formation of inflammatory
pseudomembranous lesions. The diphtheria exotoxin is secreted by C. diphtheriae and its
adsorption into the bloodstream and transmission into other organs can induce cytoxicity
and ultimately lead to death. The mode of action of DT has been characterized in depth
through decades of work [7, 294], and involves binding and entry of DT into host cells and
subsequent inhibition of protein synthesis through the inactivation of eukaryotic elongation
factor 2 (eEF-2). DT is a 60 kDa polypeptide chain, about 535 amino acids in length,
possessing a characteristic AB toxin architecture consisting of two subunits linked by a
disulfide bond. The B subunit is responsible for cell receptor binding and membrane
translocation, and the A subunit is responsible for intracellular catalytic activity.
Toxicity is achieved through the following steps. Following secretion, the DT C-terminal
receptor-binding (R) domain (immunoglobulin-like beta-sandwich fold) in the B subunit
binds to human heparin-binding epidermal growth factor (HB-EGF) on host cell mem-
branes. DT is then taken up by an endosome, and the middle translocation (T) domain
(colicin-like fold) of the B subunit undergoes pH-driven conformational changes in the en-
dosomal membrane, which facilitates translocation of the catalytic domain (C domain, or
A subunit) cargo into the host cytosol [7, 294]. For the C-terminal domain to be released,
a disulfide bond linking the A and B fragment must be reduced as well as proteolytically
nicked by furin and other proteases [78]. At this point, the C domain, which adopts a beta-
alpha structure and possesses ADP-ribosylatransferase activity, transfers an ADP-ribose
moiety from NAD to a unique post-translationally modified histidine residue termed diph-
thamide on eEF-2. ADP-ribosylation of eEF-2 results in blockage of protein synthesis and
cell death.
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In 2003, the first genome sequence of C. diphtheriae (strain NCTC13129) was published,
following an ongoing outbreak of re-emerging diphtheria in Europe, revealing genomic
insights into its pathogenicity [295]. DT is encoded on a mobile, temperate bacteriophage
that integrates into the Corynebacterium genome at tRNAArg loci [296, 297]. The tox
gene encoding DT is localized at the 30 side of the integrated corynephage, is flanked by
an att integration site, and is found in a region with relatively low C+G content (43%),
which has been suggested to reflect a potentially recent insertion event into the phage
[298]. An important regulator of tox gene expression is an iron-dependent transcriptional
repressor (DtxR), which not only represses tox expression but also acts more globally in
the regulation of other iron-sensitive genes [299]. Iron limitation is a common strategy for
bacterial growth suppression by hosts, and in turn is exploited by numerous pathogens
(including C. diphtheriae) to upregulate their virulence genes.
In addition to C. diphtheriae, two related species of Corynebacterium (C. pseudotu-
berculosis, and C. ulcerans) have been identified with tox -carrying corynephages. These
corynephages possess unique differences from those in C. diphtheriae [297], and encode DT
variants that exhibit high (95%) sequence identity to classic C. diphtheriae DT. Both C.
ulcerans and to a lesser extent C. pseudotuberculosis have been shown to be capable of
producing diphtheria-like symptoms in humans, but are primarily associated with zoonotic
infections [300, 301].
Despite considerable knowledge on DT structure, function, and mechanism, very little
is known about the relationship of DT sequences to other proteins. Although the mech-
anism of the DT catalytic domain is shared with other ADP-ribosylating toxins such as
Pseudomonas ExoA and cholix toxin [302, 51], no homologs of DT have been identified to
date that possess multiple DT domains indicative of common evolutionary ancestry. There-
fore, the evolutionary origin and molecular ancestry of DT is unclear. Based on similar
work exploring botulinum neurotoxin evolution and diversity [99, 2, 1, 4], we hypothesized
that there may exist additional homologs of DT beyond the Corynebacterium genus, which
if identified could provide insights into its evolutionary relationships and history. In this
study, we mined available genomes for DT homologs including 134,749 prokaryotic species
in the current Genbank release. We report the bioinformatic discovery of the first homologs
of DT outside of Corynebacterium. These putative DT-like toxins possess low identity but
conserve DT’s three domain architecture and key active sites, and are the closest phylo-
genetic relatives to DT in the current database. DT homologs are most unique in their R
binding domains, suggesting that the specificity of DT toward humans may have evolved
in part through fine-tuning and accelerated evolution of receptor binding. Based on the
taxonomic sources of these homologs and patterns of evolutionary diversification, we pro-




Homolog detection and sequence analysis
A data set of DT and DT-like protein sequences was obtained by first performing BLASTp
search against the NCBI nr database (Mar. 29, 2018). Identical sequences and synthetic
constructs were removed from the data set. Domain architectures were predicted using the
CDD and verified by comparison to other databases using InterProScan. Only proteins
containing more than one predicted DT domain were retained, resulting in a final data set
of 27 DT and DT-like proteins.
A notable sequence outlier was the Austwickia chelonae DT-like protein (NCBI acces-
sion number WP_040322835.1), which contains a portion of a diphtheria T domain and a
full R domain. Analysis of this genomic region revealed a frameshift mutation, that when
corrected resulted in a full-length DT-like gene also containing the C domain (sequence
translated from NCBI accession number NZ_BAGZ01000024, region 41461-42285, com-
plement). The concatenated full-length sequence was used for phylogenetic analysis, but is
potentially a pseudogene that has been interrupted by a frameshift mutation. It is unclear
whether this represents a true frameshift mutation or a sequencing error.
Phylogenetic analysis
A multiple sequence alignment of the data set was created using CLUSTAL-OMEGA (ver-
sion 1.2.1, [130]) using default parameters. Phylogenetic trees were inferred using maximum
likelihood (RAXML version 8.2.4; 1000 rapid bootstraps, automatic model selection with
gamma-distributed rates across sites, and a thorough ML search [135]), Bayesian infer-
ence (MRBAYES version 3.2.6 [185]; gamma-distributed rates across sites, WAG model
of evolution, 1,000,000 generations with Metropolis-coupled Markov chain Monte Carlo
sampling) and neighbour-joining (BioNJ [303] as implemented in SEAVIEW version 4.5.4
[304]; default parameters) methods. All tree-building methods were congruent in high-level
topology. The statistical overrepresentation within the Actinobacteria was quantified by
computing the probability that randomly selected taxa from the GTDB bacterial tree of
life [305] could result in six or more actinobacterial species by chance (permutation test,
100,000 iterations).
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Sequence and structural modelling
Transmembrane regions were predicted using TMHMM [306]. Structural models for all DT-
like proteins were generated using I-TASSER [187]. Each putative domain was modeled
separately, with domain regions defined based on alignment to the DT reference structure
(PDB accession number 1MDT, [307]). Sequence regions and structure prediction results
are available in Table B.1. Structural models for each DT-like domain were structurally
aligned to the corresponding domain in DT using PYMOL (http://pymol.org). PyMol’s
align function was used to perform a sequence-guided structural alignment, and the fit
of the superimposed structures was evaluated by root mean squared deviation. Solvent-
accessible surface area for 1MDT was calculated using FreeSASA [308].
Analysis of evolutionary conservation
Per-residue sequence conservation was computed and mapped to the crystal structure of DT
using ConSurf [309] with the Bayesian method for calculating conservation scores. Thirty-
one sites were invariant across the alignment and therefore received the lowest normalized
scores (most conserved) according to the ConSurf algorithm. Sequence conservation was
also visualized using WebLogo [310] with default parameters.
Genomic context analysis
Genome sequences for three corynephage genomes and the genomes of all organisms con-
taining predicted DT-like genes were downloaded from the NCBI Genome database. Re-
gions 15 kb up- and downstream of DT-like genes were selected for the plot used in Figure
3.9, depicted in R using genoPlotR version 0.1 [163]. The genomes containing DT-like genes
were searched for the presence of corynephage-like viral DNA using BLASTN version 2.2.31
[112] as well as the phage search tool, PHAST [311].
3.1.3 Results
Genome mining identifies diphtheria toxin homologs outside of the Corynebac-
terium genus
We searched the GenBank database (Mar 29, 2018, 177,666 total genomes) with corynephage
beta DT as a query (PDB identifier 1MDT) using BLASTp. The closest full-length matches
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to DT are variants present in C. diphtheria, C. ulcerans, and C. pseudotuberculosis, with
sequence identities ranging from 95 to 100% (Table 3.1). Beyond this group, we identified
several homologs with lower identities (23-34%), weaker but significant E -values (1×10-36 to
6×10-12), and detectable alignments spanning partial coverage (51-85%) of the full-length
DT query sequence (Table 3.1). These detectable DT homologs include predicted protein
sequences from the genomes of Austwickia chelonae, Streptomyces albireticuli, Strepto-
myces sp. TLI_053, Streptomyces roseoverticillaticus, Streptomyces sp. MBT76, Strep-
tosporangium nondiastaticum, and Seinonella peptonophila. Reciprocal searches performed
with these sequences as queries identified DT with E -values <1×10-10 in all cases, confirm-
ing their direct homology to DT.
Table 3.1: Detection of diphtheria toxin-related sequences in the NCBI GenBank database. The per-
centage of identical and similar residues as well as query coverage (Iden., Sim., and Cov., respectively) are
calculated relative to PDB identifier 1MDT.
Accession Iden. Sim. Cov. E-value Phylum Family Genus/Species
1MDT 100 100 100 0 Actinobacteria Corynebacteriaceae
Corynebacterium
diphtheriae
AAN28948.1 95 97 100 0 Actinobacteria Corynebacteriaceae
Corynebacterium
ulcerans
WP_014654963.1 95 97 99 0 Actinobacteria Corynebacteriaceae
Corynebacterium
pseudotuberculosis
WP_040322835.1 34 51 51 1×10-36 Actinobacteria Dermatophilaeceae
Austwickia
chelonae
WP_073156187.1 27 43 78 1×10-27 Firmicutes Thermoactinomycetaceae
Seinonella
peptonophila
WP_078659863.1 28 47 68 1×10-23 Actinobacteria Streptomycetaceae
Streptomyces
roseoverticillatus
PSJ28985.1 27 46 68 1×10-22 Actinobacteria Streptosporangiaceae
Streptosporangium
nondiastaticum




WP_093864399.1 25 43 65 2×10-21 Actinobacteria Streptomycetaceae
Streptomyces sp.
TLI_053
WP_095582082.1 23 39 85 6×10-12 Actinobacteria Streptomycetaceae
Streptomyces
albireticuli
Intriguingly, all of these genomes (with the exception of Seinonella) are members of the
phylum Actinobacteria, which also contains Corynebacterium (Table 3.1). This taxonomic
overrepresentation within the Actinobacteria is highly nonrandom (p <0.0001, permutation
test, Figure 3.1), further suggesting the common ancestry of these sequences. Although
these species all occur within the Actinobacteria, it is important to note that they are phy-
logenetically scattered among many other lineages that lack DT-like genes. This suggests
that DT-like genes are not monophyletically distributed, and that lateral gene transfer
and/or gene loss has played a role in the evolution of these genes. Interestingly, the list of
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species containing DT-like genes includes some known pathogens; for example, S. albireti-
culi is a pathogen of nematodes [312] and has algicidal activity [313], and A. chelonae is
a pathogen that causes skin infections in reptiles and other wild animals ([314, 315]; see
Discussion).
Phylogenetic analysis suggests an ancestral radiation of DT-like lineages
Next, we aligned representative Corynebacterium DT sequences with the detected DT-like
homologs, and performed phylogenetic analysis using maximum likelihood, Bayesian, and
neighbour-joining reconstruction (see Materials and Methods). All three methods pro-
duced trees that were identical in clade topology with 98-100% support of all major clades
(Figures 3.2 and 3.3). The resulting midpoint-rooted phylogenetic tree reveals an ances-
tral diversification of DT-like sequences into six main lineages. All Corynebacterium DT
proteins form a monophyletic lineage with low diversity and 100% clade support. The
Corynebacterium clade is subdivided into a subclade of DT sequences predominantly from
C. diphtheriae and a sister group of DT sequences from C. ulcerans. The Corynebacterium
DT group forms a larger group with DT-like sequences from A. chelonae with 100% clade
support. We have denoted this group α1. Although there is evidence of a frameshift
mutation in this gene (see Materials and Methods), which raises questions about its pseu-
dogenicity, these are the most closely related sequences to DT phylogenetically, and also
possess the highest sequence identity to DT (34%, Table 3.1). Neighbouring the Austwickia
+ Corynebacterium group (α1) is an earlier diverging lineage (α2), which includes various
Streptomyces spp. and Streptosporangium nondiastaticum, which also has 100% bootstrap
support. Finally, a group of two divergent DT-like sequences from Seinonella peptonophila
and S. albireticuli (group β) clustered separately from the remaining DT homologs with
100% bootstrap support. The observed incongruence between the gene and species phy-
logeny (Figures 3.2 and 3.1) is again indicative of lateral transfer of DT-like genes (e.g., a
possible transfer between Streptomyces and Streptosporangium in lineage α2).
DT homologs conserve protein domain architecture but have variable R do-
mains
Next, we performed sequence and structural modelling to assess the conservation of protein
domain architecture in DT homologs. At the level of protein domains, all DT homologs
possess detectable diphtheria-like ADP ribosyltransferase (catalytic, C) and translocation
(T) domains (Figure 3.4), and this annotation was supported by four separate domain















Figure 3.1: Phylogenomic distribution of taxa encoding diphtheria toxin (DT) and diphtheria toxin-like
proteins. Gene presence/absence was mapped onto the bacterial tree of life using the Genome Taxonomy
Database (GTDB) tree (http://gtdb.ecogenomic.org/) using AnnoTree 1. The full bacterial tree is
shown on the left and highlights the phylum Actinobacteria, which contains all DT-like sequences identified
in this study except the example in Seinonella peptonophila. The right panel shows the distribution of
DT-like sequences within the phylum Actinobacteria, demonstrating the scattered distribution of DT-like
sequences across bacteria.
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Figure 3.2: Maximum likelihood phylogenetic tree of amino acid sequences from DT and identified
DT-like homologs. Clade support values for all three methods are shown above each node (maximum
likelihood/Bayesian/neighbour-joining). Bayesian and neighbour-joining methods were identical in high-
order topology (Figure 2.10). *This protein sequence was encoded by two separate open reading frames
in the Austwickia chelonae genome. See Methods for further details.
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Figure 3.3: Phylogenetic tree of diphtheria toxin and diphtheria toxin-like proteins inferred using three
different methods (maximum likelihood, Bayesian, and neighbour joining). For all three methods, branch
order remained largely consistent.
[116], and HHpred [114]). Interestingly, although C-terminal regions similar in length to
the DT receptor binding (R) domain are present in all of the homologs, these regions
are highly divergent in sequence and were not recognizable using existing DT-R domain
models with the exception of the A. chelonae C-terminal fragment (Figure 3.4). Notably,
the C-terminal domain from S. peptonophila had a statistically significant alignment score
with DT-R despite low identity (26.7%, E -value = 0.031 using SSEARCH36 [316]).
We then predicted structures for the three regions of each DT-like toxin using I-TASSER
[255]. Consistent with sequence-based analysis, structure predictions for the C and T do-
mains exhibited high similarity to DT, whereas the predicted structures of the R domains
exhibited limited similarity (Figure 3.4). However, importantly, the DT-R domain was
detected as the top scoring structural template for A. chelonae, S. albireticuli, and S.
peptonophila (Table B.1), respectively, suggesting structural similarity. Consistent with the
identification of T domains in DT-like homologs, predicted transmembrane helix propen-
sities using TMHMM [306] resulted in a characteristic, conserved pattern over this region,
which supports previous models of T domain-mediated translocation (Figure 3.4). Overall,
these results suggest that the identified DT homologs possess DT-like C and T domains,
but possess C-terminal binding domains that are divergent in sequence but likely related
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in structure.
DT homologs conserve key functional sites
We then examined the multiple alignment (Figure 3.5) to assess whether key residues
in DT are conserved in DT homologs (Table B.2). Functionally important residues in
the C domain include His-21 [317], Tyr-65 [318], and the critical Glu-148 [319], which
participate in NAD+ binding and catalysis (with residue numbers relative to diphtheria
toxin PDB identifier 1MDT). Glu-148 is completely conserved in all DT homologs, Tyr-65
in 7/8 homologs, and His-21 in 6/8 homologs (missing only in group β) (Figures 3.5 and
3.6). Additional residues that participate in NAD-binding are Thr-23, Tyr-27, and Tyr-54.
Tyr-54 is completely conserved but Thr-23 and Tyr-27 are substituted in all homologs.
Following the C domain in DT is the disulfide bond formed by Cys-186 and Cys-201. A
pair of cysteine residues are conserved in all DT-like homologs, and located either in the
same alignment position or in the adjacent (±1) position (Figures 3.5 and 3.6). Within
the disulfide linker region, a furin cleavage site (RxxR) is conserved in 6/8 DT homologs,
and again is present in group α but missing in group β.
Within the T domain, several key residues have been identified as important for mem-
brane binding and translocation activity, including the critical Pro-345 [321, 322], Glu-349
[323], and Asp-352 [323, 324]. Pro-345, along with a nearby Gly-348 is completely con-
served in all homologs, while E-349 and D-352 are conserved among group α (Figure 3.6).
The presence of these key residues, the similarity of transmembrane propensity (Figure
3.4), and T domain homology, strongly suggests conservation of translocation function.
Finally, a co-crystal structure of DT complexed with heparin-binding epidermal growth
factor (HB-EGF) has revealed the residues that form the DT-receptor interface [325] (PDB
identifier 1XDT). DT residues within 3 Å of HB-EGF are S381, H384, H391, R462, D465,
S506, D507, and K526 (Figure 3.7). Although in part due to a poor alignment in the C-
terminal region, none of these residues are conserved, suggesting the possibility of altered
binding specificity.
The presence/absence of these key residues and motifs mapped onto the phylogenetic
tree reveals an interesting evolutionary pattern (Figure 3.6). That is, almost all features
important for DT function are conserved within lineage α, which not only supports the
common ancestry of this group, but suggests the emergence of DT-specific functionality
in the ancestor of this lineage. The absence of key catalytic sites, the furin cleavage site,
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Figure 3.4: Predicted domain architectures, sequence and structural modeling of diphtheria toxin (DT)
homologs. (A) Domain architectures of DT homologs inferred using the NCBI CDD search tool with an
E -value threshold of 0.01. The domains are colored as follows: catalytic (C) domain, blue; translocase
(T) domain, green; and the receptor binding (R) domain, yellow. (B) Transmembrane helix propensities
predicted via TMHMM scores. All T domains of DT-like proteins show a characteristic pattern over the
membrane-inserting alpha helical region. (C) Structural models of C, T, and R domains predicted using I-
TASSER. Structural alignment was performed using PyMol (http://pymol.org/), and the average RMSD
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Figure 3.5: Multiple sequence alignment of DT and DT-like protein sequences. Conserved positions
are highlighted, and the secondary structure based on the structure of DT (PDB identifier 1MDT) is
plotted above the alignment. Below the alignment, the per-residue relative accessibility is depicted. Image
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Figure 3.6: Presence/absence of key functional sites and motifs in DT and DT-like homologs. Key
functional sites in DT were defined based on previous literature (see text), and their presence/absence
pattern has been arranged based on the phylogenetic topology from Figure 3.2. *This protein sequence




Figure 3.7: (A) A surface model of diphtheria toxin (DT, grey surface; PDB identifier 1XDT) complexed
with heparin-binding epidermal growth factor (HB-EGF, green cartoon). Residues that contact HB-EGF
are shown in orange, with additional stick representations. (B) All identical residues between the putative
receptor binding domain of the Austwickia chelonae DT-like protein and DT are shown in red. Residues
near the HB-EGF (blue cartoon with lines) interaction pocket are conserved, as well as several more distant
residues.
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DT homologs reveal purifying selection on known sites and suggest novel sites
of functional importance
The MSA of DT with its newly identified homologs is important to provide insights into
the potential for conserved functionality among these homologs, but it also facilitates “evo-
lutionary footprinting” of the MSA, which has not been possible previously due to limited
sequence variation in the DT family. Evolutionary footprinting allows one to measure the
degree of purifying selection that has acted on individual residues in the MSA, which may
not only detect sites of known importance but novel sites as well.
A total of 31 DT residues show evidence of strong purifying selection (Figure 3.8 see
residues highlighted in red). Included among these residues are the known functional sites,
Tyr-54, Tyr-65, Glu-148, and Pro-345. Mapping of evolutionary conservation onto the DT
structure (Figure 3.8) reveals conservation of the key residues centered around the NAD-
binding/catalytic site in the C domain, strong general conservation of the translocation
domain, and weak conservation of the R domain. Evidence of purifying selection can also be
seen in sequence logos (Figure 3.8), which shows elevated conservation of key residues in DT
compared to neighbouring positions. Aside from residues of known functional importance
in DT, conservation footprinting predicted 27 additional residues under strong purifying
selection. Of these, 13 occur in the C domain, 10 of these occur in the T domain, and
four of these occur in the R domain. Seven of these are exposed sites on the DT surface
(residues with a solvent-accessible surface area greater than the mean for 1MDT), and six
of these are buried sites and are therefore likely to reflect structural constraints (residues
with zero solvent-accessible surface area). An example predicted residue of functional
importance based on conservation analysis is Lys-299, which is invariant among all of the
DT-like sequences. It is tempting to speculate that this surface-exposed residue and the
neighbouring Glu-298, which is substituted to Asp in some homologs, may aid in pH-driven
DT translocation.
DT homologs have novel genomic contexts and do not appear to reside in
corynephage loci
Finally, one important question concerning the identified homologs is their degree of simi-
larity at the level of genomic architecture and content. Do the identified DT-like homologs
reside within genomic regions suggestive of a corynephage origin similar to DT, or do they
occur in novel loci? Can other important genes in DT regulation be identified within the




































































































































































































































Figure 3.8: Conservation footprinting of the DT sequence family. (A) Sequence logos for three key
segments of conservation highlighted in B. These three regions contain many of the most highly conserved
residues between DT and DT-like proteins, including several of the residues required for catalytic and
translocation activity in DT. (B) Per-residue sequence conservation scores based on the DT family sequence
alignment (residue numbering based on PDB identifier 1MDT). Conservation scores were computed using
ConSurf. The domain boundaries of DT are indicated below the conservation scores as follows: catalytic
(C) domain, blue; translocase (T) domain, green; and the receptor-binding (R) domain, yellow. (C)
Evolutionary conservation scores mapped to the DT protein structure (1MDT).
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Shown in Figure 3.9 is a plot of the genomic architectures surrounding each of the
homologs, which has been arranged based on the evolutionary relationships of the DT-
like genes themselves. Except for an orthologous region shared between Streptomyces sp.
MBT76, S. nondiastaticum, and S. roseoverticillatus (Figure 3.9), DT-like genes share little
similarity overall, with virtually no similarity between corynephage loci within Corynebac-
terium and the DT-like group. Thus, it is unlikely that these toxins have simply been
transferred to these species via a standard corynephage, and more likely that they have
been acquired through an independent mechanism, or perhaps lost genomic evidence of
mobile acquisition over time.
We also searched the genomes containing the DT-like genes for homologs of DtxR,
the iron-mediated DT transcriptional repressor responsible for tox expression only under
iron-limiting growth conditions [326]. Only one genome, Streptomyces sp. TLI_053, had
a significant match (chromosome: I; 4,423,119 to 4,423,805; E = 3×10-66; 51% identity),
suggesting that DtxR may not be involved in the regulation of these DT-like genes. Other
regulatory genes are present adjacent to some of the DT homologs, including an FNR-
type transcription factor gene adjacent to the S. roseoverticillatus DT-like gene, which
is known to regulate genes under anaerobic conditions and is essential for virulence in
some pathogens [327]. Also present is a TetR-family gene, which is a common family of
transcription factors in Streptomyces genomes [328]. Thus, the conditions necessary for
expression of DT-like genes are currently unclear and appear different from those used by
C. diphtheriae to regulate DT.
3.1.4 Discussion and Conclusions
In this work, we have identified the first homologs of DT in bacterial species outside of
Corynebacterium genus. These homologs are the closest relatives of DT (within currently
available genomic databases), possess a DT-like domain architecture and conserve key
functional sites. Since these toxins form lineages that cluster outside of the DT group, it
is likely that they reflect early-diverging DT-like lineages that predate the emergence of
Corynebacterium DT. This model is supported by their occurrence within phylogenetically
neighbouring species of Actinobacteria, a phylum that includes Corynebacterium, Aust-
wickia, and Streptomyces as descendant lineages. Also consistent with this model is the
finding that DT-like genes do not appear to be carried by corynephages, but rather have
an independent evolutionary history and mode of acquisition.
A major question concerning these homologs is whether they are functional toxins. Al-
though biochemical studies of these proteins are necessary to answer this question, based
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Figure 3.9: Genomic context surrounding DT and identified DT-like genes. Corynebacterium DT genes
are highlighted in dark red, and DT-like genes are shown in lighter red. Detectable orthology between
genes based on top reciprocal BLAST matches is indicated by gray lines. Corynebacterium DT genes are
located within corynephages and there is clear synteny between both strains. However, identified DT-like
genes are associated with novel genomic architectures that share some synteny between each other but not
to tox -carrying corynephages. The S. albireticuli DT-like gene occurs as an isolated contig and therefore
genomic context is lacking. Putative transcriptional regulators (blue), transposases (green), and integrases
(teal) have been highlighted.
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on the bioinformatic analyses presented here, we hypothesize that these genes encode A-B
toxins with a DT-like mechanism. Their domain structure, combined with the conserva-
tion of catalytic sites and key residues, suggests that DT-like proteins may be capable of
host-receptor binding (although only A. chelonae exhibits strong similarity to the DT-R
domain), translocation into the cytosol, furin-mediated cleavage and disulfide linkage, and
binding and transfer of ADP to a target protein. However, the identity of the target or-
ganism, cell type, and even target protein is unknown at this point, which is a recurring
theme and disadvantage of bioinformatically identified versus protein toxins identified from
clinical isolates [1].
Although DT-like toxins share numerous features in common with DT, they are also
distinct from DT in several respects, and these differences provide potential insights into
their functionality. They cluster outside of the Corynebacterium DT lineage in phyloge-
netic analysis, their putative binding domains are divergent in sequence from DT and lack
numerous human HB-EGF binding residues, and importantly, they have never been as-
sociated with human infection before. Based on these differences, it is possible that the
DT-like toxins target different (nonhuman) hosts. Consistent with this idea, the closest
homolog of DT is the DT-like protein from A. chelonae, which was originally named Der-
matophilus chelonae but later reclassified [329]. Interestingly, A. chelonae was first isolated
from a nose scab of a snapping turtle and shown to have low infectivity for mammals [314].
Subsequently, A. chelonae has been associated with skin diseases and lesions in snakes and
reptiles [315, 330] similar to C. ulcerans in mammals. Although the DT-like gene is likely
a pseudogene in the sequenced Austwickia genome, it is possible that a functional copy
may exist in related strains, and the appearance of a DT-like gene in a skin pathogen is
nonetheless noteworthy. It is tempting to speculate that the DT-like toxin plays a role
in the pathogenesis of A. chelonae, and indeed may be responsible for the tissue death
observed in A. chelonae-associated infections.
It is unclear from sequence analysis alone whether DT-like proteins are capable of bind-
ing DT’s canonical target HB-EGF. Although the presence of HB-EGF is conserved across
vertebrates, it displays sequence variation among different groups. For example, HB-EGF
exhibits 97-99% identity across primates, and quickly drops among other vertebrates, from
88% in cows (human vs. cow), to 81% in mice (human vs. mouse), 71% in chickens (human
vs. chicken), and 56% identity in lizards (human vs. green anole). On the other hand,
the enzymatic target of the DT C domain, eEF-2, displays extreme sequence conservation
among vertebrates (95-100% identity for the organisms listed above). Based on this, an
intriguing possibility is that DT-like proteins have maintained enzymatic function but di-
versified in terms of receptor binding. The conservation observed in the C and T domains
could reflect stricter functional constraints in these domains and smaller variation among
92
their target molecules, while greater divergence in the R domain could be the product of co-
evolutionary pressure or potentially specialization for different target receptors or different
hosts. If this model is correct, this would implicate the DT R domain as the evolutionary
determinant of DT specificity and toxicity in humans.
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3.2 Structural characterization of diphtheria toxin ho-
mologs
3.2.1 Introduction
As demonstrated in the preceding chapter, diphtheria toxin homolog sequences possess
notable similarities to diphtheria toxin (DT), and conserve several functional features
[5]. These properties suggest that diphtheria toxin homologs also adopt a similar three-
dimensional structure. To investigate this, as part of ongoing work, Sugiman-Marangos et
al. have recombinantly expressed, purified, and structurally characterized the DT homologs
from Seinonella peptonophila (SP) and Streptomyces albireticuli (SA). These sequences are
compared below in Table 3.2, which demonstrates that the sequences of SA and SP are
distinct from DT and each other.
Table 3.2: Pairwise amino acid sequence identities between DT and the DT homologs from Seinonella
peptonophila (SP) and Streptomyces albireticuli (SA).
DT SP SA
DT
1MDT 100 - -
SP
WP_073156187.1 28 100 -
SA
WP_095582082.1 23.4 30.3 100
3.2.2 Methods
Chimera generation and protein purification
E. coli codon-optimized gBlocks R© gene fragments for full-length DT, SA and SA were
purchased from Integrated DNA Technologies (IDT). Two strains were used: E. coli
str. BL21(DE3) for SP, and B834(DE3) for SA. Primary amino sequences were ob-
tained from NCBI database entries WP_072564851, WP_095582082, andWP_073156187,
respectively. Strain B834(DE3) was chosen in order to supplement with heavy atom
derivativized selenomethionine. Individual domains were amplified by PCR, and domain-
swapped chimeras were generated with the NEBuilder R© HiFi DNA Assembly Cloning Kit
(New England BioLabs). All toxins and chimeras were expressed and purified with cleav-
able N-terminal 6His-SUMO fusions as lBioLabs), grown to an OD600 of 0.8 in LB media,
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and induced for 18 hours at 18 ◦C using 0.1mm IPTG. Cell pellets were pelleted by centrifu-
gation and then re-suspended in lysis buffer (20mm Tris pH 8.0, 500mm NaCl) and lysed
by 3-passes through an Emulsiflex C3 (Avestin) at 15,000 psi. Cell lysates were clarified by
centrifugation (20 minutes at 18,000×g) and bound to a 5mL HisTrapTM FF Crude col-
umn (GE Healthcare) and eluted with 50-75mm imidazole. Eluted protein was diluted to
∼150mm NaCl and incubated overnight at 4 ◦C with SUMO protease to cleave the affinity
tag. Cleaved protein was separated from SUMO, SUMO protease and uncleaved protein
with Ni-NTA resin, concentrated by centrifugation and exchanged into 20mm Tris pH 7.5,
150mm NaCl by dialysis.
Crystallization
All crystals were grown by hanging-drop vapor diffusion at 20 ◦C. For SA, 1 µL of selenome-
thionine derivatized SA (11.8mgmL−1) was mixed with 1 µL of mother liquor (10mm Tris-
HCl pH 7.0, 200mm calcium acetate hydrate, 20% PEG3000) and dehydrated over 200µL
of mother liquor. Diffraction quality SA crystals were obtained following successive rounds
of micro-seeding and flash frozen in liquid nitrogen without any additional cryoprotectant.
SP crystals were grown from drops containing 1 µL SP (15.8mgmL−1) and 1 µL mother
liquor (100mm potassium iodide, 22% PEG3350) dehydrated over 200µL of mother liquor.
SP crystals used for data collection were grown following successive rounds of micro-seeding
in drops dehydrated over 550mm ammonium sulfate, and flash frozen in liquid nitrogen
without any additional cryoprotectant. Data sets were collected remotely at a wavelength
of 0.979 Å for SA crystals and 2.0 Å for SP crystals on the AMX beamline at NSLSII
(Brookhaven National Labs).
Structure solution
All diffraction data was processed with XDS using the AutoPROC package [331]. Structure
solution of SA by SAD phasing was carried using the CRANK2 pipeline [332] in CPP4
[333]. The initial solution yielded 39 heavy atom sites (selenium) with an FOM of 56.8,
producing a partial model with an Rfactor of 43.37% (Buccaneer). A single monomer from
the partial model was used to perform molecular replacement using the PHENIX software
package [334], which located 4 copies of SA in the asymmetric unit, which were then re-
built with PHENIX-AutoBuild. SAD phasing of SP was performed with PHENIX-AutoSol,
yielding 18 heavy atom sites (iodine) with an FOM of 35.2 and a partial model (monomer)
with an Rfactor of 48.6%. Model building and refinement was carried out through multiple
95
iterations of manual building in Coot[335] and PHENIX-Refine until R and Rfree values
converged and geometry statistics reached suitable ranges.
Sequence and structural comparisons
Global pairwise sequence alignments used in Table 3.2 were calculated using needle from
the EMBOSS package [106] with a gap opening penalty of 10, gap extension penalty of
0.5, and the BLOSUM30 scoring matrix to improve alignment between distantly-related
sequences. Structural alignments used in Table 3.3 and Figure 3.11 were calculated and
visualized using PyMol. The crystal structures of SP and SA were separated into domains
based on alignment with the structure of diphtheria toxin (PDB identifier 1MDT, [307]).
Each SP and SA domain was subsequently used as a search query against sets of non-
redundant protein structures from the PDB using the DALI [336] and VAST [337] web
servers on July 30, 2019. The results of these structural comparisons were visualized using
R. Protein cartoons were made using the Pro-origami web server [338].
3.2.3 Results
SA and SP are structurally similar to DT
Similar to DT, the crystal structures of the DT homologs (Figure 3.10a) possess a 3-
domain structure, with homologous catalytic (C), translocase (T), and receptor-binding
(R) domains. SP and SA both possess an α + β catalytic domain, a hydrophobic α-helix
rich T domain, and a jelly-roll-like R domain. The largest structural displacements occur in
loop regions, which contributes to their relatively high RMSD after superposition (Figure
3.10a; Table 3.3); additionally, the structural alignment algorithm used to calculate RMSD
considers only aligned positions, and as such these RMSD values actually underestimate the
overall topological differences between DT and SP or SA. Nevertheless, when the individual
domains of SP and SA are compared to all other structures in the PDB, DT is consistently
the best-scoring match (Figure 3.10b) using two different structural comparison algorithms
(DALI and VAST [336, 337]). For the SP and SA C domains, the top-scoring match after
DT was cholix toxin, an ADP-ribosyltransferase toxin from Vibrio cholerae with known
similarity to DT [94].
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Table 3.3: Per-domain structural alignments of DT homologs with DT and associated RMSD values.
The RMSD of the structural alignments for every domain were calculated by PyMol using PDB 1MDT as
a reference. The high RMSD of SP’s C domain can be partially explained by the presence of non-conserved
flexible loops, as well as an extended unique α-helix.
C domain T domain R domain
SP 10.190 4.322 5.184
SA 2.229 5.635 4.634
The homologs’ structures contain several unique structural features. The secondary
structure elements for each domain are visualized in cartoon representations in Figure
3.11. The C domains of SP and SA feature generally elongated α-helices compared to
DT. The C terminus of the SP C domain also contains a unique, extended α-helix of
28 amino acids (residues 208-236) that partially occludes the NAD+ binding site. The
corresponding α-helix in DT is comprised of only 12 amino acids. Further, the SP α-helix
contains a slight preference for positively charged residues (containing a total of six K or
R residues), with K216, K232 and R239 having externally facing side chains, representing
potential interactors. The topology of the T domains from DT, SP, and SA are largely
the same, and all are predicted to possess an overall negative charge at neutral pH (pI of
4.94, 5.31, 5.17, respectively). The R domains SP and SA are larger than DT (by 28 and
23 residues), and notably contain unique loops and a short C-terminal helical turn that sit
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Figure 3.10: Crystal structures of two diphtheria toxin (DT) homologs. (a) DT (PDB identifier 1MDT)
and the DT-related proteins from Seinonella peptonophila (SP) and Streptomyces albireticuli (SA) adopt
a three-domain structure with similar topology. The RMSD of the structural alignment of full-length SP
and SA to DT (calculated using PyMol, with PDB identifier 1MDT as a reference) is indicated. In (b) and
(c), two structure-based search algorithms (DALI and VAST) were used to compare the domains of SP
and SA to sets of non-redundant structures in the PDB. For both SP (b) and SA (c), for every domain (C,
T, and R, labels indicated vertically), DT is the highest-ranked structural match by Z-score (red lines).
The second-highest match for the SA and SP C domains is cholix toxin, excepting SA’s C domain when

























































































































































































































































































































































Figure 3.11: Two-dimensional topology diagrams of DT (PDB identifier 1MDT) and the newly solved
structure of DT homologs SP and SA. Each query was separated into distinct domains (see Methods) and
used as a query to the Pro-origami web server. Each secondary structural element is rainbow-coloured
from N to C. The topologies of each domain are similar to DT in SP and SA, although they possess several
unique features. In particular, SP contains an elongated α-helix within its C domain, and the region of
the DT R domain corresponding to the EGF interface is different in SP and SA.
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3.2.4 Discussion and Conclusions
In additional to sequence conservation, SP and SA possess significant structural similarities
to DT. For both SP and SA, and for each of their C, T, and R domains, DT is respectively
the closest structural relative. After DT, the closest relative of the homologs’ C domains is
cholix toxin, an ADP-ribosyltransferase toxin from Vibrio cholerae [94]. The DT homologs
also feature unique structural elements, such as the large C-terminal α-helix in the SP C
domain. Consistent with patterns in sequence conservation, the T domains of SP, SA,
and DT possess nearly identical structural folds. The R domains of SP and SA are the
most divergent in sequence, but maintain structures similar to DT’s R domain. A notable
feature unique to the R domains of SP and SA is the apparent insertion of a short helical
turn corresponding to the EGF-binding region of the DT R domain.
Additional characterization is required to determine how the structural differences
unique to SP and SA affect their function. In the solved structures, neither homologs’ C
domain appeared to have bound an NAD+ moiety, and both lack electron density within
the C domain binding pocket that might correspond to the ligand. As well, a unique C-
terminal α-helical element in the SP C domain may occlude the NAD+ binding pocket. It
is possible that ligand-induced conformational changes alter the structure of the C domain
to prevent occlusion in SP, and ligand-induced conformational changes may also be possible
for the SA C domain. Nonetheless, the interaction between ADP-ribosyltransferase toxins
with eEF-2 seems to be strongly conserved, since the interaction is mechanistically similar
to eEF2’s interaction with the eukaryotic ribosome [339]. This makes the appearance of
structural novelties like the SP C-terminal α-helix more surprising. These outstanding
questions make it desirable to obtain structures with an NAD+ ligand or an appropriate
structural analog to confirm these C domains do indeed bind NAD+.
A similarly surprising difference is seen in the SP and SA R domains, which appear to
contain loops and a short turn that interfere with the binding interface between DT and
HB-EGF [325]. If the R domains of SP and SA are capable of binding human HB-EGF, it
might utilize a different binding mechanism, or binding potentially involves conformational
change in the R domains to better accommodate the receptor protein. An intriguing
alternative explanation is that the R domains of SP and SA may simply be optimized for
a different receptor.
It remains to be seen whether SP and SA are capable of performing the same functions
as DT: binding a surface receptor, translocating into host cells, and ADP-ribosylating a
host protein. Beyond that, the particular biological role of these sequences in virulence
must be examined in vivo. Although Streptomyces albireticuli is known to invade the ep-
ithelium of Caenorhabditis elegans [312], relatively little is known about the pathogenicity
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or ecology of either organism, which makes pursuing an in vivo approach more difficult. It
is unlikely that SP and SA have no function in vivo. Even if SP and SA were recent acqui-
sitions through lateral gene transfer, they must presumably have performed some function
in the source bacterium. Given that SP and SA have significant sequence and structural
similarity to DT, it seems probable that this original function was to intoxicate host cells.
A logical goal is therefore to elucidate which host types are susceptible, and further, to
determine the relevance of this intoxication to the toxin producer’s life cycle.
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Chapter 4
Evolution of the large clostridial toxin
translocase domain
Material in this chapter has been accepted for publication. When published, the manuscript
will be available from the following source:
1. Orrell, K. E., Mansfield, M. J., Doxey, A. C., & Melnyk, R. A. (2019). The C. dif-
ficile toxin translocase is an evolutionarily conserved apparatus for bacterial protein
delivery into host cells. Nature Communications (accepted).
4.1 The C. difficile toxin translocase is a conserved
apparatus for bacterial protein delivery into host
cells
4.1.1 Introduction
Large Clostridial Toxins (LCTs) are a family of bacterial toxins comprised of six proteins
(TcdA, TcdB, TcsL, TcsH, TpeL, TcnA) [340, 341], defined first by their similar biochemi-
cal, immunological and pharmacological effects [342], and later differentiated by their clini-
cal phenotype. TcdA and TcdB are the major causative agents of C. difficile infection, the
leading cause of hospital-acquired diarrhea in developed countries [288], while other LCTs
are implicated in gas gangrene, enterocolitis and toxic shock syndrome [343, 344, 345, 346].
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Although LCTs vary in their clinical manifestation, they all have highly similar structure
and function. LCTs are high molecular weight (>200 kDa) single-chain polypeptides, shar-
ing between 36-90% sequence identity [340] and inactivate GTPases in the Ras superfamily
by glycosylation [347]. In order to gain entry into cells and access cytosolic GTPases, LCTs
utilize their multi-domain architecture [348], much like other AB toxin families, including
diphtheria toxin (DT) [7] and botulinum neurotoxin (BoNT) [349]. In brief, using their
central translocation and receptor-binding domain (herein referred to as T-domain), LCTs
bind cell surface receptors and undergo receptor-mediated endocytosis. Low-pH mediated
conformational changes in acidified vesicles culminates in insertion of regions of the T-
domain into the endosomal membrane, resulting in formation of a translocation pore. The
translocation pore facilitates passage of the LCT glycosyltransferase (GTD) and cysteine
protease (CPD) into the cytosol, where the GTD is proteolytically released.
While much is known about the enzymatically active LCT domains, the function(s) of
the LCT T-domain have remained much more elusive [348]. The LCT T-domain is much
larger than the T-domain of other similar toxins (LCT: >100 kDa [350]; BoNT: ∼50 kDa
[349]; DT: ∼20 kDa [7]), and has a unique structural fold at high pH [350]. The LCT
T-domain at high pH is mostly composed of extended β-sheets, with a hydrophobic α-
helical region that extends and wraps around the β- sheet structures. Within the β-sheet
enriched region of the T-domain, four different LCT receptors have been identified (Tcdb:
CSPG4 [351], Fzd [63, 352], PVRL3 [353]; TcdA: LDLR [64]; TpeL: LRP1 [354]) that
all bind within the C-terminal region of the T-domain, with one receptor (CSPG4) also
binding partially to the C-terminal repeating region (CROPS) of TcdB [355]. The dual
functionality of the LCT T-domain to bind receptors and facilitate translocation has made
it difficult to disentangle receptor-binding from translocation, although several studies have
concluded that the N-terminal region of the T-domain is important for pore formation and
translocation. We and others have identified a pore-forming region between residues 956-
1115 [356, 357, 358], which maps to the hydrophobic α-helical stretch in the T-domain,
and important pore formation and translocation residues clustered between residues 1035-
1107 [357]. Recently, the structure of full length TcdB was solved at endosomal pH with
3 neutralizing VHHs [359]. Conformational changes can be observed within the pore-
forming region, although binding of a VHH within the pore-forming region and lack of
a membrane prevent a complete understanding of the toxin structure at low pH and in
the membrane. Outside 956-1115, the functional significance of the N-terminal region of
the T-domain remains unclear. Comparison of the six LCT T-domain sequences does not
reveal any striking patterns in conservation or hydropathy, and by extension, obvious clues
into important functional regions [348].
In the past five years, genomics-driven approaches have facilitated the discovery of hun-
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dreds of bacterial toxin homologs, providing fundamental insights into toxin evolution and
diversity [1]. Although homologs of major AB-toxins such as BoNT [99, 2, 181, 3], DT [5],
and others [96, 51] have been identified using bioinformatic approaches, there have been
no genomics-driven approaches to uncover and characterize LCT homologs. For BoNT
and DT, most studies have focused on identification and characterization of homologs con-
serving the full toxin architecture, such as the BoNT-like toxin in a commensal strain
of Enterococcus faecium [2, 181]. Among multidomain homologs, the receptor (which in
other toxins is distinct from the T-domain) and effector domains are the most extensively
analyzed, since these domains contain well-characterized functionally important residues.
Compared to receptor and effector domains, less is known about AB toxin transloca-
tion, and to date, no study has used genomics to elucidate AB toxin translocation. Since
homologs have been critical to understand the function of countless other proteins, we
speculate that T-domain homologs have the potential to make significant strides in our
understanding of toxin translocation. Understanding the process of translocation is not
only critical for a complete understanding of toxin entry and uptake into cells, but also has
numerous applications, both in therapeutic interventions of toxin-mediated diseases, and in
biotechnology applications, such as bacterial toxin-mediated drug delivery [360, 361, 362].
In order to unravel the function of the elusive LCT T-domain and to gain insights into
translocation, we took a genomics-driven approach to uncover distant homologs of the LCT
T domain. Here, we use the hundreds of newly uncovered LCT-T containing proteins to
shed light on LCT-T domain diversity and distribution, and to pinpoint an evolutionarily
conserved determinant of translocation present in hundreds of proteins. Our results provide
fundamental insights into translocation of a group of medically and biotechnologically
relevant toxins.
4.1.2 Methods
Detection of proteins containing LCT-like T domains, data set curation, and
annotation
The TcdB T-domain (UniProt ID P18177.3, residues 800-1814) was used as a query for two
iterations of PSI-BLAST [112] (with default parameters: BLOSUM62 substitution matrix,
gap existence 11, gap extension 1) against the NCBI non-redundant protein database (nr)
on June 13, 2019. A total of 1,573 protein sequences were retrieved. Proteins labeled as
“partial” or otherwise truncated, as well as any proteins with <100 amino acids upstream
of the translocase were removed from the data set. The T-domains from this set of se-
quences were further reduced to a final set of 203 non-redundant sequences by clustering
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with USEARCH (v10.0.240, [107]) at 90% identity. These sequences were aligned with
the L-INS-I algorithm of the MAFFT package (v7.407, [131]), and a maximum likelihood
tree was inferred using RAxML (v8.2.4, [135]) with automatic evolutionary model selection
(LG), 4 gamma-distributed rate categories, automatic bootstopping with autoMRE, and a
thorough ML search. This was visualized using the ape package in R [363]. This tree and
alignment were used as inputs to the Consurf web server and related to the structure of
TcdA [309], depicted using PyMol (available from https://pymol.org). Protein domains
were annotated using InterProScan (v5.33-72, [126, 364, 184, 118, 121]) and transmembrane
helix prediction was performed with TMHMM2.0 [306]. AnnoTree was used for phyloge-
nomic visualization of species containing LCT-T homologs across the bacterial tree of life
[365]. Proteome-level Pfam annotations from the AnnoTree database were used to deter-
mine the domains most correlated with an annotated LCT pore-forming domain model
(Pfam model PF12920), the top 100 of which are available in Table C.1. Metagenomic sur-
veys were performed using EBI’s MGnify server (http://www.ebi.ac.uk/metagenomics)
using the TcdB translocase (UniProt ID P18177.3, residues 800-1814) as the query. Ge-
nomic context plots were generated using genoPlotR (version 0.8.9, [163]).
Pathogenicity analysis of LCT-T homologs
The association of bacterial organisms with pathogenicity was assessed based on where the
organism was isolated and reviewing the literature, where possible. Broadly, an organism’s
level of pathogenicity was categorized into one of four possibilities: no known pathogenicity
or host association, host-associated with no known pathogenicity, known pathogen of non-
human hosts, and known pathogen of humans.
Comparison of effector diversity from different AB toxin families
The effector domains from different toxin families were retrieved by searching with each
toxin’s translocase domain as a query (BoNT: PDB identifier 3BTA, residues 548-865;
DT: SwissProt identifier P00588.2, residues 232-383) against the NCBI non-redundant
protein database with two iterations of PSI-BLAST. For DT and BoNT, the entire portion
upstream of the translocase hit region was extracted and treated as the effector region.
For the LCT family, the effector region was more difficult to define because it contains
the glycosyltransferase domain as well as the autoproteolytic cysteine peptidase domain,
and not all LCT-T homologs have detectable peptidase domains. Thus, the entire region
upstream of translocases in proteins lacking a peptidase, and the regions upstream of
peptidases in peptidase-containing sequences, were extracted separately to yield the set of
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LCT effectors. The putative effector regions from BoNT, DT, and the LCTs were clustered
at increments of 5% cluster sequence identity between 50% and 100% using USEARCH.
Effector types were assigned using InterProScan.
Generation of toxin chimeras and TcdB 851-1473
Regions of the TcdB T-domain were amplified from a codon-optimized TcdB gene for
expression in E. coli, and fused into a pET28a vector using the In-Fusion HD Cloning
(Clontech). Vectors for ADPR-[truncated TcdB T-domain]-DTR chimeras contained the
diphtheria toxin (DT) ADP-ribosyltransferase (ADPR) (defined here as residues 1-201)
with an intact furin cleavage site and DT receptor binding region (DTR) (defined as in DT
as amino acids 378-535), and the vector for GTD-CPD-[TcdB 851-1473]-DTR chimera con-
tained the TcdB glucosyltransferase (GTD) and cysteine protease domain (CPD) (defined
here in TcdB as residues 1-543 and 544-799, respectively) and the DT receptor binding
region (DTR). For regions of the TcdB T-domain truncation beginning at 851 or 881, a
short linker (four glycine followed by one serine (G4S)) was added between the truncated
TcdB T-domain, and the CPD or ADPR.
Expression and purification of recombinant toxin chimeras and TcdB 851-1473
Toxin chimeras and TcdB 851-1473 were transformed into E. coli BL21 DE3 competent
cells and expressed with N-terminal H6-SUMO and C-terminal Strep tags or an N-terminal
H6-SUMO tag, respectively. A total of 20mL of overnight culture was inoculated into 1.0L
of TB with 50 µgmL−1 kanamycin and induced at OD600 ∼0.6-0.8 with 1mm isopropyl-β-
thiogalactopyranoside (IPTG) at 25 ◦C for 4 hrs or 18 ◦C overnight. Cells were harvested
by centrifugation and resuspended with lysis buffer (20mm Tris pH 8.0, 500mm NaCl)
and lysed by an EmusliFlex C3 microfluidizer (Avestin) at 15,000 psi. Whole cell lysates
were then centrifuged at 15,000g for 20 min and filtered through a 0.2 µm filter. Proteins
were purified by Strep-Tactin affinity chromatography using a Strep-Tactin column (GE
Healthcare) and eluted in 20mm Tris pH 8.0, 150mm NaCl, 1mm D-desthiobiotin and
5% glycerol. For TcdB 851-1473, the H6-SUMO tag was removed by adding 1U of Sumo
protease (Life Sensor) to purified protein in 20mm Tris-HCl pH 8.0 containing 150mm NaCl
and 1mm DTT. The cleavage reaction mixture was incubated at 25 ◦C for 2hrs followed
by purification using His-Pure Ni-NTA resin (Thermo Scientific) to remove the His-Sumo
protease and His-Sumo tag from the purified protein samples. All protein were verified
by SDS-PAGE, concentrated with a 30,000 MWCO ultracentrifugation device. Protein
concentration was calculated by densitometry using ImageJ software.
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HPTS/DPX dye release from liposomes
The HPTS/DPX dye release assay was based on protocols from Genisyuerek et. al.
2011 [358]. In brief, liposomes were prepared with 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) (Avanti Polar Lipids), with 0.8% 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxy-
pentyl)iminodiacetic acid)succinyl] (nickel salt) (DGS-NTA[Ni]) (Avanti Polar Lipids). Af-
ter drying down with N2, the lipid film was resuspended in 20mm Tris, 150mm NaCl,
pH 8.0, 35mm 8-Hydroxypyrene- 1,3,6-trisulfonic acid (HPTS) and 50mm (p-xylene-bis-
pyridinium bromide) (DPX) (Thermo Fischer). Lipid vesicles were subjected to 10x freeze-
thaw cycles and extruded using a 200µm filter. To get rid of un-encapsulated dye, the lipid
vesicles were then subjected to gel filtration and eluted in 20mm Tris, 150mm NaCl. To
assess fluorophore leakage, protein were added in a ratio of 1:10,000 with liposomes, such
that the final liposome concentration was ∼400µm. The fluorescence was monitored in
a 96-well opaque plate (Corning) (excitation 403 nm, emission 510 nm) in high pH buffer
(20mm Tris, 150mm NaCl, pH 8.0) or low pH buffer (20mm Na-acetate, 150mm NaCl,
pH 4.5) (toxin chimeras), or with citrate-phosphate buffers ranging from pH 4.0-pH 7.5 in
0.5 pH increments (TcdB 851-1473). To determine total HPTS fluorescence, Triton X-100
was added to each well to a final concentration of 0.3%. All spectra were normalized to
100% dye release by 0.3% triton.
Cell viability
Vero cells were cultured in DMEM (Wisent) with 10% FBS (Wisent). Vero cells were
seeded at a density of 4,000 cells per well in 96-well plates (Corning) and cultivated at
37 ◦C and 5% CO2 overnight. Toxin chimeras were added to Vero cells in a serial dilution
of 1/3 (ranging from ∼50-100 nm; Figure C.2) and incubated at 37 ◦C and 5% CO2. After
48 hrs, cell viability was assessed by PrestoBlue Cell Viability Reagent (Life Technologies).
Fluorescence was read on a Spectramax M5 plate reader (Molecular devices). For each
toxin condition, the data were blank subtracted (i.e. buffer only, no cells) and normalized
(cells, untreated, representing 100% viable cells) and converted to fraction viable cells.
From these data, dose response curves and half-maximal effective concentrations (EC50
values) were generated and calculated using Prism software.
Protein synthesis inhibition
Vero cells stably expressing NanoLuc (Nluc) Luciferase (Promega) were cultured in DMEM
(Wisent) with 10% FBS (Wisent) and 1% penicillin/ streptomycin (Wisent). Vero Nluc
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cells were seeded at a density of 4,000 cells per well in 96-well plates (Corning) and culti-
vated at 37 ◦C and 5% CO2 overnight. Toxin chimeras were added to Vero NLuc cells in a
serial dilution of 1/3 (ranging from ∼50-100 nm; Figure C.2) and incubated at 37 ◦C and
5% CO2 for 24 hrs. Nano-Glo Luciferase Assay substrate and buffer (Promega) were added
to cells as per the manufacturer’s instructions, and luminescence was read on a Spectramax
M5 plate reader at (Molecular Devices). For each toxin condition, the data were blank
subtracted (i.e. buffer only, no cells) and normalized (cells, untreated, representing 0%
protein synthesis inhibition) and converted to fraction protein synthesis inhibition. From
these data, dose response curves and half-maximal effective concentrations (EC50 values)
were generated and calculated using Prism software.
Cell rounding
Vero cells were cultured in DMEM (Wisent) with 10% FBS (Wisent). Vero cells were
seeded at a density of 8,000 cells per well in 96-well plates (Corning) and cultivated at
37 ◦C and 5% CO2 overnight. The next day, media was exchanged with serum-free media
and cells were intoxicated by adding toxin chimeras at 1 nm. After 3 hrs, light microscope
images were taken at 10x magnification to assess rounding of cells.
Rac1 glucosylation
Vero cells (ATCC, Cat #CCL-81) were cultured in DMEM (Wisent) with 10% FBS
(Wisent) and 1% penicillin/streptomycin (Wisent). Vero cells were seeded at a density
of 100,000 cells per well in 6-well plates (Corning) and cultivated at 37 ◦C and 5% CO2
overnight. The next day, media was exchanged with serum-free media and cells were in-
toxicated by adding GTD-CPD-TcdB(851-1473)-DTR or TcdB at 1 nm. After 1 hr, media
was aspirated from cells, cells were washed with PBS and lysed by addition of Laemmli
loading buffer with beta-mercaptoethanol (Bio-Rad) to each well. Samples were heated to
90 ◦C before immediately loading on an SDS polyacrylamide gel. Following electrophoresis,
samples were transferred to nitrocellulose using standard wet transfer protocols, blocked
with 5% w/v non-fat powdered milk (Biobasics) in Trisbuffered saline (TBS; 5 g/100mL,
with a final concentration of 0.1m Tris HCl, 0.15m NaCl) and probed for total Rac1
(1:1,000 dilution) with Anti-Rac1 antibody 23A8 (Millipore Signma, Cat #05-389( or for
non-glucosylated Rac1 (1:1,000 dilution) with Anti-Rac Mab102 (BD Biosciences, Cat
#610651). Anti-α-tubulin (1:5,000 dilution; Sigma, Cat #T5168) was used as the loading
control. Following overnight incubation with the primary antibody, the blot was washed
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with TBS/0.1% Tween20 and incubated with (1:10,000 dilution) with Anti-mouse conju-
gated horseradish peroxidase (GE Healthcare, Cat #NXA931V) for 60 min. After the final
washes in Tris-buffered saline with Tween20, chemiluminescent detection was carried out
using Clarity Western ECL Substrate (Bio-Rat) and exposing to BioMax MR film (Kodak).
Stability studies
TcdB 851-1473 (5-10 µm) was incubated in citrate-phosphate buffers ranging from pH 4.0-
pH 7.5 in 0.5 pH increments at room temperature in presence and absence of 20 mM
dodecylphosphocholine (DPC). After 30 minutes, samples were spun at 5,000 × g for 5
minutes to pellet aggregates (but not detergent). The supernatant was removed from each
sample, and mixed 1:1 with Laemmli loading buffer with beta-mercaptoethanol (Bio-Rad)
and boiled for 2 min. Samples were then loaded onto an SDS-PAGE gel and stained using
GelCode Blue (Thermo Fisher).
Circular dichroism (CD) spectroscopy
Far-UV CD spectra were recorded at room temperature using a J-810 spectropolarimeter
(Jasco) with 0.1 cm path length cuvettes. Protein was added to a final concentration of 5-
10 µm in presence or absence of 20mm dodecylphosphocholine (DPC) in citrate-phosphate
buffers ranging from pH 4.0-pH 7.5 in 0.5 pH increments. After 30 minutes at room temper-
ature, all samples were spun down at 5,000 × g for 5 minutes to pellet aggregates but not
detergent. The supernatant was removed for each sample, and CD spectra were acquired
from 250 to 190 nm at 50 nmmin−1, with a data pitch of 0.1 nm and three accumulations.
Spectra were then averaged, blank subtracted and converted to mean residue ellipticity
using standard formulas.
4.1.3 Results
LCT-T containing proteins are widespread in pathogenic bacteria outside of
clostridia
To begin to explore the distribution, diversity, and function of the LCT T-domain, we
searched 200,270 available genomes (8,141 eukaryotes, 192,129 prokaryotes) within the
Genbank database, and retrieved all sequences containing an LCT-like T-domain. To this
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Figure 4.1: Discovery of LCT-like translocases in diverse species. (a) The search strategy for discovering
proteins with LCT-like translocases began by searching the NCBI non-redundant protein database (NR)
using the TcdB T-domain as a query (UniProt P18177.3), followed by two iterations of PSI-BLAST
searches. After removal of partial and poorly aligning sequences, a total of 1,104 LCT and LCT-T homologs
were retrieved. (b) A redundancy-removed and pruned alignment of translocase sequences was used to
generate a maximum likelihood phylogeny. Each tip represents a sequence cluster centroid, and coloured
according to their genus (genera that represent more than 1% of the total data set are coloured). Tip
radius is proportional to the size of the cluster.
(UniProt ID P18177.3, residues 800-1814). After removing partial and truncated hits a
remarkable 1,104 sequences were uncovered, including 335 LCT sequences found in various
clostridia (C. difficile, C. perfringens, C. novyi and Paeniclostridium sordellii, previously
C. sordellii), and an unprecedented 769 sequences in species outside of clostridia (hereafter
referred to as LCT-T homologs; Figure 4.1a). LCT-T homologs share an average of 18.6%
amino acid identity with the TcdB translocase, reflecting remote homology, and are mostly
found distributed among the class Gammaproteobacteria (688 sequences across 32 genera);
of the 32 genera, sequences are mostly found in Pseudomonas (419 sequences), followed by
Vibrio (72 sequences) and Providencia (67 sequences) (Figure 4.1b). The patchy distribu-
tion of LCT-T homolog sequences across the bacterial tree of life indicates that evolution
by lateral gene transfer has likely played a strong role in the family’s evolution, a pattern
that has been observed in other toxin families (Figure 4.2) [365].
Consistent with their wide taxonomic distribution, analysis of metagenomes revealed
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LCT-T homologs in a broad distribution of environments (Figure 4.3). We detected LCT-
T homologs in human gut, soil, wastewater, marine and aquatic environments, where the
T-domains of other AB toxins (i.e. BoNT, DT) were conspicuously absent (Figure 4.3).
Notably, LCT-T homologs were not encoded within analogous LCT pathogenicity loci
(PaLoc) [366], with genes for toxin regulation (tcdR, tcdC ) or toxin export (tcdE ). De-
spite their occurrence in a wide variety of genomic contexts (Figure 4.4), many LCT-T
homolog genes were located near components of type I, III, IV, and VI secretion systems,
and through proteomic association, the top co-occurring protein families with the LCT-
T domain included secretion systems, along with many other virulence genes and mobile
genes, including transposons and insertion elements (Table C.1). Together with their phy-
logenetic distribution, these data suggest that LCT-T homologs may function as putative
toxins, many of which utilize non-LCT modes of bacterial secretion and export.
In line with their toxin-like genomic signatures, 74% of LCT-T containing proteins
were found in organisms with evidence of pathogenicity. In addition to species with known
pathogenic potential, homologs were found in a range of host-associated microbes, which
may be suggestive of cryptic pathogenic potential. Of the known pathogenic species, 22%
were human pathogens, including Pseudomonas fluorescens, Photorhabdus asymbiotica,
Serratia mascerens and several species of Providencia (P. alcalifaciens, P. rettgeri, P. stu-
artii); these bacteria are generally opportunistic pathogens, and are associated with severe
diseases in immunocompromised individuals [367, 368, 369, 370, 371, 372]. Interestingly,
the majority of remaining LCT-T homolog sequences occurred in species associated with
pathogenicity in non-human hosts, including species of Vibrio, Pseudomonas, Xenorhab-
dus and Photorhabdus, which are known pathogens of aquatic organisms, insects, and
fungi [373, 374]. Notably, species of Pseudomonas, Xenorhabdus, and Photorhabdus pro-
duce insecticidal toxins FitD and Mcf, which have with previously noted homology to the
TcdA/TcdB T-domain [375]. Although the association of LCT-T containing proteins with
disease or infection is not known, their presence in pathogenic species strengthens the claim
of a putative toxin functionality.
LCT-T homologs occur in putative toxins with diverse effector types
We next annotated the individual domains within all 1,104 LCT-T containing proteins, to
determine the types of effectors upstream of (and therefore, potentially translocated by)
LCT-T homologs. In support of a putative function as a toxin, most LCT-T containing
proteins have upstream “LCT toxin domains”, with ∼30% of sequences containing a glyco-
syltransferase (GTD-containing), ∼20% with a glycosyltransferase and cysteine protease








Figure 4.2: Phylogenomic distribution of organisms encoding proteins with LCT-like T domains. Or-
ganisms encoding at least one protein with an LCT-like T domain (red highlighting) are mostly found































Figure 4.3: Phylogenetic placement of metagenomic LCT-like translocases onto the tree of LCT translo-
cases from Figure 4.1. Coloured circles represent metagenomically-derived sequences with significant simi-
larity to the TcdB translocase. Sequence fragments from human gut metagenomes include nearly identical
matches to segments of the TcdA and TcdB translocases. Metagenomic sequences from other environ-
ments generally have lower identity to the TcdB translocase, and place more closely to sequences from
Pseudomonas and Vibrio spp.
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5 kb
Clostridiodes difficile str. 630
CP010905.2 765383−803515
Paeniclostridium sordellii str. VPI 9048
NZ_AQGJ01000153.1 1−31258
Clostridium novyi str. GD211209
NZ_CM003331.1 255117−290360
Clostridium perfringens C str. JGS1495
ABDU01000064.2 46162−81492
Pseudomonas fluorescens str. PA3G8
NZ_KN639173 528826−565839
Providencia stuartii str. Crippen
NZ_LVIE01000002 106911−142586
Photorhabdus luminescens str. LN2
JQOC01000005.1 102473−141307
Xenorhabdus nematophila str. F1
NZ_HF952043.1 232135−269724
Yersinia mollaretii ATCC 43969
NZ_AALD02000011.1 54923−90316





























































































Figure 4.4: Genomic architecture of genes with LCT-like translocases. In C. difficile, the LCT genes
tcdA and tcdB are found in a pathogenicity locus (PaLoc) that also contains the regulator tcdR and
the holin gene tcdE, responsible for exporting the toxin genes. Other LCTs are found in loci with some
shared features. Outside of the clostridia, proteins with LCT-like translocase domains are found in a
wider variety of genomic contexts; a small subset is shown here. These proteins are associated with the
presence of secretion systems, but otherwise have few commonalities. One apparently conserved locus,
shared between many species of Pseudomonas and highlighted in pink, is related to B12 metabolism.
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4.5a). We also identified proteins containing different toxin families upstream of LCT-T
domains (e.g., a homolog of anthrax toxin lethal factor in WP_102423241.1 from Vibrio
sp. 10N.261.52.A1). Interestingly, ∼40% of sequences have upstream sequences that are
not annotated, containing protein(s) either falling below detection thresholds and/or are
novel, uncharacterized proteins. By comparison, through the same type of analysis, the
putative effectors of DT-T and BoNT-T homologs were predominantly ADP ribosyltrans-
ferases (ADPR) and peptidases, respectively, the well-known effectors of DT and BoNT
(Figure 4.5b).
With respect to the size of the upstream translocated cargo, we found that the LCT-
Ts on average translocate much larger proteins: 965 amino acids, compared to 479 amino
acids for BoNT-T homologs: and 218 amino acids DT-T homologs (Figure 4.5b). Moreover
we found that the translocated cargo had greater sequence diversity, regardless of cluster-
ing at any sequence identity (Figure 4.5c). These data suggest that although each AB
toxin-translocase may be fine-tuned for translocating particular types of effector, LCT-T
translocases may be capable of translocating more diverse effectors with a wider range of
sequence and size diversity.
Evolutionary footprinting identifies a conserved region across LCT-T homologs
Next, we leveraged the greatly expanded number and diversity of newly identified LCT-T
homologs to uncover conserved molecular features of the T-domain of LCT-T homologs.
Alignment of the TcdB T-domain and LCT-T homologs revealed a shared core region,
with a distribution of start and end sites at amino acids 815 (±6 residues) and 1514 (±99
residues), respectively (Figure 4.6a). In the context of the best characterized homolog,
TcdB, this region encompasses regions previously implicated in pore-formation and translo-
cation [356, 357]. Within this stretch are three distinct regions (region i: 956-1019; region
ii: 1029-1078; region iii: 1090-1110) that share a remarkably similar pattern of hydropathy
- one small peak, followed by two larger peaks - that map to putative membrane-insertion
regions (Figure 4.6b) [356]. Furthermore, many of residues that were found to be highly
conserved within region ii and region iii among the LCT-T homologs (TcdB residues: I1035,
D1037, L1041, P1095, G1098, I1099, L1106 and V1107) correspond to residues in TcdB
that were previously shown to be implicated in pore formation and/or translocation (Fig-
ure 4.6c) [357]. The conservation of important translocation features is consistent with the
LCT-T homologs functioning as protein translocases in putative toxins.
The identification of an evolutionarily-conserved region in LCT-T homologs led us to
hypothesize that such smaller-sized forms of the larger T-domain might comprise the core























































































































































Figure 4.5: Analysis of proteins with LCT-like T-domains. (a) Proteins with LCT-like T-domains can
be found in three domain architecture types: LCT-like (red; 147 sequences), GTD-containing (blue; 246
sequences), CPD-containing (yellow; 65 sequences), and variable (other) composition (grey; 316 sequences).
Within each domain architecture, two examples are shown. (b) By clustering the effectors at different levels
of sequence identity, the diversity of effectors between the translocation domain families can be compared.
At all levels of identity, the LCT family yields the largest number of effector sequence clusters, suggesting
the LCT T-domain transports more diverse cargo than BoNT or DT translocases. (c) Comparison of
effector lengths and types between BoNTs, DTs, and LCTs. The DT family possesses the smallest effectors,
most of which are ADP-ribosyltransferases (ADPRs). The BoNT effector family is comprised mostly of






























































































































































































































































































































































































































































































































Position of match to TcdB














Figure 4.6: Patterns of sequence conservation among LCT-like T-domains. (a) The distribution of
BLAST matches to the TcdB T-domain demonstrates that the region common to all LCT-like T domains
is limited to within the first 700 amino acids of the N terminus. (b) The structural context of the mean
BLAST start (815) and end (1515) sites, as mapped on to the TcdA T domain (PDB 4R04). Normalized
sequence conservation for the region spanning residues 815 to 1356 shows three main peaks of sequence
conservation (i, ii, and iii). Two of these conserved regions correspond to an average increase in predicted
transmembrane helix propensity. (c) Within the three sequence conservation peaks, several sites known
to result in the loss of translocation activity in TcdB (underlighted with black boxes and denoted with an
asterix) are conserved among LCT-like T-domains. However, several strongly conserved residues are not
associated with a loss of translocation function, suggesting they are related to some other key function in
LCT-like T-domains (including Y991 and D1005).
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Figure 4.7: Defining the evolutionarily conserved and minimal LCT translocase region. (a) Construct
design of ADPR-[truncated TcdB T-domain]-DTR chimeras. (b) Dye release from HPTS/DPX loaded
liposomes at pH 4.5, with truncated TcdB T-domains coloured as follows: 800-1500 (red), 800-1473 (green),
800-1394 (yellow), 800-1338 (blue). (c) Quantification of dye release from HPTS/DPX loaded liposomes
after 20 minutes, at pH 4.5 (grey) and pH 8.0 (black) (N=3). (d) EC50 values from cell viability (black)
and protein synthesis inhibition (grey) of Vero cells (N=4). Panels e, f, g, h the same as a, b, c, d,
respectively, but with truncated TcdB T domains 851-1500 (red), 851-1473 (green), 851-1394 (yellow),
851-1338 (blue).
this directly, we used the relative distribution frequency of start and end sequence coverage
sites as guides to design a series of T-domain truncations in the most well characterized
LCT homolog, TcdB, generating TcdB truncations with two different N-terminal start sites
(viz., residues 800 and 851), and a variable C-terminus (X = 1500, 1473, 1394, 1338) (Figure
4.7, Figure C.1). In order to assess translocation in cell-based assays, we developed a pore
formation/translocation platform using the DT ADP-ribosyltransferase (ADPR) and the
DT receptor-binding domain (DTR) as a scaffold, such that test chimeras would have the
general ADPR-[truncated TcdB T-domain]-DTR architecture. We used DT because of the
well-established and facile readout of the ADPR (protein synthesis) and the robust binding
of DTR to the ubiquitous HB-EGF receptor, present on many cell lines. Practically, the
ADPR and DTR domains are amenable to greater levels of expression in E. coli over the
GTD, CPD of LCTs, making a DT-TcdB chimera a more feasible platform to screen a
large number of constructs.
We subjected the chimeras to two rounds of experimental testing, first testing their
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ability to form pores, and then, their ability to translocate. To probe pore formation,
we pre-loaded liposomes with the quenched dye-pair HPTS/DPX, and monitored dye re-
lease (fluorescence) over time, with dye release as a surrogate for pore formation. To
assess translocation, we evaluated intoxication (indirect measure of ADPR translocation
into the cytosol) and protein synthesis inhibition (direct measure of ADPR translocation
into the cytosol). All TcdB truncations formed pores in our dye release assay (Figure
4.7b, c); however only two truncations were able to facilitate translocation (i.e. 800-1500,
800-1473) (Figure 4.7d); constructs were considered non-toxic if unable to intoxicate cells
at concentrations up to 50 nm, the highest concentration we could test all chimeras (Fig-
ure C.2). In line with the above data, we found that all TcdB T domain truncations
starting at residue 851 formed pores (Figure 4.7f, g), while only 851-1500, 851-1473 were
able to facilitate translocation (Figure 4.7h, (Figure C.2). Further truncation to 881 (i.e.
881-1473); however, abrogated translocation (Figure C.2). Taken together, these results
indicate that residues 851-1473 comprise all of the components needed for pore-formation
and translocation.
To further interrogate the evolutionarily conserved (and minimal TcdB) translocase,
we also produced TcdB 851-1473 in a hybrid TcdB-DT system, with the GTD and CPD
of TcdB and the receptor-binding domain of DT, such that the chimera was GTD-CPD-
[TcdB(851-1473)]-DTR (Figure 4.8a, (Figure C.1). To evaluate translocation, we assessed
cell rounding and Rac1 glucosylation (both direct measure of GTD translocation into the
cytosol) and intoxication (indirect measure of GTD translocation into the cytosol). TcdB
851-1473 caused cells to round (Figure 4.8), glucosylated Rac1 (Figure 4.8c) and intoxicated
cells (Figure 4.8d), while GTD-CPD-DTR lacking any of the TcdB T-domain did not cause
cells to round and was non-toxic, reinforcing TcdB 851-1473 as a functional translocase
region.
The evolutionarily conserved translocase retains its form and function
With the discovery of an evolutionarily conserved translocase shared among distant LCT-T
homologs, and a minimal LCT translocation region, we aimed to further investigate the
properties of TcdB 851-1473. We were able to recombinantly produce soluble TcdB 851-
1473 to high levels of purity for characterization. TcdB 851-1473 exhibited pH-dependent
pore formation, with maximal dye release at pH 4.0 and minimal dye release above pH 5.0
(Figure C.3). To further gauge the behaviour of TcdB 851-1473 as a function of pH, we
assessed stability and conformational changes of TcdB 851-1473 in the presence and absence
of a membrane mimetic, dodecylphosphocholine (DPC). At low pH (i.e. pH 4.0, 4.5, 5.0),
TcdB 851-1473 rapidly aggregated out of solution (Figure C.3d), but remained in solution
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Figure 4.8: TcdB 851-1473 functions as a translocase in a hybrid TcdB-DT context. (a) Construct
design of GTD-CPD-[TcdB(851-1473)]-DTR and GTD-CPD-DTR (i.e. ∆T-domain). (b) Light microscopy
images of Vero cell rounding, assessed after 3 hrs. Representative images are shown for untreated cells, and
for cells treated with TcdB, ∆T-domain and GTD-CPD-[TcdB(851-1473)]-DTR. All protein were added
to cells at a final concentration of 1 nm. (c) Fraction cell viability of Vero cells incubated with GTD-CPD-
[TcdB(851-1473)]-DTR, with 1.0 indicating 100% viable cells and 0 indicating 0% viable cells (N=4). (d)
Western blot to detect total Rac1, non-glucosylated Rac1 and tubulin in untreated Vero cells, and for
cells treated with TcdB or GTD-CPD-TcdB(851-1473)-DTR. All protein were added to cells at a final
concentration of 1 nm.
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and soluble in presence of DPC (Figure C.3e), suggesting that low pH results in exposure of
hydrophobic surfaces of the translocase, which readily insert into the hydrophobic interior
of the DPC micelle to prevent aggregation. By circular dichroism (CD) spectroscopy, at
high pH (pH 7.5 to 6.0), TcdB 851-1473 had the characteristic spectra of a helical protein,
with minima at 208 nm and 222 nm (Figure C.3f). Upon lowering of pH and in the
presence of DPC, TcdB 851-1473 underwent structural changes, transforming into a protein
with a mixture of both helical and β-sheet content, with a minimum at 218 nm (Figure
C.3g). Taken together, our data indicated that TcdB 851-1473, and by extrapolation, the
evolutionarily conserved region, when isolated is autonomous as it retained proper folding
and function, and more specifically, pore formation and translocation activity.
4.1.4 Discussion and Conclusions
In this work, we conducted a targeted search to identify proteins that have homology to
the T-domain of TcdB. TcdB is the best characterized member of the small LCT family, of
which there was previously only 6 total members (TcdA, TcdB, TcsL, TcsH, TpeL, TcnA).
Querying just the T-domain of TcdB, rather than the entire toxin, enabled identification
of proteins with little or no homology in any of the other three domains, that would have
otherwise gone undetected using other bioinformatic strategies. This approach facilitated
the identification of hundreds of LCT-T containing proteins distributed widely throughout
the bacterial kingdom, including in pathogenic species outside of clostridia. Conservation
of hydropathy and key residues (clustered in conserved regions ii and iii) supports the
function of these regions as pore-forming elements, suggesting that LCT-T homologs have
highly similar membrane-inserted structures of LCTs, indicating that homologs could be
utilized to gain insights into the translocation pore, and broadly, translocation.
There are very few studies of LCT translocation [356, 357, 376, 377], which may reflect
the difficulty in studying the process. Homologs (especially for membrane proteins) have
been used countless times to gain structural and functional insights of more relevant fam-
ily members, helping to circumvent numerous experimental obstacles, and we hope that
LCT-T homologs could be exploited for this function. In addition to functioning as an
experimental proxy for LCTs, LCT-T homologs revealed strongly conserved residues that
were not 100% conserved in LCTs (such as TcdB D1103), suggesting that some critically
important residues may only be apparent through analysis of hundreds of distant homologs.
In addition to important single residues, it is intriguing that, similar to BoNT and DT [3],
a PxxG (more specifically, PxxGL) motif was identified as being strongly conserved in
LCT-T homologs. We hope this study provides the platform to begin to interrogate these
novel and uncharacterized translocation features.
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One of our most striking findings was that of an evolutionarily conserved transloca-
tion region, which we show acts as a functional and minimal translocase in TcdB, and in
isolation, retains low-pH mediated pore formation activity; notably, our studies indicated
that pore formation alone is not sufficient for translocation, as many LCT regions could
form pores but not translocate. On its own, the identified minimal conserved translocase
may not be the most efficient or even abundant translocator among LCT-T homologs, but
instead reflects the minimal necessary and sufficient requirements for translocation. Fur-
ther, in the specific context of LCTs, although TcdB 851-1473 may not be as efficient as
the entire T-domain to facilitate translocation, due to its smaller size (70 kDa vs. 100 kDa
full length TcdB T-domain), favorable expression and conservation of pH-dependent pore
formation and translocation activities, the protein is an ideal candidate for mechanistic
studies of pore formation and translocation.
In comparing the T-domains of BoNT and DT, we found that the T-domains of AB
toxins are predominantly associated with one type of effector: ADPR (DT), peptidases
(BoNT) and GTD (LCT). We speculate that the association of a translocase family with
an effector family may be indicative of translocase-effector co-evolution, implying that AB
toxin T-domains are fine-tuned to translocate a particular effector type. This perhaps
clarifies why three AB toxin translocase domains exist, instead of just one. Although each
translocase may be best suited to translocate a particular effector type, LCT T-homologs
seem to accommodate effectors of greater sequence diversity, length, and potentially type.
We speculate that LCTs may in turn be more amendable as translocation scaffolds for
protein cargo that is larger and more diverse in sequence. The potential permissiveness
of LCT-T homologs may have direct applications in bacterial toxin drug delivery, where
bacterial toxins are harnessed to deliver therapeutic cargo (namely proteins) into cells
[360]. We think an interesting application of this work is to explore the potential of LCTs
as a delivery platform, and we hope that this study motivates future research into this
application.
With the identification of hundreds of new LCT-T homologs, our work raises the in-
triguing question of the ecological role(s) of LCT-T containing proteins. Bioinformatics is
a powerful starting point for toxin identification, and provides clues into the putative toxin
functionality of LCT-T homologs. Further guidelines are still required for definitive toxin
identification, such as Falkow’s molecular Koch’s postulates [89], which require that toxins
(or virulence factors) exist only in a pathogenic strain, with mutation or deletion of the
virulence factor resulting in loss of pathogenicity. We hope our work provides a starting
point and framework to further interrogate the function and ecological significance of these




[...] we have to remember that what we observe is not nature
in itself but nature exposed to our method of questioning.
Physics and Philosophy: the Revolution in Modern Science
Werner Heisenberg
Research into bacterial toxins began nearly 150 years ago, just as microbiology had
begun to develop as a discipline in its own right. Then and now, studies of toxigenic
pathogens have spurred much research, primarily in medicine and epidemiology. Beyond
the considerable impact toxin research has had on human health, toxins have proven useful
for a wide variety of purposes. The discovery that botulinum neurotoxins cleave SNAREs
and thereby inhibit neurotransmitter release established the role of SNAREs in exocytosis,
and at the same time provided strong evidence in favour of the quantal release hypothesis
[52, 378, 379, 380]. The fact that the adenylate cyclase toxin of Bordetella pertussis is only
active when injected intracellularly has been exploited to discover effector proteins from
pathogens like Salmonella, Yersinia, and Xanthomonas [54, 381, 382, 383]. Diphtheria
toxin - the cause of mortality rates as high as 10% in diphtheria disease, which in some
areas once afflicted as many as 1 in 20 children [384] - has now been re-engineered as
an immunotoxin to kill cancer cells [385]. In a field that has already proven fruitful, the
research and research applications made possible by genomics seem especially promising.
In the following chapter, I briefly describe the contributions of the research presented in
this thesis, discuss some of its limitations, and conclude with a prospective for the field.
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5.1 Summary of major findings
In Chapter 2, several analyses the botulinum neurotoxin family were presented, focusing
on the identification of novel variants from genomic data. Chapter 3 presents a similar
genomic survey for diphtheria toxin, presenting the first sequences directly homologous to
the toxin outside of Corynebacterium. Chapter 4 utilizes bioinformatic methods to hone
in on the process of toxin translocation in large clostridial toxins. In each case, genome
sequencing has enabled the discovery of novel and diverse toxin sequences that may have
gone unnoticed through traditional toxin identification methods. The main differences
between each chapter are that they highlight different aspects of toxin evolution. In bo-
tulinum neurotoxins, novel toxins and toxin gene cluster sequences appear to be much
more widespread than previously thought, and further, genomically-identified neurotoxin
homologs appear to possess functional novelties compared to currently described lineages.
Similarly, genomically-identified diphtheria toxin homologs greatly expand its protein fam-
ily and known taxonomic distribution, but also display significant structural conservation.
In large clostridial toxins, the evolutionary analysis of distantly related sequences facili-
tates detailed functional analysis of the TcdB translocase domain. In short, it is possible
to gain many insights into toxin families when they are examined from an evolutionary
perspective.
5.1.1 Evolution of botulinum neurotoxins
The discovery of a protein related to botulinum neurotoxins (BoNTs) in Enterococcus fae-
cium provides evidence of the first closely-related BoNT sequence outside of Clostridium,
far closer than the homolog in Weissella oryzae (or, BoNT/Wo [101]) [99]. Moreover, it
provides the first evidence of BoNT-related sequences in Enterococcus. The strain observed
in this experiment was not associated with disease, and appeared to be most closely re-
lated to commensal strains 1, but nonetheless reveals the apparent ability of Enterococcus
to acquire and potentially disseminate bont genes. Since enterococci continue to be a
major source of hospital-acquired infection [156, 157], the acquisition of a bont-like gene
is certainly noteworthy. Additionally, preliminary functional characterization results (see
Zhang et al. [2]) suggest that BoNT/En is capable of inducing botulism-like paralysis
making BoNT/En a potential health concern, although toxicity is only observed at un-
usually high concentrations for BoNTs. The closest phylogenetic relative of BoNT/En is
1The thesis includes only the bioinformatic portions of the published paper. For details on results and
methods not included in this thesis, see the publication by Zhang et al. [2].
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the recently-described BoNT/X [155]. As the two group together and separately from the
rest of the BoNT family, it is possible that they represent a large, early-branching clade of
BoNTs that has remained undiscovered. Considering there is no specific mechanism known
for the transfer of a clostridial gene cluster in to Enterococcus, it is possible that BoNT/En
was transferred from a different, unknown host bacterium.
A genomic screen for additional BoNT-related sequences revealed partial and complete
BoNT homologs in a variety of other species, including bacteria and fungi. The identified
sequences have many conserved BoNT characteristics, particularly in their metalloprotease
domains. Surprisingly, BoNT-related sequences with metalloprotease domains provided a
link between the BoNT protease and a family of type III secretion system (T3SS) metal-
loprotease effectors (NleD in Escherichia coli, and HopH1 in Pseudomonas syringae). The
relationship between the two is distant, but BoNT, BoNT-like proteases, and the T3SS
effectors clearly have large segments in common, including catalytic residues. Two BoNT-
specific insertions clearly differentiate the two families, and given the extended interaction
of BoNT with its substrate, it is likely that these regions play a role in determining sub-
strate specificity. Analysis of the translocase regions from BoNT-related sequences revealed
similarity both to BoNT translocases, fungi sequences of unknown function, and diphthe-
ria toxin (DT) translocases. Among the BoNTs, residues that play a role in membrane
insertion in DT are strongly conserved. This finding is remarkable because the roles of
particular residues in BoNT translocation remain largely unknown; recently, a structure-
based study of BoNT translocation provided strong evidence that these conserved residues
do indeed participate in translocation [386].
A family of BoNT-related sequences was discovered in Chryseobacterium piperi. One
C. piperi sequence, designated Cp1, was found to induce necrotic cell death in human cells
using a metalloprotease-dependent mechanism. Its cellular target(s) remains unknown,
since inducing expression of the Cp1 protease causes death too rapidly to yield samples
suitable for proteomic analysis. However, since the canonical BoNT target proteins VAMP,
SNAP25, and syntaxin were not cleaved by Cp1, its activity must be due to cleavage of
some other host substrate(s). This observation underscores another evolutionary facet of
the BoNT family. Although it is possible to rationally design a BoNT protease capable of
cleaving targets beyond traditional BoNT substrates [387], it seems that Cp1 does so nat-
urally. Thus, genomically-identified BoNT-related sequences demonstrate both sequence
and functional diversity within the BoNT family. It is likely that genomic investigations
will continue to uncover more novel BoNTs with novel functions [388].
Between Cp1 and BoNT/En, it seems that the BoNT family is not restricted to Clostrid-
ium species [389]. The distribution of OrfX proteins across distantly related bacteria
suggests that the OrfX cluster is similarly not restricted to clostridia. The OrfX gene
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clusters with the greatest similarity to BoNT gene clusters are encoded by the various
genomically-identified BoNT-related sequences, including the clusters containing BoNT/X
in C. botulinum str. 111, BoNT/En in E. faecium, and the recently identified PMP1 in
Paraclostridium bifermentans [260]. Outside of these neurotoxin-containing OrfX clusters,
the OrfX clusters found in Bacillus thuringiensis, Bacillus sp. 2SH, Brevibacillus, and
Paenibacillus are the most similar by analysis of sequence content and phylogenetics. No-
tably, B. thuringiensis, Brevibacillus spp., and Paenibacillus spp. are broadly associated
with insect pathogenicity. Indeed, many OrfX gene clusters are found in the genomes of
distantly related insect pathogens, and these OrfX clusters typically contain non-BoNT,
toxin-related sequences.
The nature of the relationship between OrfX proteins and insect pathogenicity is un-
known. In BoNTs, the analogous genes of hemagglutinin clusters are known to form toxin
complexes with NTNH proteins. It has thus been widely assumed that OrfX proteins par-
ticipate in a similar complex, although the evidence to support this is relatively sparse. It
is possible that the lack of evidence for OrfX-BoNT complex formation is related to insect-
specific functions or conditions, whereas most BoNT experiments have been performed
with mammalian cells. Although this is speculative, what is clear based on comparative
genomics is that the OrfX gene cluster appears to be a flexible component or scaffold of
many different toxin clusters, and also that orfX genes undergo lateral gene transfer in-
dependently of bont genes. As such, while it cannot be ruled out that OrfX proteins do
indeed function analogously to HA proteins by complexing with toxins and assisting uptake
through the gut [149], based on the structural similarity of OrfX proteins to membrane
permeability-increasing proteins [261] and the association of OrfX-related genes with di-
verse toxin-related genes, an additional possibility is that OrfX proteins may participate
more generally in toxin release and export. The relatively broad taxonomic distribution
of orfX genes and their association with a variety of host types means that significant
characterization efforts will be required to address these outstanding questions about OrfX
functionality.
5.1.2 Discovery and analysis of diphtheria toxin homologs
Homologs of diphtheria toxin (DT) are distributed broadly among the phylum Actinobacte-
ria, with many diverse variants found in species of Streptomyces. In addition to significant
sequence similarity (E -values «1×10-10), several residues that are known to contribute to
DT function are strongly conserved in DT homologs, notably including the catalytic E148
residue. Overall, the catalytic (C) and translocase (T) domains of DT homologs are more
similar to DT than the receptor binding (R) domain. This might reflect stricter functional
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constraints in the C and T domains compared to the R domain [390, 391], but is also po-
tentially related to the strong conservation seen among orthologs of DT’s catalytic target
(eEF-2) compared to its receptor (HB-EGF). The identification of diphtheria toxin-related
sequences outside of Corynebacterium has further implications for the gene family. In
Corynebacterium, the tox gene encoding diphtheria toxin is located within a corynephage
[296, 297], implicating the phage as the major mechanism for lateral gene transfer. While
this may be true within Corynebacterium, none of the DT-related sequences are predicted
to reside within phages. In fact, only one of the Streptomyces genomes containing a DT-
related sequence had evidence of any phage, and the phage locus did not contain the toxin
gene. This suggests that the corynephages are not the sole mechanism for lateral gene trans-
fer of tox -related genes. Furthermore, functional characterization of the DT homologs is
necessary to determine whether or not these proteins are capable of DT-like functionality,
although the lack of a known host suitable for in vivo experimentation complicates matters.
In addition to sequence similarity, the DT homologs from Seinonella peptonophila (SP)
and Streptomyces albireticuli (SA) exhibit structures highly similar to DT. SP and SA are
both larger than DT, and in general possess larger α-helices, but their overall topologies
are similar to DT, and DT’s domains are the best structural matches currently in the
Protein Data Bank. It is worth noting that neither structure was solved with a bound
NAD+ ligand. Since the SA and SP positions aligning to DT’s NAD+-binding residues
are not conserved, it is necessary in the future to verify their C domains are capable of
coordinating an NAD+ ligand or an appropriate structural analog. As well, the R domains
of SP and SA both contain extraneous loop regions within the binding interface of DT to
HB-EGF. Further research is clearly needed to determine the effects of these structural
differences on the proteins’ functions, whatever those functions may be.
5.1.3 Conservation of the large clostridial toxin translocase do-
main
The large clostridial toxin (LCT) family currently consists of a set of six proteins found
in several clostridia: TpeL in Clostridium perfringens, TcsH and TcsL in Paeniclostridium
sordellii, TcnA in Clostridium novyi, and TcdA and TcdB in Clostridioides difficile. TcdA
and TcdB are particularly important because of their role in hospital-acquired C. difficile
infections. Between the two, TcdB appears to play a more important role, making the
function of TcdA less clear [392, 393]. At any rate, LCTs can be considered functionally
modular, containing regions that perform specific functions. In other toxin families, the
functions of binding a target receptor, translocating into the cell, and intoxicating the host
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are essentially independent. The LCTs are unique in that the translocation domain seems
to be intimately related to receptor binding, since the C-terminal region of the translocase
appear to contribute to receptor binding, which involves binding multiple distinct receptors
[63, 351, 352, 353, 64, 354, 355]. The task of differentiating between the functions of
translocation and receptor binding in TcdB is not possible through comparison of the
six canonical LCTs. However, by including more distantly related sequences within the
LCT translocase family, it is possible to the narrow down the regions related to the basal
function of translocation, common to all members of the family. Within this broader family,
the translocase N-terminal region is much more strongly conserved than the C terminus.
Indeed, these results suggest the conserved N-terminal region (residues 851-1473) encodes
a minimal translocase capable of delivering cargo into cells.
Proteins containing an LCT-like translocase can be found in a wide variety of bacteria.
Many species with LCT-like translocases are associated with pathogenicity or infections in
a variety of hosts, and some proteins containing an LCT-like translocase are in fact toxins,
including Pseudomonas FitD and Photorhabdus Mcf [375]. Most proteins with LCT-like
translocases have not been functionally characterized, although many are annotated with
glucosyltransferase domains. Considering the only characterized members of the LCT-like
translocase family are toxins, and that the LCT translocase tends to associate with known
effector domains, it seems likely that many of these sequences of unknown function are
toxins. The potential effector regions associated with LCT-like translocases possess more
sequence diversity than comparable toxin families, suggesting that the LCT translocase
potentially permits more diverse effector cargo. If so, it is possible that the LCT translocase
will be a useful scaffold for future immunotoxin therapeutics.
5.2 The limitations of bioinformatic predictions
All biological techniques require a set of assumptions to hold true in order for their con-
clusions to be valid, including any in vivo, in vitro, in silico, or statistical tests. While
the approximations made by most methods simplify data interpretation, the reality is that
their assumptions may not reflected in the data. Although some techniques are robust to
deviation (for example, that Student’s t-test can be considered valid for non-normal data
given sufficient sample size [394, 395]), models can suffer a loss of predictive power or be
vitiated entirely when their assumptions are violated [396, 397]. The question, then, is
how severely these deviations impact the interpretation of results. In this section, I discuss
some of the factors that confound the interpretation of the experiments presented here.
For the sake of clarity, it is worth distinguishing between technical and biological sources
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of error, although the two are generally related.
5.2.1 Sources of error in bioinformatic analyses
Homology detection
Many experiments in bioinformatics begin by identifying a set of homologous sequences,
which usually relies on sequence alignment. When these homologous sequences are derived
from a large variety of distantly related organisms, the sequence identities of the resulting
alignments are likely to be low. As the identity of the alignment decreases, it becomes
increasingly difficult to distinguish statistically significant alignment scores (and by exten-
sion, homology) from random alignments, particular for alignments below 30% identity
(the so-called twilight zone of homology) [110, 111]. The toxin alignments for the BoNTs,
DTs, and LCT translocases and their respective homologs approach or exceed this cutoff.
Further, not all toxin-related sequences have matches to families or domains in protein
functional annotation databases, which might be related to the limitations of annotated
sequence databases, or perhaps more fundamentally reflects that annotation methods are
not equally applicable across protein families [398]. Another more specific error in de-
tecting homologs is homologous over-extension by PSI-BLAST [399], which is used several
times in the thesis. Homologous over-extension introduces two types of error; in the first,
repeated search iterations produce progressively worse alignments and eventually introduce
non-homologous sequences. In the second, repeated PSI-BLAST iterations produce align-
ments that extend past the boundaries of homologous regions, which degrades the quality
of the position-specific scoring matrix [399].
The issues related to homologous sequence detection are unlikely to significantly affect
the results in any of the three chapters for several reasons. First, the phenomenon of
homologous over-extension was originally noted by repeated PSI-BLAST iterations with
Pfam domains, becoming most apparent after 4 iterations [399]. The homologous sequence
sets used here were retrieved after a maximum of three PSI-BLAST iterations, which
has been deliberately selected as a conservative cutoff to decrease the chance of spurious
alignments. Pfam domains, which enabled the detection of homologous over-extension
through their well-defined domain boundaries, were used here to annotate the detected
sequences separately from the PSI-BLAST result. Generally, the PSI-BLAST-detected
sequences share at least one Pfam domain in common with the query toxin sequence,
which supports a homologous relationship. These domain annotations are also capable of
distinguishing between types of partial homologs seen for a given query; this differentiates,
for example, BoNT-metalloprotease homologs from BoNT-translocase homologs. Domain
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annotations were therefore used to partition sets of sequences in order to limit analysis
to homologous regions, which diminishes the second effect of homologous over-extension.
Second, potentially homologous sequences were consistently subjected to further analysis
by multiple sequence alignment (using several multiple alignment algorithms including
MUSCLE [129], ClustalO [130], and MAFFT [131]), inferring phylogenies (using several
phylogenetic methods including maximum likelihood [135] and Bayesian estimation [185]),
and examination of conserved functional residues and motifs. Each of these lines of evidence
increases or decreases support for a homologous relationship independently of the method
used to detect them. Finally, the fundamental assumption about homology employed by
statistical sequence alignment methods is that the simplest explanation for a statistically
significant alignment score is homology. As stated by Pearson and Sierk [400], this approach
makes no assumptions about alignments with scores below statistical significance, which
may or may not be related. One can easily imagine a scenario where a particular sequence
in a homologous family diverges such that alignment with any of the other family members
produces a non-significant alignment score. If that circumstance does arise (regularly or
rarely), methods for homology detection based on alignment scores actually represent a
consistent underestimation of a homologous family’s true diversity.
Homology is a property that must be inferred on the basis of evidence. For each of
the BoNTs, DTs, and LCTs, the evidence strongly supports a homologous relationship be-
tween the toxin-like sequences presented here and the toxin sequences used to detect them.
It is not possible to quantify homology, which is a binary characteristic - either a set of
sequences are related or they are not. However, by themselves, alignment statistics like
E -values do give a measure of the statistical significance of an alignment by comparing it
to randomly sampled alignments. In all cases, the BoNT-, DT- and LCT-like sequences do
produce statistically significant alignments (E -values «1×10-3). The detected alignments
span several hundred residues up to the length of a full-length toxin query, and the align-
ments are detected within databases containing hundreds of millions of sequences. In other
words, the chance that these alignments are spurious is very low. Beyond that, the detected
toxin-like sequences often have multiple annotated domains in common with their query
toxin and preserve key motifs for toxin function. As an example, the exhaustive pairwise
comparison between the BoNT/A1 protease with all protease sequences in MEROPS (at
the time of the analysis, the database consisted of 1,103,662 sequences) [124] corroborated
that the M91 peptidases are the BoNT peptidases’ next closest family. This result was
congruent with phylogenetic trees that distinguished BoNT, divergent BoNT homologs,
and M91 peptidases, which was again consistent with features like domain annotations.
To summarize, the analyses of BoNT-, DT-, and LCT-like sequences all provided positive
evidence for homology, which went well beyond statistically significant alignment scores.
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Genomes as a source of predicted proteins
Although there are now hundreds of thousands of sequenced bacterial genomes, decidedly
few of them are complete, closed genomes. Based on statistics from the NCBI Genome
database at the time of writing (plotted in Figure 1.2), the number of complete prokaryotic
genomes is ∼2,600 out of ∼210,000 total, or slightly above 1%. Most bacterial genome se-
quences instead consist of a number of loosely connected contiguous sequences (contigs) or
scaffolds, ranging from 1 to 2746 sequence fragments (with a mean of 1420 and standard
deviation of 857.75). This discontiguity is partly a consequence of sequencing platforms
that produce relatively short read lengths, which are then stitched together to create assem-
bled genome sequences (using for example de Bruijn graphs [401]). Increasing sequencing
depth can provide better coverage of a genome, but repetitive regions will continue to be
a problem if read lengths are smaller than the length of a genomic repeat regardless of
sequencing depth [402, 403]. Long-read sequencing platforms have the potential to address
this - read lengths as long as 882kb were reported in a recent effort to sequence the hu-
man genome by nanopore sequencing [404] - but comparatively high per-base error rates
create additional problems, such as errors in protein prediction [405]. As well, platform-
independent biases will continue to be a problem, including general patterns in resolving
G+C biases and homopolymer repeats [80, 406, 81]. As it currently stands, a hybrid ap-
proach that takes advantage of multiple sequencing platforms seems to be optimal, but
continued improvements in long-read sequencing may yet rival the accuracy of short-read
or hybrid approaches [407].
For the BoNT-related toxins in E. faecium and C. piperi, long-read sequencing was
necessary to close gaps in short-read assemblies. In the case of C. piperi, in an initial draft
genome assembly, homopolymer errors yielded apparent frameshift mutations in some of
the bont-related genes that were only resolved by combining short- and long-read sequenc-
ing data with Pilon [182, 408]. The problem of fragmentary genome assemblies is increased
in fungal genomes, which appear to contain partial homologs of BoNT and LCTs [409],
since eukaryote genomes tend to be much larger and more repetitive than prokaryotes’.
Another potential example can be seen in the Austwickia chelonae diphtheria homologs,
where the C and T domains appear to be separated by a premature stop codon. A read
pile-up generated by aligning the sequencing reads to the assembled genome did not reveal
obvious homopolymer or similar common sequencing errors. However, Jiang et al. re-
ported the genome sequence of another A. chelonae strain (LK16-18) [410] associated with
serious skin infections in crocodile lizards [411] which appears to contain an intact copy
of the DT-like gene (NCBI protein accession WP_116115734.1; NCBI assembly number
GCF_003391095.1). Notably, the assembly reported by Jiang et al. used a combination
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of single-molecule real time (Pacific Biosciences) and solid-phase amplification (Illumina)
sequencing. While it is possible that the originally-identified Austwickia DT-like gene did
in fact contain a frameshift mutation, the identification of a strain containing an intact
copy suggests this may have simply reflected a sequencing error. The LCTs pose a unique
problem in that their C-terminal receptor-binding domains [355] contain oligopeptide re-
peats that may impede accurate genome assembly. In general, many BoNT, DT, and
LCT homologs are encoded within short contigs, which decreases the informative value of
genomic context analysis.
The accuracy of the toxin homolog sequences derived from genomes is limited by cur-
rent sequencing technologies. Unfortunately, it is currently infeasible to re-sequence and
re-annotate the thousands of genomes containing toxin-related sequences within the course
of a doctoral program. Nonetheless, the recent evidence of an uninterrupted full-length
DT homolog in Austwickia, as predicted in Chapter 3, is cause for cautious optimism. As-
suming the sequenced DNA originated from a single clonal population, toxin-related genes
predicted from fragmented and error-containing assemblies are more likely to be slightly
improved over time (for example, by more accurately predicting gene sequences and im-
proved contig scaffolding) than completely invalidated. In other words, the genes predicted
from fragmented genome assemblies likely represent real encoded genes, notwithstanding
sequencing and assembly errors. As sequencing technology continues to improve, the qual-
ity of genome assemblies will also improve, and the existence of toxin-related genes will be
substantiated or refuted.
Phylogenetic inference
The objective of phylogenetic methods is to generate a tree describing the ancestry of a set
of homologous sequences. Many factors affect the accuracy of phylogenetic inference, the
first of which is alignment quality. The accuracy of tree topology decreases with decreasing
alignment quality; unbalanced alignments and trees containing clades with long branch
lengths have a pronounced effect [412]. Unbalanced multiple alignments can be caused by
inadequate taxon sampling (which is addressed more thoroughly in section 5.2.2). Long
branch artifacts were first noted as a problem for early phylogenetic methods [413] but have
persisted among model-based methods [414, 415]. Long branch artifacts form spurious
phylogenetic groupings because of homoplasy or degradation of the phylogenetic signal in
deep-branching trees [416]. A problem more specific to Bayesian inference is the general
inflation of support values compared to maximum likelihood bootstraps [417, 418].
The analyses presented here possess some of these problematic characteristics and other
properties that negatively affect phylogenetic inference. As an example, I focus on phyloge-
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netic issues associated with the analysis of BoNT sequences, although similar issues apply
to the DT and LCT families. In the BoNT family, there are clearly identifiable recombina-
tion events that have produced chimeric or mosaic toxin sequences (serotypes C/D, D/C,
and more recently H/A [419]). Ignoring the effects of recombination tends to produce inac-
curacies, especially in determining rate heterogeneity between sites [420, 421]. Phylogenetic
networks, rather than phylogenetic trees, can potentially alleviate this by demonstrating
the support for multiple tree topologies at once (for example using SplitsTree [422]).
So far, the issue of recombination is restricted to canonical BoNT sequences that clearly
reside within the BoNT family. A more pressing issue for the BoNT-like toxins (BoNT/En,
BoNT/X, BoNT/Wo, and more distantly Cp1) is related to the long branches they appear
to reside on and the inequality of sampling between serotypes. The eight canonical BoNT
serotypes mostly contain more than one subtype, giving a measure of within-serotype
sequence diversity while providing more balance to the input set. Between-serotype differ-
ences vary by up to 70% amino acid identity, thereby yielding deeply branched phylogenies
because more substitutions must have occurred since their divergence. Together, uneven
sampling and inherently long branch lengths make BoNT phylogenies more prone to long
branch artifacts. The identification of additional sequence variants could conceivably help
to expand poorly represented serotypes and decrease between-serotype distances. To that
effect, a BoNT-related toxin denoted PMP1 was recently discovered in the genome of a
strain of Paraclostridium bifermentans and appears to fall within the BoNT/En-BoNT/X
clade [260]. However, it bears mentioning that some phylogenetic complexities cannot be
remedied by the addition of more sequences [415, 423, 424, 425] or inclusion of additional
sites [415], meaning that the phylogenetic issues within the BoNTs or any toxin family may
not be easily resolved.
In spite of these phylogenetic limitations, several features of the phylogenies in preceding
chapters are informative and reveal a few generalizable principles. In every toxin family
examined, the branches associated with human-specific toxins form monophyletic groups.
This is true for the BoNTs and the BoNT-like sequences, which can be clearly distinguished
from NleD-like M91 peptidases, as well as the DT sequences from Corynebacterium species,
which form a clear monophyletic lineage distinct from DT-related sequences from other
members of the phylum Actinobacteria. In both of these cases, the toxin-related sequences
from genomic data sets sit on long branches that aggregate at the base of the tree. For
BoNTs and DTs, these long branch lengths correlate with an important functional property:
the canonical BoNTs and DTs are associated with human disease, while the toxin-related
sequences are not. The BoNT-related protein BoNT/En causes mild botulism-like paralysis
in mice at high concentrations but is not associated with any human disease, and none
of the early-diverging DT-related sequences have been implicated in disease. Therefore,
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the evolutionary changes that must have occurred between the toxin-related lineages and
canonical toxin family members must be sufficient to explain the emergence of human
specificity. Although the potential for long branch artifacts makes it difficult to ascertain
their position on the tree, the toxin-related sequences appear to consistently form early-
branching clades in the toxin families. Considering the conservation of toxin features in
these early-branching lineages and their clear distinction from human-specific clades, it is
tempting to speculate that most of these toxin-related sequences represent early-diverging
toxin family members adapted for non-human hosts.
5.2.2 Biological factors affecting results
Inadequate and uneven sampling of pathogens, toxin sequences, and toxigenic
microorganisms
Inadequate taxon sampling creates issues for phylogenetic inference, but it is only one
aspect of a broader predicament. Pathogens and their toxins are chiefly discovered and
described because of an association with disease, and human disease in particular. This
produces a bias toward the kinds of microbes that are already known to produce diseases,
while the types and strains of microbes that do not produce disease or display attenuated
virulence go under-sampled or undetected. This anthropocentric bias is reflected in se-
quencing efforts and databases 2. As a result, considerably less is known about obligate or
opportunistic pathogens with non-human hosts. Toxin-related sequences (BoNT-like, DT-
like, and LCT-like) are mostly found in bacteria only loosely associated with pathogenicity,
particularly in non-human hosts. This includes the association of BoNTs and BoNT gene
clusters with insects, DTs in a reptile skin pathogen [329, 410, 411] and environmental
isolates of Streptomyces spp., and LCTs in insect pathogens and environmental isolates
2The NCBI genome database currently contains 532 Clostridium genome assemblies (including all se-
quenced species and strains of the genus) compared to 10,882 genome assemblies for Salmonella enterica.
More broadly, the NCBI Sequence Run Archive (SRA) contains raw sequencing information for differ-
ent kinds of sequencing experiments (including whole genome sequencing, microarray data, and many
others), which provides a rough estimate of potential taxonomic biases in sequencing efforts. The SRA
currently contains 11,432 samples matching the text query “Clostridium” versus 260,461 samples match-
ing “Salmonella enterica”. By comparison, “Austwickia chelonae”, an organism not commonly implicated
in human disease, has 3 genome assemblies and matches 3 samples in the SRA. These numbers are not
intended to make any statement about the relative value of research in any organism - any research with
the potential to alleviate the burden of suffering caused by the pathogens of humans, other animals, or
plants, is valuable in the view of the author - but instead to highlight the limitations of currently available
sequencing information.
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of Pseudomonas species. These environments and organisms are simply not studied to
the same level of depth or scrutiny as others more clearly associated with human dis-
ease. Many toxin-related sequences are clearly distinct from other members of their family
(∼30% amino acid identity), but are represented by a single known sequence that is likely a
part of a larger, undiscovered subfamily; ideally, sequencing efforts in these uncharacterized
environments and the identification of additional organisms with toxin-related sequences
will supply a more complete description of these subfamilies.
Most toxin-related sequences are derived from organisms represented by a single genome
sequence. A single sequenced genome from a given strain of bacteria can provide an ad-
equate representation of the species, or it might represent only a fraction of the genomic
diversity present in the species [426]. In Bacillus anthracis, fewer than five genomes might
provide an adequate description of its pangenome, whereas a similar level of pangenomic
completeness for Streptococcus agalactiae might require hundreds of sequenced genomes
[426]. On the other hand, the complete pangenomic description of a species is likely not
feasible given that the processes of conjugation, transduction, transposition, and trans-
formation generate new genotypes constantly, between closely-related organisms and by
lateral gene transfer between distantly related taxa. The rates of lateral gene transfer and
thereby “pangenomic evolution” remain mostly unknown, but are surely related to many
properties, some of which are likely taxon-specific (for example, the rate of lateral transfer
in to Streptomyces spp. appears to be relatively slow [427]). There is some evidence that
the rate of lateral gene transfer is much higher than rates of sequence evolution [428]. Like
rates of lateral gene transfer, an enormous number of factors affect substitution rates [429],
and new alleles can also be generated through recombination, insertions, and deletions.
Between changes at the level of the genome and changes at the level of particular genes,
any given sequenced genome represents a snapshot of an organism rather than a complete
description of its genome, which is, in all likelihood, a dynamic construction. This presents
two contrary problems for genomes as a source of toxin sequences: first, that toxin genes
can be a part of the pangenome but go undetected because of insufficient sampling, and
second, that a correctly identified toxin-related sequence may be be a transient addition
to a genome rather than a permanent acquisition. Although the issues outlined above will
persist, sufficient genome sampling approaching pangenomic completeness would help to
minimize the negative effects of these two problems.
Are genomically-derived toxin-related sequences actually toxins?
The relationship between sequence, structure, and function is complex. That the toxin-
related sequences of BoNTs, DTs, and LCTs display significant sequence similarity has been
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thoroughly demonstrated. The toxin-related sequences also exhibit structural similarity,
exemplified by the light chains of BoNT/X [430], BoNT/Wo [102], and the DT-related
sequences of Seinonella peptonophila and Streptomyces albireticuli. However, determining
the structure of a protein does not always clarify what functions they perform, as seen for
OrfX proteins [261] or the structures of DT-related sequences reported here. Therefore, in
spite of observed sequence and structural similarities, establishing the relationships between
these features and function remains a challenge. Some limited examples of shared toxin
functionality have been demonstrated here - as seen in the BoNT-like cleavage of SNARE
proteins by BoNT/En [2] and potentially BoNT/Wo [101], or the conserved activity of
the evolutionarily conserved minimal TcdB translocase - but the functions of toxin-related
sequences are for the most part unknown.
Unlike traditional methods for toxin identification, where a known phenotype is caused
by an unknown toxin, the goal for genomically-predicted toxin-related sequences is its in-
verse: identifying a phenotype associated with a toxin genotype. One major hindrance to
estimating a toxin’s phenotype is that it is intrinsically linked to host specificity. Attempt-
ing to associate a toxin-related sequence with a phenotype is analogous to attempting to
find a lock after being given a key when one does not even know which door to check.
Many toxin-related sequences are found in the genomes of organisms lacking any apprecia-
ble description of their ecological context, and thus their interactions with different hosts
are unknown. The fact that most toxin-related sequences are not associated with signif-
icant diseases in humans or other organisms therefore has many plausible explanations.
The toxin-related sequence might produce a significant and obvious disease phenotype in
a narrow host range that has yet to be examined; or, the toxin acts in a way to explicitly
attenuate virulence, as may be the case for certhrax [97, 98] and typhoid toxin [92]; or,
the proteins could have some other function. It is not trivial to distinguish between these
possibilities and the range of possible hosts for a given toxin sequence is vast.
Assuming one knows the host target of toxin-related sequence, an important aspect of
further characterization is the development of in vivo models. While in silico methods can
help to identify and characterize toxin sequences and in vitro approaches can be used to
evaluate their functions and mechanisms, many questions about toxin biology can only be
answered in through in vivo experimentation. The use of in vivo models made it possible
to establish anthrax toxin as the cause of death in systemic anthrax infections [37, 38]. De’s
isolation of cholera toxin [39] was made possible by his earlier development of an ex vivo
rabbit ileal loop model [431]. These key insights into toxin biology were only possible by
examining toxin function in the context of living host organisms. As an example from this
work, it would be valuable to determine the contribution of the Austwickia chelonae DT-
like sequence to virulence in crocodile lizards, assuming the DT-like sequence is functional
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[410, 411]. More generally, appropriate in vivo models will help to assess the questions
of how and when toxin-related genes are expressed, as well as how toxin-related genes
influence their microbes’ lifestyle during and apart from host association. In vivo models
are capable of contributing a greater understanding of toxin biology from the perspective
of the toxin producer as well as the affected host.
In order to understand what roles toxin-related sequences have, it is necessary to gain
a greater understanding of the ecology of the microbes that encode them. This requires an
understanding of the microbes’ life cycle, how the microbes interact with different types
of hosts, and how the presence or absence of toxin genes affects these properties. It is
important to consider also the diversity of the microbe, including pathogenic and non-
pathogenic varieties. Pathogenic and non-pathogenic strains of related organisms are still
capable of interaction and lateral gene transfer, even though pathogenic varieties are more
likely to have received attention [432]. A comprehensive understanding of a pathogen’s
diversity must also include varieties that are resistant to culturing methods, which for some
taxa may represent a considerable fraction (as an example, the spore-forming members of
the phylum Firmicutes are consistently undersampled in metagenomic data sets [433, 434]).
These factors and others contribute to an underestimation of pathogen diversity, which
necessarily results in gaps of knowledge about even basic aspects of pathogen biology. It is
perhaps counterintuitive, but an improved understanding of pathogens and their toxins in
part requires an improved understanding of their non-pathogenic and non-toxic relatives.
5.3 Final remarks
In spite of the aforementioned limitations, a few key conclusions can be gleaned from
this thesis. The most generalizable principle can be summarized in Liebniz’s quote that
“nature does not make leaps” [435] - an idea popularized by Linnaeus [436] and invoked
in Heisenberg’s essay that introduced this chapter [437]. In other words, all families of
bacterial toxins are the product of a continuous evolutionary process, and the bacterial
toxins that afflict humans can be understood as branches within broader toxin families.
Examining toxins from a broad evolutionary perspective allows for the discovery of novel
toxins with unique properties, improves our understanding of the evolutionary shifts that
yield highly potent and host-specific toxins, and is able to grant a deeper understanding
of toxin functionality. It is a testament to the predictive power of evolution that this
knowledge can be gained from naturally noisy and incomplete biological data, consistent
with the dictum that nothing in biology makes sense except in the light of evolution [438].
This thesis presents the first relatives of historically significant and medically relevant
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bacterial protein toxins. The toxin families of clostridial neurotoxins and diphtheria tox-
ins, initially described more than a century ago [8, 29, 27, 33, 34, 35, 36], can now be
contextualized within their gene families using data derived directly from whole bacterial
genomes. Genomic data also yields greater insights into the behaviours of toxins affiliated
with more modern afflictions, including those related to large clostridial toxins. Although
it is difficult to ascertain the functions of toxin-related sequences, the evidence strongly
suggests that many of them are themselves toxins. In fact, the conservation of toxin fea-
tures, their early-diverging branches in their respective phylogenetic trees, and their lack
of association with human disease together imply that these sequences represent toxins
adapted for non-human hosts, where they may elicit disease pathologies similar to those
found in humans.
Many toxin-related sequences are highly dissimilar from other members of their families,
suggesting they represent larger, uncharacterized subfamilies. As such, continued efforts
to study the diversity of microbes and their hosts through genomics and metagenomics
will deliver valuable insights into the diversity of pathogens and toxin sequences [388].
This diversity is paramount to understanding evolutionary dynamics within toxin families,
but also reaps additional benefits. The identification of novel toxin sequences with unique
functions has the potential to develop novel and improved toxin-based therapeutics. Fur-
thermore, the improved understanding of toxin function facilitated by evolutionary studies
could contribute valuable insights to immunotoxin development or the design of inhibitors,
vaccines, and antibodies. In doing so, it is possible to harness the agents of disease and
affliction and direct them toward more humane goals.
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Supplementary Material: Chapter 2
A.1 Supplementary Table 1
Table A.1: Sequence identifiers, categories and protein lengths for each sequence used in this study. All
sequences were retrieved from the NCBI nr database and are publicly available.
Accession Species Classification Length
WP_055473237.1 Streptomyces pathocidini Actinobacteria 1066
WP_083906476.1 Acaricomes phytoseiuli Actinobacteria 1370
SDT83331.1 Streptomyces sp. TLI 053 Actinobacteria 495
WP_058043469.1 Streptomyces sp. MBT76 Actinobacteria 512
EFL04418.1 Streptomyces sp. AA4 Actinobacteria 2761
WP_030364034.1 Streptomyces roseoverticillatus Actinobacteria 519
SDS61334.1 Streptomyces sp. TLI 053 Actinobacteria 231
GAO13068.1 Streptomyces sp. NBRC 110027 Actinobacteria 841
BAF91946.1 Clostridium botulinum str. Osaka 05
BoNT B6
BoNT 1291
ABM73981.1 Clostridium botulinum BoNT E2 BoNT 1252
AFV91339.1 Clostridium botulinum str.
CDC66177 BoNT E9
BoNT 1251
ACQ51417.1 Clostridium botulinum Ba4 str. 657
BoNT BvA4
BoNT 1296
KEI05265.1 Clostridium botulinum CD str.
BKT2873 BoNT CD
BoNT 1291
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AEN25581.1 Clostridium botulinum BoNT B7 BoNT 1291
ADA79573.1 Clostridium botulinum BoNT F5 BoNT 1277
ABM73977.1 Clostridium botulinum str. CDC
795 BoNT B3
BoNT 1291
ACA46990.1 Clostridium botulinum B1 str. Okra
BoNT Ba4
BoNT 1291
CAA44558.1 Clostridium botulinum BoNT E1 BoNT 1252
BAP25804.1 Clostridium botulinum BoNT B2 BoNT 1291
CAA38175.1 Clostridium botulinum BoNT D BoNT 1276
ADA79566.1 Clostridium botulinum BoNT F3 BoNT 1279
AER11392.1 Clostridium botulinum str. E134
BoNT E8
BoNT 1252
EEP52948.1 Clostridium butyricum E4 str.
BoNT E BL5262 BoNT E4
BoNT 1252
ABS38337.1 Clostridium botulinum A str. Hall
BoNT A1
BoNT 1296
EDT74844.1 Clostridium butyricum 5521 BoNT
E
BoNT 1252
CBA17654.1 Clostridium botulinum BoNT CD BoNT 1280
ABS41202.1 Clostridium botulinum F str. Lan-
geland BoNT F1
BoNT 1278
ACD14195.1 Clostridium botulinum B str. Ek-
lund 17B BoNT B4
BoNT 1291
ADU57954.1 Clostridium botulinum BoNT F6 BoNT 1275
ABM73985.1 Clostridium botulinum BoNT B2 BoNT 1291
ACT33194.1 Clostridium botulinum BoNT A5 BoNT 1296
EES49627.1 Clostridium botulinum E1 str.
BoNT E Beluga BoNT E1
BoNT 1252
BAH84879.1 Clostridium botulinum BoNT DC BoNT 1285
ACA57525.1 Clostridium botulinum A3 str. Loch
Maree BoNT A3
BoNT 1292
EDS76240.1 Clostridium botulinum C str. Ek-
lund BoNT C
BoNT 1280
CAA52275.1 Clostridium botulinum BoNT G BoNT 1297
BAD90567.1 Clostridium botulinum BoNT C BoNT 1291
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BAB03522.1 Clostridium butyricum str. LCL 095
BoNT E5
BoNT 1251
ADA79579.1 Clostridium baratii BoNT F7 BoNT 1268
ACO83782.1 Clostridium botulinum A2 str. Ky-
oto BoNT A2
BoNT 1296
BAQ12790.1 Clostridium botulinum str 111
BoNT X
BoNT 1306
KGO12225.1 Clostridium botulinum BoNT H
BoNT B
BoNT 1291
ADA79562.1 Clostridium botulinum BoNT F4 BoNT 1277
ADA79557.1 Clostridium botulinum BoNT F2 BoNT 1280
AER11391.1 Clostridium botulinum str. IBCA97
BoNT E7
BoNT 1252
CAM91125.1 Clostridium botulinum E str. K35
BoNT E6
BoNT 1252
KGO15617.1 Clostridium botulinum BoNT H
BoNT Fa
BoNT 1288
KEH96501.1 Clostridium botulinum D str. 16868
BoNT D
BoNT 1287
ACQ51206.1 Clostridium botulinum Ba4 str. 657
BoNT BvBb5
BoNT 1291
ACD53549.1 Clostridium botulinum E3 str.
Alaska E43 BoNT E3
BoNT 1252
OTO22244.1 Enterococcus sp. 3G1_DIV0629 BoNT 1280
WP_034687877.1 Chryseobacterium piperi Chryseobacterium 388
KFF17709.1 Chryseobacterium piperi partial Chryseobacterium 2112
WP_034687879.1 Chryseobacterium piperi Chryseobacterium 695
WP_034681279.1 Chryseobacterium piperi Chryseobacterium 1747
WP_034687193.1 Chryseobacterium piperi Chryseobacterium 1496
WP_034687872.1 Chryseobacterium piperi Chryseobacterium 1467
WP_034681281.1 Chryseobacterium piperi Chryseobacterium 1617
WP_034687874.1 Chryseobacterium piperi Chryseobacterium 1116
NZ_BAGZ01000024:
3993143386
Austwickia chelonae Diphtheria 260
WP_040322835.1 Austwickia chelonae Diphtheria 274
WP_073156187.1 Seinonella peptoniphila Diphtheria 606
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ABU25232.1 Corynephage beta Diphtheria 563
4AE0.1 Corynebacterium diphtheria Diphtheria 535
WP_071569945.1 Corynebacterium diphtheriae Diphtheria 560
BAG06869.1 Corynebacterium ulcerans Diphtheria 560
WP_029975703.1 Corynebacterium ulcerans Diphtheria 560
WP_038617330.1 Corynebacterium ulcerans Diphtheria 560
WP_044032678.1 Corynebacterium ulcerans Diphtheria 560
AAV70486.1 Corynebacterium diphtheriae Diphtheria 536
AND74674.1 Corynebacterium diphtheriae bv.
mitis
Diphtheria 560




BAB03348.1 Corynephage beta Diphtheria 535
AMP42519.1 Corynebacterium diphtheriae Diphtheria 560
AMP42520.1 Corynebacterium diphtheriae Diphtheria 560
WP_014835773.1 Corynebacterium ulcerans Diphtheria 560
AAW22870.1 Corynebacterium ulcerans Diphtheria 560
P00588.2 Corynebacterium diphtheria Diphtheria 567
WP_054467370.1 Corynebacterium ulcerans Diphtheria 560
WP_003850266.1 Corynebacterium diphtheria Diphtheria 560
KHN96101.1 Metarhizium album ARSEF 1941 Fungal 730
XP_018137534.1 Pochonia chlamydosporia 170 Fungal 874
XP_007815863.1 Metarhizium acridum CQMa 102 Fungal 905
KID82327.1 Metarhizium guizhouense ARSEF
977
Fungal 994
KID81771.1 Metarhizium guizhouense ARSEF
977
Fungal 734
KFG79709.1 Metarhizium anisopliae Fungal 704
XP_007806665.1 Metarhizium acridum CQMa 102 Fungal 795
KJZ74539.1 Hirsutella minnesotensis 3608 Fungal 951
KHN97968.1 Metarhizium album ARSEF 1941 Fungal 707
XP_007825170.1 Metarhizium robertsii ARSEF 23 Fungal 1082
KOM18317.1 Ophiocordyceps unilateralis Fungal 723
KJK83643.1 Metarhizium anisopliae BRIP 53293 Fungal 1048
KFG84249.1 Metarhizium anisopliae Fungal 909
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KID84774.1 Metarhizium guizhouense ARSEF
977
Fungal 1081
KID84474.1 Metarhizium guizhouense ARSEF
977
Fungal 290
XP_018138178.1 Pochonia chlamydosporia 170 Fungal 1069
KFG84771.1 Metarhizium anisopliae Fungal 994
XP_014548865.1 Metarhizium brunneum ARSEF
3297
Fungal 908
EQL01877.1 Ophiocordyceps sinensis CO18 Fungal 615
XP_014541277.1 Metarhizium brunneum ARSEF
3297
Fungal 1082
KOM20214.1 Ophiocordyceps unilateralis Fungal 798
XP_008600141.1 Beauveria bassiana ARSEF 2860 Fungal 172
XP_006673829.1 Cordyceps militaris CM01 Fungal 990
KOM18061.1 Ophiocordyceps unilateralis Fungal 1006
KYK53973.1 Drechmeria coniospora Fungal 753
OAR01471.1 Cordyceps confragosa Fungal 901
XP_006672770.1 Cordyceps militaris CM01 Fungal 1046
KOM19981.1 Ophiocordyceps unilateralis Fungal 676
XP_018701747.1 Isaria fumosorosea ARSEF 2679 Fungal 966
KJZ72439.1 Hirsutella minnesotensis 3608 Fungal 732
KJK78274.1 Metarhizium anisopliae BRIP 53293 Fungal 994
KOM17722.1 Ophiocordyceps unilateralis Fungal 692
KID81025.1 Metarhizium guizhouense ARSEF
977
Fungal 1026
KFG78556.1 Metarhizium anisopliae Fungal 1082
KID81342.1 Metarhizium guizhouense ARSEF
977
Fungal 1051
KHN96509.1 Metarhizium album ARSEF 1941 Fungal 799
XP_007813862.1 Metarhizium acridum CQMa 102 Fungal 731
KHN94110.1 Metarhizium album ARSEF 1941 Fungal 850
OAA45953.1 Cordyceps brongniartii RCEF 3172 Fungal 896
XP_014576605.1 Metarhizium majus ARSEF 297 Fungal 707
XP_007821069.1 Metarhizium robertsii ARSEF 23 Fungal 680
KOM19459.1 Ophiocordyceps unilateralis Fungal 1134
KJK74733.1 Metarhizium anisopliae BRIP 53293 Fungal 777
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XP_008597266.1 Beauveria bassiana ARSEF 2860 Fungal 905
XP_007823153.1 Metarhizium robertsii ARSEF 23 Fungal 994
KHN96007.1 Metarhizium album ARSEF 1941 Fungal 182
XP_014574393.1 Metarhizium majus ARSEF 297 Fungal 1052
KOM22197.1 Ophiocordyceps unilateralis Fungal 872
KFG79783.1 Metarhizium anisopliae Fungal 790
KFG84514.1 Metarhizium anisopliae Fungal 680
OAA46382.1 Metarhizium rileyi RCEF 4871 Fungal 1144
KGQ06896.1 Beauveria bassiana D1 Fungal 958
XP_007815132.1 Metarhizium acridum CQMa 102 Fungal 700
KZZ89413.1 Aschersonia aleyrodis RCEF 2490 Fungal 775
OAA38271.1 Cordyceps brongniartii RCEF 3172 Fungal 957
KFG81441.1 Metarhizium anisopliae Fungal 961
KID85357.1 Metarhizium guizhouense ARSEF
977
Fungal 908
KOM22373.1 Ophiocordyceps unilateralis Fungal 1051
ODA78204.1 Drechmeria coniospora Fungal 795
KJK91804.1 Metarhizium anisopliae BRIP 53284 Fungal 1041
XP_008593942.1 Beauveria bassiana ARSEF 2860 Fungal 892
XP_018701218.1 Isaria fumosorosea ARSEF 2679 Fungal 864
KJK74458.1 Metarhizium anisopliae BRIP 53293 Fungal 300
KJZ74925.1 Hirsutella minnesotensis 3608 Fungal 779
KOM17891.1 Ophiocordyceps unilateralis Fungal 800
KGQ09460.1 Beauveria bassiana D1 Fungal 892
KJZ75232.1 Hirsutella minnesotensis 3608 Fungal 967
OAA33269.1 Aschersonia aleyrodis RCEF 2490 Fungal 776
KOM19891.1 Ophiocordyceps unilateralis Fungal 684
KJK77338.1 Metarhizium anisopliae BRIP 53293 Fungal 909
XP_018141808.1 Pochonia chlamydosporia 170 Fungal 836
KJZ77068.1 Hirsutella minnesotensis 3608 Fungal 651
KZZ93685.1 Aschersonia aleyrodis RCEF 2490 Fungal 882
KOM20843.1 Ophiocordyceps unilateralis Fungal 667
EQL03202.1 Ophiocordyceps sinensis CO18 Fungal 707
XP_018702425.1 Isaria fumosorosea ARSEF 2679 Fungal 970
OAA33955.1 Cordyceps brongniartii RCEF 3172 Fungal 984
KZZ97314.1 Aschersonia aleyrodis RCEF 2490 Fungal 1053
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XP_014543958.1 Metarhizium brunneum ARSEF
3297
Fungal 1055
KOM18203.1 Ophiocordyceps unilateralis Fungal 759
OAA38924.1 Cordyceps brongniartii RCEF 3172 Fungal 835
KID83117.1 Metarhizium guizhouense ARSEF
977
Fungal 802
KHN95172.1 Metarhizium album ARSEF 1941 Fungal 686
KZZ88788.1 Aschersonia aleyrodis RCEF 2490 Fungal 634
KHO00998.1 Metarhizium album ARSEF 1941 Fungal 846
XP_006671066.1 Cordyceps militaris CM01 Fungal 1164
OAA70995.1 Cordyceps confragosa RCEF 1005 Fungal 953
KOM19467.1 Ophiocordyceps unilateralis Fungal 620
EQL04075.1 Ophiocordyceps sinensis CO18 Fungal 965
KFG86514.1 Metarhizium anisopliae Fungal 1048
KHO02117.1 Metarhizium album ARSEF 1941 Fungal 907
XP_007825853.1 Metarhizium robertsii ARSEF 23 Fungal 908
KJK76584.1 Metarhizium anisopliae BRIP 53293 Fungal 782
XP_014544711.1 Metarhizium brunneum ARSEF
3297
Fungal 680
KID86267.1 Metarhizium guizhouense ARSEF
977
Fungal 467
KID82428.1 Metarhizium guizhouense ARSEF
977
Fungal 644
KID61384.1 Metarhizium anisopliae ARSEF 549 Fungal 782
EXU95574.1 Metarhizium robertsii Fungal 631
ODA76424.1 Drechmeria coniospora Fungal 969
XP_014581715.1 Metarhizium majus ARSEF 297 Fungal 903
KZZ92552.1 Aschersonia aleyrodis RCEF 2490 Fungal 1024
KJK78185.1 Metarhizium anisopliae BRIP 53293 Fungal 1082
KJZ71660.1 Hirsutella minnesotensis 3608 Fungal 986
KID82801.1 Metarhizium guizhouense ARSEF
977
Fungal 819
KYK58955.1 Drechmeria coniospora Fungal 969
KID82824.1 Metarhizium guizhouense ARSEF
977
Fungal 463
XP_007824532.1 Metarhizium robertsii ARSEF 23 Fungal 704
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KJK84451.1 Metarhizium anisopliae BRIP 53293 Fungal 680
KHN94021.1 Metarhizium album ARSEF 1941 Fungal 673
XP_018700026.1 Isaria fumosorosea ARSEF 2679 Fungal 830
KGQ03580.1 Beauveria bassiana D1 Fungal 905
XP_014540776.1 Metarhizium brunneum ARSEF
3297
Fungal 994
KOM19284.1 Ophiocordyceps unilateralis Fungal 1163
XP_014539926.1 Metarhizium brunneum ARSEF
3297
Fungal 790
OAA52226.1 Cordyceps brongniartii RCEF 3172 Fungal 945
KJK74970.1 Metarhizium anisopliae BRIP 53293 Fungal 704
KJK83642.1 Metarhizium anisopliae BRIP 53293 Fungal 305
XP_011411449.1 Metarhizium robertsii ARSEF 23 Fungal 827
KOM17955.1 Ophiocordyceps unilateralis Fungal 960
XP_014576580.1 Metarhizium majus ARSEF 297 Fungal 759
ODA80573.1 Drechmeria coniospora Fungal 857
XP_008599538.1 Beauveria bassiana ARSEF 2860 Fungal 219
KGQ05150.1 Beauveria bassiana D1 Fungal 458
KJZ71838.1 Hirsutella minnesotensis 3608 Fungal 756
KOM19347.1 Ophiocordyceps unilateralis Fungal 1135
XP_014575725.1 Metarhizium majus ARSEF 297 Fungal 704
KYK56264.1 Drechmeria coniospora Fungal 912
KJZ74384.1 Hirsutella minnesotensis 3608 Fungal 788
XP_008602550.1 Beauveria bassiana ARSEF 2860 Fungal 836
OAA52037.1 Metarhizium rileyi RCEF 4871 Fungal 711
XP_006674368.1 Cordyceps militaris CM01 Fungal 1035
XP_014574395.1 Metarhizium majus ARSEF 297 Fungal 637
EQL00592.1 Ophiocordyceps sinensis CO18 Fungal 940
XP_007816336.1 Metarhizium robertsii ARSEF 23 Fungal 1052
XP_008601493.1 Beauveria bassiana ARSEF 2860 Fungal 970
OAA75559.1 Cordyceps confragosa RCEF 1005 Fungal 931
KJZ70085.1 Hirsutella minnesotensis 3608 Fungal 471
OAA39888.1 Cordyceps brongniartii RCEF 3172 Fungal 902
KJZ78148.1 Hirsutella minnesotensis 3608 Fungal 775
WP_011267300.1 Pseudomonas syringae M91 198
CUV34250.1 Ralstonia solanacearum M91 245
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AEX33777.1 Xanthomonas arboricola pv. pruni M91 146
WP_077142976.1 Pseudomonas syringae M91 215
WP_061231638.1 Leptospira noguchii M91 334
WP_074375462.1 Xanthomonas translucens M91 204
GAE50625.1 Xanthomonas arboricola pv. pruni
str. MAFF 311562
M91 230
ADX47300.1 Acidovorax avenae subsp. avenae
ATCC 19860
M91 212
WP_026053328.1 Leptospira santarosai M91 245
WP_069342860.1 Pandoraea sp. ISTKB M91 222
WP_074052393.1 Xanthomonas vesicatoria M91 213
WP_071011456.1 Ralstonia solanacearum M91 219
WP_024689564.1 Pseudomonas syringae group M91 212
CAP52016.1 Xanthomonas campestris pv.
campestris
M91 249
CTP91498.1 Xanthomonas translucens pv. poae M91 221
WP_020738886.1 Sorangium cellulosum M91 260
WP_004471278.1 Leptospira santarosai M91 361
WP_057176762.1 Paraburkholderia caribensis M91 206
AMV47536.1 Paraburkholderia caribensis M91 284
AEG71857.1 Ralstonia solanacearum Po82 M91 225
WP_074812007.1 Pseudomonas syringae M91 230
WP_064048191.1 Ralstonia solanacearum M91 219
SEI45716.1 Pseudomonas sp. NFR16 M91 234
AIL29259.1 Pseudomonas syringae pv. actini-
diae
M91 201
WP_019994798.1 Aureimonas ureilytica M91 179
WP_075251160.1 Xanthomonas oryzae M91 168
WP_006453000.1 Xanthomonas gardneri M91 218
WP_064297220.1 Ralstonia solanacearum M91 221
AIE45643.1 Acidovorax citrulli M91 197
WP_035542658.1 Burkholderia sp. UYPR1.413 M91 238
WP_006073522.1 Vibrio M91 214
WP_039558791.1 Ralstonia solanacearum M91 186
WP_011409781.1 Xanthomonas oryzae M91 155
WP_036949404.1 Providencia alcalifaciens M91 240
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WP_063885037.1 Pseudomonas syringae M91 183
KPY01823.1 Pseudomonas amygdali pv. mori M91 212
KPY92388.1 Pseudomonas syringae pv. tomato M91 236
WP_019702312.1 Acidovorax M91 213
WP_069191536.1 Escherichia coli M91 231
GAE54985.1 Xanthomonas arboricola pv. pruni
MAFF 301420
M91 219




WP_076037893.1 Xanthomonas campestris M91 207
WP_004771984.1 Leptospira kirschneri M91 283
WP_017115174.1 Xanthomonas vasicola M91 206
WP_016971449.1 Pseudomonas tolaasii M91 184
WP_074686786.1 Acidovorax citrulli M91 216
KFA31217.1 Xanthomonas vasicola pv. vasculo-
rum NCPPB 1326
M91 202
KPY56004.1 Pseudomonas amygdali pv. sesami M91 226
KPW50752.1 Pseudomonas syringae pv.
berberidis
M91 221
CUV20876.1 Ralstonia solanacearum M91 234
WP_075241300.1 Xanthomonas oryzae M91 171
WP_071615581.1 Ralstonia solanacearum M91 218
WP_061944074.1 Collimonas pratensis M91 265
AMP07033.1 Collimonas pratensis M91 304
KPX28235.1 Pseudomonas coronafaciens pv.
garcae
M91 159
WP_075242222.1 Xanthomonas oryzae M91 167
KTB84937.1 Pseudomonas syringae pv. syringae
PD2774
M91 196
WP_011003174.1 Ralstonia solanacearum M91 217
WP_071895715.1 Ralstonia solanacearum M91 183
WP_070931164.1 Mycobacterium chelonae Mycobacterium 990
WP_070931163.1 Mycobacterium chelonae Mycobacterium 391
EES49602.1 Clostridium botulinum E1 str.
BoNT E Beluga NTNH E1
NTNH 1163
(continued on next page)
182
Table A.1 – (continued from previous page)
Accession Species Classification Length
ACD14165.1 Clostridium botulinum B str. Ek-
lund 17B NTNH B4
NTNH 1196
KGO15578.1 Clostridium botulinum BoNT H
NTNH A
NTNH 1164
ACD52603.1 Clostridium botulinum E3 str.
Alaska E43 NTNH E3
NTNH 1163
ACA57431.1 Clostridium botulinum A3 str. Loch
Maree NTNH A3
NTNH 1159
BAQ12789.1 Clostridium botulinum str 111
NTNH X
NTNH 1174
CAA61228.1 Clostridium botulinum NTNH G NTNH 1198
BAF91945.1 Clostridium botulinum str. Osaka 05
NTNH B6
NTNH 1197
BAP25803.1 Clostridium botulinum str. Prevot
25 NTNH B2
NTNH 1197
KEH96500.1 Clostridium botulinum D str. 16868
NTNH D
NTNH 1196
KGO12234.1 Clostridium botulinum BoNT H
NTNH B
NTNH 1197
EDS76246.1 Clostridium botulinum C str. Ek-
lund NTNH C
NTNH 1196
EEP54802.1 Clostridium butyricum E4 str.
BoNT E BL5262 NTNH E4
NTNH 1163
ACQ51342.1 Clostridium botulinum Ba4 str. 657
NTNH BivA4
NTNH 1159
CAM91124.1 Clostridium botulinum E NTNH E6 NTNH 1163
EDT74767.1 Clostridium butyricum 5521 NTNH
E
NTNH 1163
KEI05264.1 Clostridium botulinum CD str.
BKT2873 NTNH CD
NTNH 1196
ACT33193.1 Clostridium botulinum NTNH A5 NTNH 1193
ABS37375.1 Clostridium botulinum A str. Hall
NTNH A1
NTNH 1193
ACA47084.1 Clostridium botulinum B1 str. Okra
NTNH B1
NTNH 1197
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ACO85717.1 Clostridium botulinum A2 str. Ky-
oto NTNH A2
NTNH 1159
ADU57953.1 Clostridium botulinum NTNH F6 NTNH 1165
ABS40335.1 Clostridium botulinum F str. Lan-
geland NTNH F1
NTNH 1163
AGR53839.1 Clostridium baratii NTNH F7 NTNH 1162
ACQ51274.1 Clostridium botulinum Ba4 str. 657
NTNH BvB
NTNH 1197
OTO22243.1 Enterococcus sp. 3G1_DIV0629 NTNH-like 1192
AAO37454.1 Clostridium tetani E88 TeNT tetani TeNT 1315
WP_027699549.1 Weissella oryzae SG25 WoNT Weissella 1296
WP_027699548.1 Weissella oryzae SG25 WoNTNH Weissella 1437
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A.2 Supplementary Table 2
Table A.2: Gene annotations for toxin gene clusters in Chryseobacterium piperi. Homologs were inferred
from top 100 results of a BLASTn (nucleotide) or BLASTp (protein) search, respectively.
Locus Cluster Type Annotation DNA homology Protein homol-
ogy
Notes
CJF12_06270 1 DS Flank Fatty Acid Hydrox-
ylase















































CJF12_06295 1 DS Flank BoNT_GC1_4














CJF12_06305 1 BoNT-Like BoNT_GC1_3
CJF12_06310 1 BoNT-Like BoNT_GC1_3
CJF12_06315 1 BoNT-Like BoNT_GC1_3
CJF12_06320 1 NTNH-Like NTNH_GC1_2
CJF12_06325 1 NTNH-Like NTNH_GC1_2
CJF12_06330 1 BoNT-Like BoNT_GC1_2
CJF12_06335 1 BoNT-Like BoNT_GC1_2
CJF12_06340 1 BoNT-Like BoNT_GC1_2
CJF12_06345 1 NTNH-Like NTNH_GC1_1
CJF12_06350 1 BoNT-Like BoNT_GC1_1
CJF12_06355 1 BoNT-Like BoNT_GC1_1
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A.3 Supplementary Table 3
Table A.3: Presence and absence of various features of BoNTs and BoNT-like toxins, with associated
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A.4 Supplementary Table 4
Table A.4: Nucleotide and protein identifiers from the NCBI Genome database corresponding to ORFX
gene clusters.
Nucleotide ID Start End Species Protein IDs
NOYG01000011 280147 303094 Rhodococcus sp. 06-412-2C OZC91763.1, OZC91764.1
CP012479 1238333 1262714 Arthrobacter sp. ERGS1:01 ALE05666.1, ALE05667.1, ALE05668.1
QBUG01000011 106838 131253 Promicromonospora sp. AC04 PUB23505.1, PUB23506.1, PUB23507.1
SLVI01000019 92846 108934 Promicromonospora sp.
CF082 Ga0189745_119
TCM59590.1, TCM59591.1, TCM59592.1
PHUK01000001 1143225 1166293 Kitasatospora sp. OK780 PKB46238.1, PKB46239.1
NZ_JOEH01000025 115748 137271 Streptacidiphilus jeojiense WP_084715219.1, WP_084715221.1
NZ_JQMJ01000004 1273963 1297143 Streptacidiphilus rugosus WP_037604336.1, WP_084713504.1
FN554889 6498875 6522337 Streptomyces scabiei CBG72874.1, CBG72875.1
JPPW01000417 10249 33711 Streptomyces scabiei KFG03295.1, KFG03296.1
JPPX01000225 155836 181048 Streptomyces scabiei KFF96595.1, KFF96596.1, KFF96597.1
NC_013929 6498875 6522442 Streptomyces scabiei WP_013003441.1, WP_078580200.1
NZ_KL997441 218139 243531 Streptomyces scabiei WP_037703294.1, WP_037703295.1,
WP_079024416.1
NZ_NHOD01000599 1 11925 Streptomyces scabiei WP_107473801.1
BCMM01000016 142609 167824 Streptomyces scabiei str. S58 GAQ63334.1, GAQ63335.1, GAQ63336.1
OLMK01000036 1 13313 Streptomyces sp. MA5143a SPF02795.1
NZ_VDMA01000008 168152 191057 Microbispora sp. CR1-09 WP_139575493.1, WP_139575494.1
BHFQ01000004 223103 247606 Capsulimonas corticalis str.
AX-7
GCE53538.1, GCE53539.1, GCE53540.1
NZ_FNVX01000004 236914 259797 Bacteroides ihuae str.
Marseille-P2824
WP_071145116.1, WP_071145117.1
FUWZ01000001 2268920 2291808 Chitinophaga eiseniae str.
DSM 22224
SJZ84530.1, SJZ84582.1
QKTW01000018 248073 263266 Taibaiella soli PZF72469.1, PZF72470.1, PZF72471.1
DMST01000004 1 22284 Cytophagales bacterium iso-
late UBA9432
HAP58003.1, HAP58004.1, HAP58005.1
DLUS01000425 1 12730 Cytophagales bacterium iso-
late UBA9867
HAA14938.1, HAA14939.1, HAA14940.1
DLUT01000238 1 10234 Cytophagales bacterium iso-
late UBA9868
HAA20266.1, HAA20267.1, HAA20268.1




NZ_KB913013 2148379 2174704 Rudanella lutea WP_019988038.1, WP_019988039.1,
WP_019988040.1, WP_019988041.1
PVTE01000035 130 25106 Spirosoma oryzae PRY27013.1, PRY27014.1, PRY27015.1
NZ_RPOC01000005 221970 246949 Flavobacterium sp. T13 WP_125721298.1, WP_125721300.1,
WP_125721302.1
PEIG01000001 295207 318146 Chroococcales cyanobacterium
IPPAS B-1203
PIG95165.1, PIG95166.1
LMOM01000040 1 11995 Deinococcus sp. Leaf326 KQR18755.1
NZ_SCNA01000023 13521 38984 Bacillus sp. 2SH WP_137842863.1, WP_137842864.1,
WP_137842865.1, WP_137842866.1
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QJJD01000035 1 11251 Brevibacillus laterosporus str.
MG64
RAP23898.1





RHPL01000080 1 13585 Brevibacillus laterosporus str.
Rsp
TPG82513.1, TPG82514.1




MBTG01000018 104803 128867 Paenibacillus ferrarius str.
CY1
OPH56035.1, OPH56036.1, OPH56037.1
CP019794 1947657 1973284 Paenibacillus larvae AQT84652.1, AQT84653.1, AQT84654.1,
Pseudo_CP019794.1_prot_1979












CP020327 1618255 1643883 Paenibacillus larvae subsp.
pulvifaciens str. CCM 38
AQZ46656.1, AQZ46657.1, AQZ46658.1,
AQZ46659.1
CP020557 1842644 1868273 Paenibacillus larvae subsp.
pulvifaciens str. SAG 10367
ARF68073.1, ARF68074.1, ARF68075.1,
ARF68076.1
NZ_NDGK01000036 401497 427560 Paenibacillus thiaminolyticus WP_087443774.1, WP_087443775.1,
WP_087443776.1, WP_127510999.1








NGLI01000004 148615 173789 Enterococcus faecium str.
3G1_DIV0629
OTO22240.1, OTO22241.1, OTO22242.1




JZTY01000005 1 15748 Clostridium baratii str. 771-14 KJU72373.1, KJU72374.1, KJU72375.1,
KJU72376.1
NZ_LUSO01000011 106 20128 Clostridium baratii str. 796-15 WP_039311664.1, WP_079286133.1,
WP_079286134.1, WP_079286135.1












DQ310546 1 10655 Clostridium botulinum A str.
Mascarpone
ABC25997.1, ABC25998.1, ABC26000.1




NZ_AUYW01000009 361649 388007 Clostridium botulinum A2 117 WP_033066626.1, WP_076174538.1,
WP_076174540.1, WP_076174544.1
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ABDP01000023 4825 32334 Clostridium botulinum str. Bf EDT84096.1, EDT84116.1, EDT84123.1,
EDT84152.1




























NZ_AZRQ01000040 1 11350 Clostridium botulinum str.
CDC54085
WP_025775291.1








NZ_JFGA01000189 1 11424 Clostridium botulinum str.
CDC67190
WP_033050150.1
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FOOX01000007 77844 102988 Desulfallas arcticus str.
DSM17038
SFG63163.1, SFG63181.1, SFG63207.1
MASS01000023 32306 55777 Desulfosporosinus sp. BG ODA40899.1, ODA40900.1, ODA40901.1
MVQL01000134 100534 121761 Pelotomaculum sp.
PtaB.Bin104
OPX90105.1, OPX90106.1
BGIScaffold9 73024 102439 Paraclostridium bifermentans Pbm-ORFX1, Pbm-ORFX2, Pbm-
ORFX3, Pbm-P47
FOKQ01000059 1 15222 Ruminococcus albus SFD29377.1, SFD29411.1, SFD29443.1
PHAA01000014 50956 72701 Firmicutes bacterium HGW-
Firmicutes-15
PKM77288.1
RFGF01000135 1 15732 Nitrospirae bacterium RMH30825.1, RMH30826.1, RMH30827.1
LDPZ01000045 1 14035 Aureimonas ureilytica str.
NS226
KTQ87253.1, KTQ87254.1




AAMY01000012 85960 112090 Nitrobacter sp. Nb-311A EAQ35351.1, EAQ35352.1, EAQ35353.1,
EAQ35354.1
NC_007406 950829 976957 Nitrobacter winogradskyi WP_011314189.1, WP_011314190.1,
WP_011314191.1, WP_011314192.1









LMQF01000068 72241 96595 Rhizobium sp. Leaf386 KQS83087.1, KQS83088.1, KQS83089.1
LMRG01000028 227687 252041 Rhizobium sp. Leaf453 KQT92872.1, KQT92873.1, KQT92874.1
AUSY01000019 68615 93057 Sinorhizobium sp. GW3 KSV75547.1, KSV75548.1, KSV75549.1
NZ_AUBC01000023 25134 51553 Salinarimonas rosea WP_029031725.1, WP_029031726.1,
WP_029031727.1, WP_084327582.1
LJSX01000015 1 13355 Salinarimonadaceae bacterium
HL-109
KPQ10493.1, KPQ10494.1
NZ_FMBM01000001 1428685 1446352 Salinarimonadaceae bacterium
HL-109
WP_074444051.1, WP_083204353.1
NZ_UEHD01000031 1 14737 Rhizobiales bacterium WP_112407914.1, WP_112407915.1,
WP_112407916.1
FNEB01000001 71237 95710 Lutimaribacter saemankumen-
sis str. DSM28010
SDH93581.1, SDH93615.1, SDH93644.1
NVTR01000010 14795 39287 Marinosulfonomonas sp. PHQ97418.1, PHQ97419.1, PHQ97420.1
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NZ_LOAS01000024 78286 95359 Pseudoruegeria sabulilitoris WP_068315418.1, WP_068315421.1,
WP_068315432.1, WP_082739190.1
QGKU01000038 103607 126664 Rhodobacteraceae bacterium
TG-679
PWR02329.1, PWR02330.1




AFRQ01000031 153885 178436 Achromobacter insuavis str.
AXX-A
EGP47333.1, EGP47334.1, EGP47335.1




FKIF01000007 140391 166058 Bordetella ansorpii str.
H050680373
SAI71066.1, SAI71067.1, SAI71069.1
NZ_NEVP01000004 455202 476641 Bordetella genomosp. 5 str.
AU14646
WP_094799339.1
NZ_LOWB01000135 8177 22240 Burkholderia sp. TSV86 WP_082710301.1, WP_082710302.1
CP030092 1632415 1658579 Massilia sp. YMA4 AXA90938.1, AXA90939.1, AXA90940.1,
AXA90941.1
NZ_SDAU01000007 1 15672 Enterobacteriaceae bacterium
ML5
WP_136374692.1, WP_136374693.1
CAPE01000026 64930 87831 Erwinia amylovora CCP08590.1, CCP08591.1
FR719197 21987 44888 Erwinia amylovora CBX82130.1, CBX82131.1
NC_013961 3322957 3345858 Erwinia amylovora WP_004160292.1, WP_004160293.1
NZ_CAPD01000022 401569 424470 Erwinia amylovora WP_004171016.1, WP_004171017.1
NZ_NQJL01000001 506181 529082 Erwinia amylovora WP_099257802.1, WP_099257804.1
FN434113 3322957 3345858 Erwinia amylovora str.
CFBP1430
CBA23296.1, CBA23298.1
CAHS01000021 232771 255471 Erwinia piriflorinigrans str.
CFBP 5888
CCG88684.1, CCG88685.1
NC_012214 3515945 3538978 Erwinia pyrifoliae WP_012669436.1, WP_014539531.1
FN392235 3515882 3538915 Erwinia pyrifoliae str.
DSM12163
CAY75867.1, CAY75868.1
CP002124 768201 791099 Erwinia sp. Ejp617 ADP10405.1, ADP10406.1
NC_017445 768201 791099 Erwinia sp. Ejp617 WP_012669437.1, WP_041474302.1
NC_010694 3367112 3390004 Erwinia tasmaniensis WP_012442723.1, WP_012442724.1
CU468135 3367112 3390004 Erwinia tasmaniensis str.
ET1/99
CAO98072.1, CAO98073.1
OUND01000001 748277 769899 Arsenophonus endosymbiont
of Aleurodicus floccissimus
SPP31287.1
FN545172 1 18646 Arsenophonus nasoniae CBA72105.1, CBA72106.1,
Pseudo_FN545172.1_prot_8




NZ_NGVR01000030 84480 107462 Proteus columbae WP_100160135.1, WP_100160136.1
CVRZ01000013 107917 123129 Proteus vulgaris CRL64650.1, CRL64651.1, CRL64652.1,
CRL64653.1
NZ_BCTS01000011 17443 40359 Serratia ficaria WP_061796564.1, WP_061796565.1
NZ_PQGI01000007 4789 27696 Serratia marcescens WP_103681903.1, WP_103681904.1
AAQJ02000001 707439 730371 Rickettsiella grylli EDP46360.1, EDP46936.1
DOTR01000013 19323 44324 Halomonas campaniensis iso-
late UBA11284
HCA01106.1, HCA01107.1, HCA01108.1
CP022286 1048219 1073222 Halomonas sp. N3-2A ASK18679.1, ASK18680.1, ASK18681.1
AFQW01000048 1 20388 Halomonas sp. TD01 EGP19388.1, EGP19389.1, EGP19390.1
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NZ_GL949757 168487 193491 Halomonas sp. TD01 WP_009723554.1, WP_009723555.1,
WP_083817071.1
NZ_NKHL01000056 1 13494 Pseudomonas bohemica WP_110946518.1, WP_110946520.1
PISL01000046 19070 42013 Pseudomonas hunanensis str.
P11
PKF23524.1, PKF23525.1
NZ_KK214957 7793 30694 Pseudomonas monteilii WP_021784075.1, WP_028698029.1
PJCG01000017 60221 76519 Pseudomonas monteilii str.
CY06
PKI23724.1, PKI23725.1
RBLH01000001 4923371 4946272 Pseudomonas plecoglossicida
str. ZKA3
RKS49527.1, RKS49528.1
LDJF01000015 7248 30134 Pseudomonas putida KMY35635.1, KMY35636.1
NC_002947 2265678 2288579 Pseudomonas putida NP_744156.2, NP_744157.1
NZ_JENB01000021 60650 83593 Pseudomonas putida WP_043200446.1, WP_050491898.1
NZ_MINE01000015 2795354 2818255 Pseudomonas putida WP_021784074.1, WP_103443912.1
NZ_NHBB01000022 53155 76098 Pseudomonas putida WP_003247214.1, WP_087535274.1
NZ_PDEH01000001 254282 277225 Pseudomonas putida WP_098089144.1, WP_098089145.1
NZ_AOUR02000091 60177 76432 Pseudomonas putida LF54 WP_021784074.1, WP_021784075.1
NZ_ALPV02000001 116469 139412 Pseudomonas putida LS46 WP_003247214.1, WP_003247215.1
AE015451 2265678 2288579 Pseudomonas putida sp.
KT2440
AAN67620.2, AAN67621.1
NNBI01000001 115342 138243 Pseudomonas putida str.
DPA1
PNG86274.1, PNG86275.1
NBWA01000085 12616 28086 Pseudomonas putida str. DZ-
F23
ORL61219.1, ORL61220.1
LSUZ01000058 16735 34052 Pseudomonas putida str. IN-
Sali382
OAS19658.1, OAS19659.1
MING01000019 1078616 1101517 Pseudomonas putida str. KH-
18-2
POG13814.1, POG13815.1
APBQ01000200 4876 27777 Pseudomonas putida str.
TRO1
ENY74411.1, ENY74412.1
NHBC01000017 54853 77796 Pseudomonas putida str.
UV4/95
OUS85781.1, OUS85782.1
NZ_BCAQ01000058 12837 35780 Pseudomonas sp. GTC 16473 WP_049586629.1, WP_049586631.1
CP011525 1893002 1915945 Pseudomonas sp. JY-Q ANI33532.1, ANI33533.1
NZ_BCAX01000013 7460 30403 Pseudomonas sp. NBRC
111121
WP_049586631.1, WP_060489093.1
NZ_BCBB01000102 36454 51751 Pseudomonas sp. NBRC
111125
WP_003247214.1, WP_060539043.1
NZ_BCBP01000041 7595 30538 Pseudomonas sp. NBRC
111139
WP_003247214.1, WP_070096344.1
QJOV01000015 7971 30914 Pseudomonas sp. SMT-1 PXZ47850.1, PXZ47851.1
CP035952 4078874 4101753 Pseudomonas sp. SNU WT1 QBF27609.1, QBF27610.1
NZ_SEIQ01000082 7091 23749 Pseudomonas sp. SWI36 WP_020193110.1, WP_129933394.1
CP026332 4204848 4227749 Pseudomonas sp. XWY-1 AUZ60466.1, AUZ60467.1
SEZV01000011 104102 128449 Pseudomonas syringae str.
MWU 13-30316
TFZ34284.1, TFZ34285.1, TFZ34286.1
NZ_PIFD01000008 1 16185 Vibrio splendidus WP_108185305.1, WP_108185306.1
NZ_PIFN01000001 1 17845 Vibrio splendidus WP_108192224.1, WP_108192225.1
NZ_PIFX01000014 1 16185 Vibrio splendidus WP_108192224.1, WP_108202954.1
NC_030990 4413562 4437678 Fusarium oxysporum XP_018236094.1, XP_018236095.1
KB730215 78110 101577 Fusarium oxysporum f. sp.
cubense race 1
ENH69816.1, ENH69817.1
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DS231697 3533457 3557573 Fusarium oxysporum f. sp. ly-
copersici 4287
KNA98048.1, KNA98049.1
JH659331 43567 67683 Fusarium oxysporum f. sp.
melonis 26406
EXK40938.1, EXK40939.1
LN649229 430582 452068 Fusarium venenatum str.
A3/5
CEI63638.1





Supplementary Material: Chapter 3
B.1 Supplementary Table 5
Table B.1: Summary of I-TASSER structural modelling results. Each diphtheria toxin-like protein was
separated into its domains according to its alignment with the crystal structure of diphtheria toxin, which
was also used to evaluate the model’s RMSD (PDB identifier 1MDT). The I-TASSER C-score varies from
-5 to 2, representing low to high confidence in the model. The domain boundaries for each subsection are
indicated in the table.
*The C domain (NZ_BAGZ01000024.1, 41687-42285) and the N-terminus of the T domain
(NZ_BAGZ01000024.1, 41462-41641) for the sequence from Austwickia chelonae were translated from
a pseudogene. The T domain was concatenated from the translated pseudogene and residues 2-87 of
WP_040322835.1.
Species Model C domain T domain R domain







model1 0.28 1.112 0.97 0.866 1.05 1.173
model2 0.62 0.617 -3.52 5.298 -5 1.13
model3 0.26 0.614 -4.03 4.585 -5 1.184
model4 0.44 1.155 -4.76 12.279 -4.94 1.174









model1 -0.47 1.112 0.55 1.202 -3.56 13.764
model2 -0.49 1.072 -3.87 16.269 -4.14 13.482
model3 -1.44 1.592 -4.52 15.196 -4.6 13.723
model4 -1.6 1.211 -4.52 8.669 -4.85 14.324
model5 -3.6 2.636 -4.58 7.573 -5 14.452
(continued on next page)
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model1 -1.02 1.162 0.62 1.032 -2.74 15.253
model2 -2.42 1.582 -3.44 14.84 -4.97 15.839
model3 -2.91 1.238 -4.64 13.396 -4.42 15.143
model4 -1.93 1.086 -4.14 12.725 -5 14.674









model1 -0.35 1.472 0.78 0.721 -4.14 11.901
model2 -1.19 1.069 -4.39 10.76 -4.57 12.818
model3 -0.55 1.361 -3.73 4.944 -4.64 12.267
model4 -2.83 0.909 -4.39 11.017 -4.36 11.81









model1 0.29 1.003 0.25 0.727 -3.84 8.88
model2 -1.78 0.981 -3.78 11.807 -4.51 6.42
model3 -3.17 1.773 -3.94 11.462 -5 11.232
model4 -4.59 0.905 -4.66 8.699 -4.77 6.73









model1 -2.15 1.392 0.26 1.191 -2.46 1.125
model2 -4.4 3.229 -4.31 6.075 -4.4 10.061
model3 -5 3.455 -4.76 6.437 -4.09 2.509
model4 -3.67 3.246 -5 8.458 -2.9 1.137









model1 -1.43 1.953 0.32 0.755 -2.7 15.619
model2 -4.01 10.512 -4.08 9.806 -5 1.875
model3 -4.02 13.268 -4.45 6.098 -5 13.803
model4 -4.24 12.012 -5 6.672 -5 10.658
model5 -4.61 3.745 -5 14.817 -5 12.406
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Table B.2: Presence/absence of key DT functional sites among DT homologs. In order, the noted sites
perform these functions in DT (and references are provided below): H21 maintains the steric structure
of the catalytic site; T23 forms hydrogen bonds with the adenosine ribose; Y27 participates in the active
site; K51 and G52 participate in the active site loop; Y54 and Y65 bind NAD; E148 is the key catalytic
residue; C186 and C201 form the disulfide bond linking A and B fragments; RxxR is the furin cleavage
site; P345, E349, and D352 participate in membrane insertion and pore formation.
Species Accession Key functional sites
Corynebacterium
diphtheriae 1MDT H21 T23 Y27 K51 G52 Y54
Corynebacterium
ulcerans AAN28948.1 H46 T48 Y52 K56 G77 Y79
Austwickia
chelonae Pseudogene* H33 A35 S39 K63 G64 Y66
Streptomyces sp.
MBT76 WP_079110321.1 H81 Y83 H87 K109 G110 Y112
Streptosporangium
nondiastaticum PSJ28985.1 H47 Y49 H53 K75 G76 Y78
Streptomyces
roseoverticillatus WP_078659863.1 H55 Y57 H64 K83 G84 Y86
Streptomyces sp.
TLI_053 SDT83331.1 H17 Y19 N23 N42 G43 Y45
Streptomyces
albireticuli WP_095582082.1 R129 V130 E134 K159 A160 Y162
Seinonella
peptonophila WP_073156187.1 R21 V23 G27 Q60 H61 Y63
Corynebacterium
diphtheriae 1MDT Y65 E148 C186 190-RVRR-194 C201
Corynebacterium
ulcerans AAN28948.1 Y90 E173 C211 215-RVRR-218 C226
Austwickia
chelonae Pseudogene* Y77 E160 C199* 206-RAKR-218 C215*
Streptomyces sp.
MBT76 WP_079110321.1 Y123 E160 C199* 248-RAKR-251 C256*
Streptosporangium
nondiastaticum PSJ28985.1 Y89 E170 C208* 214-RVKR-217 C222*
(continued on next page)
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Species Accession Key functional sites
Streptomyces
roseoverticillatus WP_078659863.1 Y97 E178 C216* 222-RVKR-225 C230*
Streptomyces sp.
TLI_053 SDT83331.1 Y56 E141 C184 189-RAKR-192 C197*
Streptomyces
albireticuli WP_095582082.1 - E266 C323 - C337*
Seinonella
peptonophila WP_073156187.1 Y74 E176 C239 - C251*
Corynebacterium
diphtheriae 1MDT P345 E349 D352
Corynebacterium
ulcerans AAN28948.1 P370 E374 D377
Austwickia
chelonae Pseudogene* P355 E359 362
Streptomyces sp.
MBT76 WP_079110321.1 P391 E395 D398
Streptosporangium
nondiastaticum PSJ28985.1 P357 E361 D372
Streptomyces
roseoverticillatus WP_078659863.1 P365 E366 D372
Streptomyces sp.
TLI_053 SDT83331.1 P333 E337 D340
Streptomyces
albireticuli WP_095582082.1 P475 E479 D485
Seinonella
peptonophila WP_073156187.1 P386 E390 E396
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C.1 Supplementary Table 7
Table C.1: Top 100 Pfam domains correlated with the LCT translocase. Proteome-wide Pfam annotations
were retrieved from the Genome Taxonomy Database. Domains associated with LCTs are bolded.
Pfam ID Clan ID Clan Name Pfam Name Pfam Description Correlation
PF12920.2 TcdA_TcdB_pore TcdA/TcdB pore
forming domain
1








PF06958.7 CL0446 Bacteriocin_TLN Pyocin_S S-type Pyocin 0.407896036
PF14564.1 Membrane_bind Membrane binding 0.345611493
PF03245.8 CL0331 EpsM Phage_lysis Bacteriophage Rz lysis
protein
0.345518375




PF07865.6 DUF1652 Protein of unknown
function (DUF1652)
0.333345129
PF13503.1 DUF4123 Domain of unknown
function (DUF4123)
0.328320429




PF09000.5 Cytotoxic Cytotoxic 0.322464262
PF07119.7 DUF1375 Protein of unknown
function (DUF1375)
0.310421646
(continued on next page)
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Pfam ID Clan ID Clan Name Pfam Name Pfam Description Correlation
PF11462.3 CL0266 PH DUF3203 Protein of unknown
function (DUF3203)
0.307089453




PF06649.7 DUF1161 Protein of unknown
function (DUF1161)
0.301704946
PF10109.4 CL0567 Phage_TACs Phage_TAC_7 Phage tail assembly
chaperone proteins, E,
or 41 or 14
0.297103359
PF09634.5 DUF2025 Protein of unknown
function (DUF2025)
0.294250433
PF07395.6 CL0257 Acetyltrans Mig-14 Mig-14 0.294003761
PF05954.6 CL0504 Phage_barrel Phage_GPD Phage late control gene
D protein (GPD)
0.292797043
PF09498.5 DUF2388 Protein of unknown
function (DUF2388)
0.287317097
PF03406.8 Phage_fiber_2 Phage tail fibre repeat 0.283954868
PF04676.9 CwfJ_C_2 Protein similar to CwfJ
C-terminus 2
0.283373472












PF03513.9 Cloacin_immun Cloacin immunity pro-
tein
0.281446515
PF06474.7 CL0421 LppaM MLTD_N MltD lipid attachment
motif
0.281316062
PF11647.3 MLD Membrane Local-
ization Domain
0.27674684




PF12306.3 CL0026 CU_oxidase PixA Inclusion body protein 0.272185422
PF01320.13 Colicin_Pyocin Colicin immunity pro-
tein / pyocin immunity
protein
0.27177386
PF10062.4 DUF2300 Predicted secreted pro-
tein (DUF2300)
0.269069383
PF12021.3 DUF3509 Protein of unknown
function (DUF3509)
0.265764007
PF11713.3 CL0093 Peptidase_CD Peptidase_C80 Peptidase C80 fam-
ily
0.265413307




PF10976.3 DUF2790 Protein of unknown
function (DUF2790)
0.263663893
(continued on next page)
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Pfam ID Clan ID Clan Name Pfam Name Pfam Description Correlation
PF06611.7 DUF1145 Protein of unknown
function (DUF1145)
0.260882618
PF05581.7 NA NA NA NA 0.260763361
PF07634.6 RtxA RtxA repeat 0.260030609




PF10144.4 CL0165 Cache SMP_2 Bacterial virulence fac-
tor haemolysin
0.258000858




PF05488.8 PAAR_motif PAAR motif 0.252857044
PF12571.3 DUF3751 Phage tail-collar fibre
protein
0.251902708




PF06790.6 UPF0259 Uncharacterised pro-
tein family (UPF0259)
0.247096601
PF05736.6 CL0193 MBB OprF OprF membrane do-
main
0.244047727
PF13693.1 CL0123 HTH HTH_35 Winged helix-turn-
helix DNA-binding
0.241707199
PF04320.9 DUF469 Protein with unknown
function (DUF469)
0.240266819
PF03889.8 ArfA Alternative ribosome-
rescue factor A
0.237133137
PF05638.7 T6SS_HCP Type VI secretion sys-
tem effector, Hcp
0.236267323
PF11293.3 DUF3094 Protein of unknown
function (DUF3094)
0.235268321
PF05947.7 T6SS_TssF Type VI secretion sys-
tem, TssF
0.234957281
PF12633.2 CL0260 NTP_transf Adenyl_cycl_N Adenylate cyclase NT
domain
0.234726283
PF09621.5 LcrR Type III secretion sys-
tem regulator (LcrR)
0.234023735




PF06942.7 CL0420 GlpM-like GlpM GlpM protein 0.23289032
PF01295.13 Adenylate_cycl Adenylate cyclase,
class-I
0.23274483
PF06672.6 CL0125 Peptidase_CA DUF1175 Protein of unknown
function (DUF1175)
0.232508376




PF04965.9 GPW_gp25 Gene 25-like lysozyme 0.231901984
PF04888.7 SseC Secretion system effec-
tor C (SseC) like family
0.231616006
PF07216.7 LcrG LcrG protein 0.231505947
(continued on next page)
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Pfam ID Clan ID Clan Name Pfam Name Pfam Description Correlation
PF04792.7 LcrV V antigen (LcrV) pro-
tein
0.231168544









PF11286.3 DUF3087 Protein of unknown
function (DUF3087)
0.227387565
PF06693.6 DUF1190 Protein of unknown
function (DUF1190)
0.227077986




PF03573.8 CL0193 MBB OprD outer membrane porin,
OprD family
0.224232333
PF11862.3 DUF3382 Domain of unknown
function (DUF3382)
0.219804078
PF05844.7 YopD YopD protein 0.217519462
PF10948.3 DUF2635 Protein of unknown
function (DUF2635)
0.216077945
PF11661.3 DUF2986 Protein of unknown
function (DUF2986)
0.215827375
PF06450.7 CL0182 IT NhaB Bacterial Na+/H+ an-
tiporter B (NhaB)
0.215760319







PF07409.7 GP46 Phage protein GP46 0.213479959
PF14567.1 CL0526 SUKH SUKH_5 SMI1-KNR4 cell-wall 0.213253186







PF10618.4 Tail_tube Phage tail tube protein 0.212457126
PF09392.5 T3SS_needle_F Type III secretion nee-
dle MxiH, YscF, SsaG,
EprI, PscF, EscF
0.211573532





PF05106.7 CL0564 Holin-III Phage_holin_3_1 Phage holin family
(Lysis protein S)
0.211297161
PF04985.9 CL0569 Phage_TTPs Phage_tube Phage tail tube protein
FII
0.211096297
PF07201.6 CL0646 T3SS HrpJ HrpJ-like domain 0.210468182
(continued on next page)
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Pfam ID Clan ID Clan Name Pfam Name Pfam Description Correlation
PF06890.7 Phage_Mu_Gp45 Bacteriophage Mu
Gp45 protein
0.210308896




PF06476.7 DUF1090 Protein of unknown
function (DUF1090)
0.209734486
PF06295.7 DUF1043 Protein of unknown
function (DUF1043)
0.209651638
PF11340.3 DUF3142 Protein of unknown
function (DUF3142)
0.209617732
PF06995.6 Phage_P2_GpU Phage P2 GpU 0.209609326
PF11354.3 DUF3156 Protein of unknown
function (DUF3156)
0.2095852
PF10679.4 DUF2491 Protein of unknown
function (DUF2491)
0.208922421




PF03974.8 Ecotin Ecotin 0.208388611
PF06794.7 UPF0270 Uncharacterised pro-
tein family (UPF0270)
0.208022718
PF07157.7 DNA_circ_N DNA circularisation
protein N-terminus
0.208012943




C.2 Supplementary Figure 1
Figure C.1: SDS-PAGE of purified TcdB constructs. (a) ADPR-[truncated TcdB domain]-DTR chimeras,
with the truncated T-domain indicated in the figure. (b) GTD-CPD-TcdB(851-1473)-DTR and ∆T-
domain. (c) TcdB 851-1473.
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C.3 Supplementary Figure 2
Figure C.2: -
DTR constructs]Cell viability and protein synthesis inhibition ADPR-[truncated TcdB T-
domain]-DTR constructs. (a) Fraction cell viability of all non-toxic constructs, tested at
both 50nM and 10 nM. The variable TcdB truncation is indicated on the x-axis. (b)
Fraction cell viability and (c) fraction protein synthesis inhibition curves of toxic ADPR-
[truncated TcdB T-domain]-DTR constructs.
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C.4 Supplementary Figure 3
Figure C.3: TcdB 851-1473 retains its form and function. (a) TcdA T-domain (pdb: 4R04), with 851-
1473 colored in green. (b) TcdB 851-1473 induced dye release quantification after 20 minutes and (c) a
kinetic trace from HPTS/DPX loaded liposomes, from pH 4.0 to pH 7.0 in 0.5 pH increments, with coloring
as follows: pH 4.0 (red), pH 4.5 (green), pH 5.0 (yellow), pH 5.5 (blue), pH 6.0 (orange), pH 6.5 (purple),
pH 7.0 (aqua), pH 7.5 (magenta) (N=3). (d) Stability of TcdB 851-1473 in aqueous buffer and with (e)
20 mM DPC from pH 4.0 to pH 7.5. (f) Circular dichroism (CD) spectroscopy of TcdB 851-1473 from pH
4.0 to pH 7.5 in 0.5 pH increments (N=3) in aqueous buffer and with (g) 20 mM DPC (N=3). Coloring
for each pH is the same as in (b) and (c).
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